{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "9e6ed5f8",
   "metadata": {},
   "source": [
    "# Clinical Trials CLassification"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "673a03cf",
   "metadata": {},
   "source": [
    "### Data Reading Phase"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "f487ae39",
   "metadata": {},
   "outputs": [],
   "source": [
    "import numpy as np\n",
    "import matplotlib.pyplot as plt\n",
    "import pandas as pd\n",
    "import seaborn as sns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "b5b8a839",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_42376/28611935.py:1: DtypeWarning: Columns (35,36,37,38,39) have mixed types. Specify dtype option on import or set low_memory=False.\n",
      "  df = pd.read_csv('/home/haider/Desktop/Office/Python/Projects/clinical-trials-analysis/data/updated_cancer_trials.csv')\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>orgstudyid</th>\n",
       "      <th>title</th>\n",
       "      <th>organization_fullname</th>\n",
       "      <th>leadsponsor</th>\n",
       "      <th>collaborators</th>\n",
       "      <th>studytype</th>\n",
       "      <th>phase</th>\n",
       "      <th>overallstatus</th>\n",
       "      <th>startdate</th>\n",
       "      <th>...</th>\n",
       "      <th>centralcontact_name</th>\n",
       "      <th>centralcontact_role</th>\n",
       "      <th>centralcontact_phone</th>\n",
       "      <th>centralcontact_phoneext</th>\n",
       "      <th>centralcontact_email</th>\n",
       "      <th>numcentralcontacts</th>\n",
       "      <th>location_facility</th>\n",
       "      <th>location_city</th>\n",
       "      <th>location_state</th>\n",
       "      <th>location_country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03878979</td>\n",
       "      <td>J1923</td>\n",
       "      <td>Preoperative Immune Checkpoint Inhibitor Thera...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Johns Hopkins Sidney Kimmel Comprehensive Canc...</td>\n",
       "      <td>Baltimore</td>\n",
       "      <td>Maryland</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04591379</td>\n",
       "      <td>REG-083-2020</td>\n",
       "      <td>Intratumoral Influenza Vaccine for Early Color...</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>University of Copenhagen</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>KÃ¸ge</td>\n",
       "      <td>Zealand</td>\n",
       "      <td>Denmark</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT06671379</td>\n",
       "      <td>SHR-A2009-301</td>\n",
       "      <td>A Randomized, Open-label, Multicenter, Phase I...</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Fei Qiu</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>0518-82342973</td>\n",
       "      <td>?</td>\n",
       "      <td>fei.qiu@hengrui.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Guangdong Provincial People's Hospital</td>\n",
       "      <td>Guangzhou</td>\n",
       "      <td>Guangdong</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04361279</td>\n",
       "      <td>SIBP-02-03</td>\n",
       "      <td>A Phase III, Multicenter, Randomized, Double-b...</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>The First Affiliated Hospital of College of Me...</td>\n",
       "      <td>Hangzhou</td>\n",
       "      <td>?</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT05799079</td>\n",
       "      <td>VICCHEM2163</td>\n",
       "      <td>Phase 2 Study of Decitabine and Cedazuridine i...</td>\n",
       "      <td>Vanderbilt-Ingram Cancer Center</td>\n",
       "      <td>Sanjay Mohan</td>\n",
       "      <td>National Comprehensive Cancer Network, Taiho O...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Vanderbilt-Ingram Services for Timely Access</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>800-811-8480</td>\n",
       "      <td>?</td>\n",
       "      <td>cip@vumc.org</td>\n",
       "      <td>?</td>\n",
       "      <td>Vanderbilt University/Ingram Cancer Center</td>\n",
       "      <td>Nashville</td>\n",
       "      <td>Tennessee</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT04164979</td>\n",
       "      <td>20195426</td>\n",
       "      <td>Phase 2 Study of Cabozantinib Combined With Pe...</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>Exelixis</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>Orange</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT00313079</td>\n",
       "      <td>HEMALL0003</td>\n",
       "      <td>A Phase I Study of mAb 216 With Chemotherapy f...</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Steven E. Coutre</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>Stanford</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT00005079</td>\n",
       "      <td>UCLA-9810046</td>\n",
       "      <td>Timing of Breast Cancer Surgery, Menstrual Cyc...</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>Jonsson Comprehensive Cancer Center</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>1999-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Rebecca and John Moores UCSD Cancer Center, Jo...</td>\n",
       "      <td>La Jolla, Los Angeles</td>\n",
       "      <td>California, California</td>\n",
       "      <td>United States, United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT05108779</td>\n",
       "      <td>QLF32004-101</td>\n",
       "      <td>Phase Ia Clinical Study of Safety, Tolerabilit...</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>...</td>\n",
       "      <td>Jin Li</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>021-38804518</td>\n",
       "      <td>?</td>\n",
       "      <td>sunypclinicaltrial@163.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Shanghai East Hospital</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT00398879</td>\n",
       "      <td>Perifosine 211</td>\n",
       "      <td>A Randomized Placebo-Controlled Study of Perif...</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2005-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>AOI Pharmaceuticals Investigative Site, AOI Ph...</td>\n",
       "      <td>Tucson, Beverly Hills, Deer Park, Monterey, Ne...</td>\n",
       "      <td>Arizona, California, California, California, C...</td>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10 rows Ã 45 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid      orgstudyid  \\\n",
       "0  NCT03878979           J1923   \n",
       "1  NCT04591379    REG-083-2020   \n",
       "2  NCT06671379   SHR-A2009-301   \n",
       "3  NCT04361279      SIBP-02-03   \n",
       "4  NCT05799079     VICCHEM2163   \n",
       "5  NCT04164979        20195426   \n",
       "6  NCT00313079      HEMALL0003   \n",
       "7  NCT00005079    UCLA-9810046   \n",
       "8  NCT05108779    QLF32004-101   \n",
       "9  NCT00398879  Perifosine 211   \n",
       "\n",
       "                                               title  \\\n",
       "0  Preoperative Immune Checkpoint Inhibitor Thera...   \n",
       "1  Intratumoral Influenza Vaccine for Early Color...   \n",
       "2  A Randomized, Open-label, Multicenter, Phase I...   \n",
       "3  A Phase III, Multicenter, Randomized, Double-b...   \n",
       "4  Phase 2 Study of Decitabine and Cedazuridine i...   \n",
       "5  Phase 2 Study of Cabozantinib Combined With Pe...   \n",
       "6  A Phase I Study of mAb 216 With Chemotherapy f...   \n",
       "7  Timing of Breast Cancer Surgery, Menstrual Cyc...   \n",
       "8  Phase Ia Clinical Study of Safety, Tolerabilit...   \n",
       "9  A Randomized Placebo-Controlled Study of Perif...   \n",
       "\n",
       "                               organization_fullname  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                    Vanderbilt-Ingram Cancer Center   \n",
       "5                   University of California, Irvine   \n",
       "6                                Stanford University   \n",
       "7                    National Cancer Institute (NCI)   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                         leadsponsor  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                                       Sanjay Mohan   \n",
       "5                   University of California, Irvine   \n",
       "6                                   Steven E. Coutre   \n",
       "7                Jonsson Comprehensive Cancer Center   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                       collaborators       studytype   phase  \\\n",
       "0                               Bristol-Myers Squibb  INTERVENTIONAL  PHASE2   \n",
       "1                           University of Copenhagen  INTERVENTIONAL  PHASE2   \n",
       "2                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "3                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "4  National Comprehensive Cancer Network, Taiho O...  INTERVENTIONAL  PHASE2   \n",
       "5                                           Exelixis  INTERVENTIONAL  PHASE2   \n",
       "6                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "7                    National Cancer Institute (NCI)  INTERVENTIONAL  PHASE3   \n",
       "8                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "9                                                NaN  INTERVENTIONAL  PHASE2   \n",
       "\n",
       "           overallstatus   startdate  ...  \\\n",
       "0              COMPLETED  2019-07-08  ...   \n",
       "1              COMPLETED  2021-02-26  ...   \n",
       "2             RECRUITING  2024-11-29  ...   \n",
       "3              COMPLETED  2019-07-25  ...   \n",
       "4             RECRUITING  2024-01-29  ...   \n",
       "5  ACTIVE_NOT_RECRUITING  2020-02-04  ...   \n",
       "6              COMPLETED     2006-05  ...   \n",
       "7              COMPLETED     1999-01  ...   \n",
       "8                UNKNOWN  2021-11-09  ...   \n",
       "9              COMPLETED     2005-08  ...   \n",
       "\n",
       "                            centralcontact_name centralcontact_role  \\\n",
       "0                                           NaN                 NaN   \n",
       "1                                           NaN                 NaN   \n",
       "2                                       Fei Qiu             CONTACT   \n",
       "3                                           NaN                 NaN   \n",
       "4  Vanderbilt-Ingram Services for Timely Access             CONTACT   \n",
       "5                                           NaN                 NaN   \n",
       "6                                           NaN                 NaN   \n",
       "7                                           NaN                 NaN   \n",
       "8                                        Jin Li             CONTACT   \n",
       "9                                           NaN                 NaN   \n",
       "\n",
       "  centralcontact_phone centralcontact_phoneext        centralcontact_email  \\\n",
       "0                  NaN                     NaN                         NaN   \n",
       "1                  NaN                     NaN                         NaN   \n",
       "2        0518-82342973                       ?         fei.qiu@hengrui.com   \n",
       "3                  NaN                     NaN                         NaN   \n",
       "4         800-811-8480                       ?                cip@vumc.org   \n",
       "5                  NaN                     NaN                         NaN   \n",
       "6                  NaN                     NaN                         NaN   \n",
       "7                  NaN                     NaN                         NaN   \n",
       "8         021-38804518                       ?  sunypclinicaltrial@163.com   \n",
       "9                  NaN                     NaN                         NaN   \n",
       "\n",
       "  numcentralcontacts                                  location_facility  \\\n",
       "0                  ?  Johns Hopkins Sidney Kimmel Comprehensive Canc...   \n",
       "1                  ?                        Zealand University Hospital   \n",
       "2                  ?             Guangdong Provincial People's Hospital   \n",
       "3                  ?  The First Affiliated Hospital of College of Me...   \n",
       "4                  ?         Vanderbilt University/Ingram Cancer Center   \n",
       "5                  ?  Chao Family Comprehensive Cancer Center, Unive...   \n",
       "6                  ?             Stanford University School of Medicine   \n",
       "7                  ?  Rebecca and John Moores UCSD Cancer Center, Jo...   \n",
       "8                  ?                             Shanghai East Hospital   \n",
       "9                  ?  AOI Pharmaceuticals Investigative Site, AOI Ph...   \n",
       "\n",
       "                                       location_city  \\\n",
       "0                                          Baltimore   \n",
       "1                                               KÃ¸ge   \n",
       "2                                          Guangzhou   \n",
       "3                                           Hangzhou   \n",
       "4                                          Nashville   \n",
       "5                                             Orange   \n",
       "6                                           Stanford   \n",
       "7                              La Jolla, Los Angeles   \n",
       "8                                           Shanghai   \n",
       "9  Tucson, Beverly Hills, Deer Park, Monterey, Ne...   \n",
       "\n",
       "                                      location_state  \\\n",
       "0                                           Maryland   \n",
       "1                                            Zealand   \n",
       "2                                          Guangdong   \n",
       "3                                                  ?   \n",
       "4                                          Tennessee   \n",
       "5                                         California   \n",
       "6                                         California   \n",
       "7                             California, California   \n",
       "8                                           Shanghai   \n",
       "9  Arizona, California, California, California, C...   \n",
       "\n",
       "                                    location_country  \n",
       "0                                      United States  \n",
       "1                                            Denmark  \n",
       "2                                              China  \n",
       "3                                              China  \n",
       "4                                      United States  \n",
       "5                                      United States  \n",
       "6                                      United States  \n",
       "7                       United States, United States  \n",
       "8                                              China  \n",
       "9  United States, United States, United States, U...  \n",
       "\n",
       "[10 rows x 45 columns]"
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df = pd.read_csv('/home/haider/Desktop/Office/Python/Projects/clinical-trials-analysis/data/updated_cancer_trials.csv')\n",
    "df.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "496d96b9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(60687, 45)"
      ]
     },
     "execution_count": 3,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "7c70a28c",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['nctid', 'orgstudyid', 'title', 'organization_fullname', 'leadsponsor',\n",
       "       'collaborators', 'studytype', 'phase', 'overallstatus', 'startdate',\n",
       "       'completiondate', 'primarycompletiondate', 'studyfirstsubmitdate',\n",
       "       'studyfirstpostdate', 'lastupdatepostdate', 'enrollment',\n",
       "       'projectedaccrual', 'eligibilitycriteria', 'designprimarypurpose',\n",
       "       'briefsummary', 'detaileddescription', 'sex', 'minimumage',\n",
       "       'maximumage', 'stdage', 'country', 'conditions', 'keywords',\n",
       "       'interventions_name', 'interventions_description', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'overallofficials_name',\n",
       "       'overallofficials_affiliation', 'oversighthasdmc',\n",
       "       'centralcontact_name', 'centralcontact_role', 'centralcontact_phone',\n",
       "       'centralcontact_phoneext', 'centralcontact_email', 'numcentralcontacts',\n",
       "       'location_facility', 'location_city', 'location_state',\n",
       "       'location_country'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "4f52196e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "nctid                           object\n",
       "orgstudyid                      object\n",
       "title                           object\n",
       "organization_fullname           object\n",
       "leadsponsor                     object\n",
       "collaborators                   object\n",
       "studytype                       object\n",
       "phase                           object\n",
       "overallstatus                   object\n",
       "startdate                       object\n",
       "completiondate                  object\n",
       "primarycompletiondate           object\n",
       "studyfirstsubmitdate            object\n",
       "studyfirstpostdate              object\n",
       "lastupdatepostdate              object\n",
       "enrollment                      object\n",
       "projectedaccrual                object\n",
       "eligibilitycriteria             object\n",
       "designprimarypurpose            object\n",
       "briefsummary                    object\n",
       "detaileddescription             object\n",
       "sex                             object\n",
       "minimumage                      object\n",
       "maximumage                      object\n",
       "stdage                          object\n",
       "country                         object\n",
       "conditions                      object\n",
       "keywords                        object\n",
       "interventions_name              object\n",
       "interventions_description       object\n",
       "primary_outcomes                object\n",
       "secondary_outcomes              object\n",
       "overallofficials_name           object\n",
       "overallofficials_affiliation    object\n",
       "oversighthasdmc                 object\n",
       "centralcontact_name             object\n",
       "centralcontact_role             object\n",
       "centralcontact_phone            object\n",
       "centralcontact_phoneext         object\n",
       "centralcontact_email            object\n",
       "numcentralcontacts              object\n",
       "location_facility               object\n",
       "location_city                   object\n",
       "location_state                  object\n",
       "location_country                object\n",
       "dtype: object"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.dtypes"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ccf5fe74",
   "metadata": {},
   "source": [
    "### Data Cleaning Phase"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "bb93372e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0         True\n",
       "1         True\n",
       "2            ?\n",
       "3            ?\n",
       "4         True\n",
       "         ...  \n",
       "60682     True\n",
       "60683     True\n",
       "60684    False\n",
       "60685    False\n",
       "60686        ?\n",
       "Name: oversighthasdmc, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['oversighthasdmc']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "a3dae04f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        2023-10-17\n",
       "1        2021-11-01\n",
       "2           2027-06\n",
       "3        2022-05-20\n",
       "4           2029-03\n",
       "            ...    \n",
       "60682    2022-02-21\n",
       "60683    2023-10-11\n",
       "60684       2010-06\n",
       "60685    2020-09-18\n",
       "60686             ?\n",
       "Name: completiondate, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['completiondate']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "fcd8bc5b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        2023-10-17\n",
       "1        2021-09-22\n",
       "2           2026-12\n",
       "3        2022-05-20\n",
       "4           2028-03\n",
       "            ...    \n",
       "60682    2022-02-21\n",
       "60683    2023-10-11\n",
       "60684       2009-11\n",
       "60685    2020-09-18\n",
       "60686       2011-04\n",
       "Name: primarycompletiondate, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['primarycompletiondate']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "570e7029",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop('projectedaccrual',axis=1,inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "5fec18da",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                   Nivolumab 480mg and surgical resection\n",
       "1                                       Influenza Vaccines\n",
       "2        SHR-A2009 monotherapy, platinum-based dual-age...\n",
       "3                                       SIBP-02, Rituximab\n",
       "4        Venetoclax, Decitabine, Cedazuridine, Bone Mar...\n",
       "                               ...                        \n",
       "60682    Bintrafusp Alfa, Pemetrexed, Carboplatin, Cisp...\n",
       "60683    Extracorporeal Photopheresis, Mogamulizumab, Q...\n",
       "60684                              Ispaghula husk, Placebo\n",
       "60685                                            Alphanate\n",
       "60686    obatoclax mesylate, bortezomib, laboratory bio...\n",
       "Name: interventions_name, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 10,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['interventions_name']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "a6668b28",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                                   Tanguy Lim-Seiwert, MD\n",
       "1                                Ismail GÃ¶genur, Professor\n",
       "2                                                      NaN\n",
       "3        Shanghai Institute Of Biological Products Co.,...\n",
       "4                                         Sanjay Mohan, MD\n",
       "                               ...                        \n",
       "60682                                           Xiuning Le\n",
       "60683                                       Pamela B Allen\n",
       "60684    Jordi Salas, MD, PhD, Luis PeÃ±a, MD, PhD, Marg...\n",
       "60685                                                  NaN\n",
       "60686                                       Joseph Tuscano\n",
       "Name: overallofficials_name, Length: 60687, dtype: object"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['overallofficials_name']"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "607b00b2",
   "metadata": {},
   "source": [
    "#### Renaming Columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "21fbb0e6",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.rename(columns={\n",
    "    'overallstatus': 'overall_status',\n",
    "    'leadsponsor':'lead_sponsor',\n",
    "    'overallofficials_name': 'overall_officials_name',\n",
    "    'overallofficials_affiliation': 'overall_officials_affiliation',\n",
    "    'oversighthasdmc': 'oversight_has_dmc',\n",
    "    'completiondate': 'completion_date',\n",
    "    'primarycompletiondate': 'primary_completion_date',\n",
    "    'studyfirstsubmitdate': 'study_first_submit_date',\n",
    "    'studyfirstpostdate': 'study_first_post_date',\n",
    "    'lastupdatepostdate': 'last_update_post_date',\n",
    "    'eligibilitycriteria': 'eligibility_criteria',\n",
    "    'designprimarypurpose': 'design_primary_purpose',\n",
    "    'briefsummary': 'brief_summary',\n",
    "    'detaileddescription': 'detailed_description',\n",
    "    'startdate': 'start_date',\n",
    "    'studytype': 'study_type',\n",
    "    'minimumage': 'minimum_age',\n",
    "    'maximumage': 'maximum_age',\n",
    "    'numcentralcontacts': 'num_central_contacts'\n",
    "}, inplace=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "28a377d9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>nctid</th>\n",
       "      <th>orgstudyid</th>\n",
       "      <th>title</th>\n",
       "      <th>organization_fullname</th>\n",
       "      <th>lead_sponsor</th>\n",
       "      <th>collaborators</th>\n",
       "      <th>study_type</th>\n",
       "      <th>phase</th>\n",
       "      <th>overall_status</th>\n",
       "      <th>start_date</th>\n",
       "      <th>...</th>\n",
       "      <th>centralcontact_name</th>\n",
       "      <th>centralcontact_role</th>\n",
       "      <th>centralcontact_phone</th>\n",
       "      <th>centralcontact_phoneext</th>\n",
       "      <th>centralcontact_email</th>\n",
       "      <th>num_central_contacts</th>\n",
       "      <th>location_facility</th>\n",
       "      <th>location_city</th>\n",
       "      <th>location_state</th>\n",
       "      <th>location_country</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT03878979</td>\n",
       "      <td>J1923</td>\n",
       "      <td>Preoperative Immune Checkpoint Inhibitor Thera...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Bristol-Myers Squibb</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Johns Hopkins Sidney Kimmel Comprehensive Canc...</td>\n",
       "      <td>Baltimore</td>\n",
       "      <td>Maryland</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT04591379</td>\n",
       "      <td>REG-083-2020</td>\n",
       "      <td>Intratumoral Influenza Vaccine for Early Color...</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>University of Copenhagen</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>KÃ¸ge</td>\n",
       "      <td>Zealand</td>\n",
       "      <td>Denmark</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT06671379</td>\n",
       "      <td>SHR-A2009-301</td>\n",
       "      <td>A Randomized, Open-label, Multicenter, Phase I...</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Fei Qiu</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>0518-82342973</td>\n",
       "      <td>?</td>\n",
       "      <td>fei.qiu@hengrui.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Guangdong Provincial People's Hospital</td>\n",
       "      <td>Guangzhou</td>\n",
       "      <td>Guangdong</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT04361279</td>\n",
       "      <td>SIBP-02-03</td>\n",
       "      <td>A Phase III, Multicenter, Randomized, Double-b...</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>The First Affiliated Hospital of College of Me...</td>\n",
       "      <td>Hangzhou</td>\n",
       "      <td>?</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT05799079</td>\n",
       "      <td>VICCHEM2163</td>\n",
       "      <td>Phase 2 Study of Decitabine and Cedazuridine i...</td>\n",
       "      <td>Vanderbilt-Ingram Cancer Center</td>\n",
       "      <td>Sanjay Mohan</td>\n",
       "      <td>National Comprehensive Cancer Network, Taiho O...</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>RECRUITING</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>...</td>\n",
       "      <td>Vanderbilt-Ingram Services for Timely Access</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>800-811-8480</td>\n",
       "      <td>?</td>\n",
       "      <td>cip@vumc.org</td>\n",
       "      <td>?</td>\n",
       "      <td>Vanderbilt University/Ingram Cancer Center</td>\n",
       "      <td>Nashville</td>\n",
       "      <td>Tennessee</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT04164979</td>\n",
       "      <td>20195426</td>\n",
       "      <td>Phase 2 Study of Cabozantinib Combined With Pe...</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>University of California, Irvine</td>\n",
       "      <td>Exelixis</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>ACTIVE_NOT_RECRUITING</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>Orange</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>NCT00313079</td>\n",
       "      <td>HEMALL0003</td>\n",
       "      <td>A Phase I Study of mAb 216 With Chemotherapy f...</td>\n",
       "      <td>Stanford University</td>\n",
       "      <td>Steven E. Coutre</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>Stanford</td>\n",
       "      <td>California</td>\n",
       "      <td>United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT00005079</td>\n",
       "      <td>UCLA-9810046</td>\n",
       "      <td>Timing of Breast Cancer Surgery, Menstrual Cyc...</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>Jonsson Comprehensive Cancer Center</td>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>1999-01</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>Rebecca and John Moores UCSD Cancer Center, Jo...</td>\n",
       "      <td>La Jolla, Los Angeles</td>\n",
       "      <td>California, California</td>\n",
       "      <td>United States, United States</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT05108779</td>\n",
       "      <td>QLF32004-101</td>\n",
       "      <td>Phase Ia Clinical Study of Safety, Tolerabilit...</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>UNKNOWN</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>...</td>\n",
       "      <td>Jin Li</td>\n",
       "      <td>CONTACT</td>\n",
       "      <td>021-38804518</td>\n",
       "      <td>?</td>\n",
       "      <td>sunypclinicaltrial@163.com</td>\n",
       "      <td>?</td>\n",
       "      <td>Shanghai East Hospital</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>Shanghai</td>\n",
       "      <td>China</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT00398879</td>\n",
       "      <td>Perifosine 211</td>\n",
       "      <td>A Randomized Placebo-Controlled Study of Perif...</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>NaN</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>COMPLETED</td>\n",
       "      <td>2005-08</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>?</td>\n",
       "      <td>AOI Pharmaceuticals Investigative Site, AOI Ph...</td>\n",
       "      <td>Tucson, Beverly Hills, Deer Park, Monterey, Ne...</td>\n",
       "      <td>Arizona, California, California, California, C...</td>\n",
       "      <td>United States, United States, United States, U...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>10 rows Ã 44 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "         nctid      orgstudyid  \\\n",
       "0  NCT03878979           J1923   \n",
       "1  NCT04591379    REG-083-2020   \n",
       "2  NCT06671379   SHR-A2009-301   \n",
       "3  NCT04361279      SIBP-02-03   \n",
       "4  NCT05799079     VICCHEM2163   \n",
       "5  NCT04164979        20195426   \n",
       "6  NCT00313079      HEMALL0003   \n",
       "7  NCT00005079    UCLA-9810046   \n",
       "8  NCT05108779    QLF32004-101   \n",
       "9  NCT00398879  Perifosine 211   \n",
       "\n",
       "                                               title  \\\n",
       "0  Preoperative Immune Checkpoint Inhibitor Thera...   \n",
       "1  Intratumoral Influenza Vaccine for Early Color...   \n",
       "2  A Randomized, Open-label, Multicenter, Phase I...   \n",
       "3  A Phase III, Multicenter, Randomized, Double-b...   \n",
       "4  Phase 2 Study of Decitabine and Cedazuridine i...   \n",
       "5  Phase 2 Study of Cabozantinib Combined With Pe...   \n",
       "6  A Phase I Study of mAb 216 With Chemotherapy f...   \n",
       "7  Timing of Breast Cancer Surgery, Menstrual Cyc...   \n",
       "8  Phase Ia Clinical Study of Safety, Tolerabilit...   \n",
       "9  A Randomized Placebo-Controlled Study of Perif...   \n",
       "\n",
       "                               organization_fullname  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                    Vanderbilt-Ingram Cancer Center   \n",
       "5                   University of California, Irvine   \n",
       "6                                Stanford University   \n",
       "7                    National Cancer Institute (NCI)   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                        lead_sponsor  \\\n",
       "0  Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                        Zealand University Hospital   \n",
       "2       Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3          Shanghai Institute Of Biological Products   \n",
       "4                                       Sanjay Mohan   \n",
       "5                   University of California, Irvine   \n",
       "6                                   Steven E. Coutre   \n",
       "7                Jonsson Comprehensive Cancer Center   \n",
       "8                      Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                   AEterna Zentaris   \n",
       "\n",
       "                                       collaborators      study_type   phase  \\\n",
       "0                               Bristol-Myers Squibb  INTERVENTIONAL  PHASE2   \n",
       "1                           University of Copenhagen  INTERVENTIONAL  PHASE2   \n",
       "2                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "3                                                NaN  INTERVENTIONAL  PHASE3   \n",
       "4  National Comprehensive Cancer Network, Taiho O...  INTERVENTIONAL  PHASE2   \n",
       "5                                           Exelixis  INTERVENTIONAL  PHASE2   \n",
       "6                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "7                    National Cancer Institute (NCI)  INTERVENTIONAL  PHASE3   \n",
       "8                                                NaN  INTERVENTIONAL  PHASE1   \n",
       "9                                                NaN  INTERVENTIONAL  PHASE2   \n",
       "\n",
       "          overall_status  start_date  ...  \\\n",
       "0              COMPLETED  2019-07-08  ...   \n",
       "1              COMPLETED  2021-02-26  ...   \n",
       "2             RECRUITING  2024-11-29  ...   \n",
       "3              COMPLETED  2019-07-25  ...   \n",
       "4             RECRUITING  2024-01-29  ...   \n",
       "5  ACTIVE_NOT_RECRUITING  2020-02-04  ...   \n",
       "6              COMPLETED     2006-05  ...   \n",
       "7              COMPLETED     1999-01  ...   \n",
       "8                UNKNOWN  2021-11-09  ...   \n",
       "9              COMPLETED     2005-08  ...   \n",
       "\n",
       "                            centralcontact_name centralcontact_role  \\\n",
       "0                                           NaN                 NaN   \n",
       "1                                           NaN                 NaN   \n",
       "2                                       Fei Qiu             CONTACT   \n",
       "3                                           NaN                 NaN   \n",
       "4  Vanderbilt-Ingram Services for Timely Access             CONTACT   \n",
       "5                                           NaN                 NaN   \n",
       "6                                           NaN                 NaN   \n",
       "7                                           NaN                 NaN   \n",
       "8                                        Jin Li             CONTACT   \n",
       "9                                           NaN                 NaN   \n",
       "\n",
       "  centralcontact_phone centralcontact_phoneext        centralcontact_email  \\\n",
       "0                  NaN                     NaN                         NaN   \n",
       "1                  NaN                     NaN                         NaN   \n",
       "2        0518-82342973                       ?         fei.qiu@hengrui.com   \n",
       "3                  NaN                     NaN                         NaN   \n",
       "4         800-811-8480                       ?                cip@vumc.org   \n",
       "5                  NaN                     NaN                         NaN   \n",
       "6                  NaN                     NaN                         NaN   \n",
       "7                  NaN                     NaN                         NaN   \n",
       "8         021-38804518                       ?  sunypclinicaltrial@163.com   \n",
       "9                  NaN                     NaN                         NaN   \n",
       "\n",
       "  num_central_contacts                                  location_facility  \\\n",
       "0                    ?  Johns Hopkins Sidney Kimmel Comprehensive Canc...   \n",
       "1                    ?                        Zealand University Hospital   \n",
       "2                    ?             Guangdong Provincial People's Hospital   \n",
       "3                    ?  The First Affiliated Hospital of College of Me...   \n",
       "4                    ?         Vanderbilt University/Ingram Cancer Center   \n",
       "5                    ?  Chao Family Comprehensive Cancer Center, Unive...   \n",
       "6                    ?             Stanford University School of Medicine   \n",
       "7                    ?  Rebecca and John Moores UCSD Cancer Center, Jo...   \n",
       "8                    ?                             Shanghai East Hospital   \n",
       "9                    ?  AOI Pharmaceuticals Investigative Site, AOI Ph...   \n",
       "\n",
       "                                       location_city  \\\n",
       "0                                          Baltimore   \n",
       "1                                               KÃ¸ge   \n",
       "2                                          Guangzhou   \n",
       "3                                           Hangzhou   \n",
       "4                                          Nashville   \n",
       "5                                             Orange   \n",
       "6                                           Stanford   \n",
       "7                              La Jolla, Los Angeles   \n",
       "8                                           Shanghai   \n",
       "9  Tucson, Beverly Hills, Deer Park, Monterey, Ne...   \n",
       "\n",
       "                                      location_state  \\\n",
       "0                                           Maryland   \n",
       "1                                            Zealand   \n",
       "2                                          Guangdong   \n",
       "3                                                  ?   \n",
       "4                                          Tennessee   \n",
       "5                                         California   \n",
       "6                                         California   \n",
       "7                             California, California   \n",
       "8                                           Shanghai   \n",
       "9  Arizona, California, California, California, C...   \n",
       "\n",
       "                                    location_country  \n",
       "0                                      United States  \n",
       "1                                            Denmark  \n",
       "2                                              China  \n",
       "3                                              China  \n",
       "4                                      United States  \n",
       "5                                      United States  \n",
       "6                                      United States  \n",
       "7                       United States, United States  \n",
       "8                                              China  \n",
       "9  United States, United States, United States, U...  \n",
       "\n",
       "[10 rows x 44 columns]"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "a8e54541",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['nctid', 'orgstudyid', 'title', 'organization_fullname', 'lead_sponsor',\n",
       "       'collaborators', 'study_type', 'phase', 'overall_status', 'start_date',\n",
       "       'completion_date', 'primary_completion_date', 'study_first_submit_date',\n",
       "       'study_first_post_date', 'last_update_post_date', 'enrollment',\n",
       "       'eligibility_criteria', 'design_primary_purpose', 'brief_summary',\n",
       "       'detailed_description', 'sex', 'minimum_age', 'maximum_age', 'stdage',\n",
       "       'country', 'conditions', 'keywords', 'interventions_name',\n",
       "       'interventions_description', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'overall_officials_name', 'overall_officials_affiliation',\n",
       "       'oversight_has_dmc', 'centralcontact_name', 'centralcontact_role',\n",
       "       'centralcontact_phone', 'centralcontact_phoneext',\n",
       "       'centralcontact_email', 'num_central_contacts', 'location_facility',\n",
       "       'location_city', 'location_state', 'location_country'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 14,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "792e627c",
   "metadata": {},
   "source": [
    "Dropping unnecessary columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "a8ad7392",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop(['nctid', 'orgstudyid','title','centralcontact_name','centralcontact_role','centralcontact_phone','centralcontact_phoneext','centralcontact_email','num_central_contacts'], axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "5e1df37e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['organization_fullname', 'lead_sponsor', 'collaborators', 'study_type',\n",
       "       'phase', 'overall_status', 'start_date', 'completion_date',\n",
       "       'primary_completion_date', 'study_first_submit_date',\n",
       "       'study_first_post_date', 'last_update_post_date', 'enrollment',\n",
       "       'eligibility_criteria', 'design_primary_purpose', 'brief_summary',\n",
       "       'detailed_description', 'sex', 'minimum_age', 'maximum_age', 'stdage',\n",
       "       'country', 'conditions', 'keywords', 'interventions_name',\n",
       "       'interventions_description', 'primary_outcomes', 'secondary_outcomes',\n",
       "       'overall_officials_name', 'overall_officials_affiliation',\n",
       "       'oversight_has_dmc', 'location_facility', 'location_city',\n",
       "       'location_state', 'location_country'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 16,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9bdc7ca0",
   "metadata": {},
   "source": [
    "checking if the location of the organization and the location of the facility are the same to see correlation "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "a48244b2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>organization_fullname</th>\n",
       "      <th>location_facility</th>\n",
       "      <th>is_same</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>Sidney Kimmel Comprehensive Cancer Center at J...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>Zealand University Hospital</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</td>\n",
       "      <td>Guangdong Provincial People's Hospital</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Shanghai Institute Of Biological Products</td>\n",
       "      <td>The First Affiliated Hospital of College of Me...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Vanderbilt-Ingram Cancer Center</td>\n",
       "      <td>Vanderbilt University/Ingram Cancer Center</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>Chao Family Comprehensive Cancer Center, Unive...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>Stanford University School of Medicine</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>National Cancer Institute (NCI)</td>\n",
       "      <td>Rebecca and John Moores UCSD Cancer Center, Jo...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Qilu Pharmaceutical Co., Ltd.</td>\n",
       "      <td>Shanghai East Hospital</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>AEterna Zentaris</td>\n",
       "      <td>AOI Pharmaceuticals Investigative Site, AOI Ph...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Prism Pharma Co., Ltd.</td>\n",
       "      <td>Emory University / Winship Cancer Institute, U...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Martin-Luther-UniversitÃ¤t Halle-Wittenberg</td>\n",
       "      <td>Universitaetsklinikum Halle</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>University of Texas Southwestern Medical Center</td>\n",
       "      <td>University of Texas Southwestern Medical Center</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>Beijing Tsinghua Chang Gung Hospital</td>\n",
       "      <td>Beijing Tsinghua Chang Gung Hospital</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>National Institutes of Health Clinical Center ...</td>\n",
       "      <td>National Naval Medical Center, Warren Grant Ma...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>University Hospital, Basel, Switzerland</td>\n",
       "      <td>Carsten T. Viehl, MD, Urban Laffer, MD, Markus...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "      <td>St. Jude Children's Research Hospital</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>Emory University Winship Cancer Institute</td>\n",
       "      <td>Emory University Winship Cancer Institute</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>Dana-Farber Cancer Institute</td>\n",
       "      <td>Brigham and Women's Hospital, Dana Farber Canc...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>Juntendo Urayasu Hospital, St. Marianna Univer...</td>\n",
       "      <td>Juntendo Urayasu Hospital, St. Marianna Univer...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>Sunnybrook Health Sciences Centre</td>\n",
       "      <td>Sunnybrook Health Sciences Centre</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>Aarhus University Hospital</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>University Health Network, Toronto</td>\n",
       "      <td>Princess Margaret Cancer Centre</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>Cure&amp;Sure Biotech Co., LTD</td>\n",
       "      <td>Cancer Insititute and Hospital,Chinese Academy...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>GOG Foundation</td>\n",
       "      <td>CCOP - Western Regional, Arizona, CCOP - Chris...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>M.D. Anderson Cancer Center</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>Emory University Winship Cancer Institute, The...</td>\n",
       "      <td>Emory University Winship Cancer Institute, The...</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>Shenzhen Yangli Pharmaceutical Technology Co.,...</td>\n",
       "      <td>The 1st Affiliated Hospital of Henan Universit...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Dong-A University</td>\n",
       "      <td>Dong-A University</td>\n",
       "      <td>True</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>Sunshine Guojian Pharmaceutical (Shanghai) Co....</td>\n",
       "      <td>The 307 Hospital of People's Liberation Army, ...</td>\n",
       "      <td>False</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                organization_fullname  \\\n",
       "0   Sidney Kimmel Comprehensive Cancer Center at J...   \n",
       "1                         Zealand University Hospital   \n",
       "2        Suzhou Suncadia Biopharmaceuticals Co., Ltd.   \n",
       "3           Shanghai Institute Of Biological Products   \n",
       "4                     Vanderbilt-Ingram Cancer Center   \n",
       "5   Chao Family Comprehensive Cancer Center, Unive...   \n",
       "6              Stanford University School of Medicine   \n",
       "7                     National Cancer Institute (NCI)   \n",
       "8                       Qilu Pharmaceutical Co., Ltd.   \n",
       "9                                    AEterna Zentaris   \n",
       "10                             Prism Pharma Co., Ltd.   \n",
       "11         Martin-Luther-UniversitÃ¤t Halle-Wittenberg   \n",
       "12    University of Texas Southwestern Medical Center   \n",
       "13               Beijing Tsinghua Chang Gung Hospital   \n",
       "14  National Institutes of Health Clinical Center ...   \n",
       "15            University Hospital, Basel, Switzerland   \n",
       "16              St. Jude Children's Research Hospital   \n",
       "17          Emory University Winship Cancer Institute   \n",
       "18                       Dana-Farber Cancer Institute   \n",
       "19  Juntendo Urayasu Hospital, St. Marianna Univer...   \n",
       "20                  Sunnybrook Health Sciences Centre   \n",
       "21                         Aarhus University Hospital   \n",
       "22                 University Health Network, Toronto   \n",
       "23                         Cure&Sure Biotech Co., LTD   \n",
       "24                                     GOG Foundation   \n",
       "25                        M.D. Anderson Cancer Center   \n",
       "26  Emory University Winship Cancer Institute, The...   \n",
       "27  Shenzhen Yangli Pharmaceutical Technology Co.,...   \n",
       "28                                  Dong-A University   \n",
       "29  Sunshine Guojian Pharmaceutical (Shanghai) Co....   \n",
       "\n",
       "                                    location_facility is_same  \n",
       "0   Sidney Kimmel Comprehensive Cancer Center at J...    True  \n",
       "1                         Zealand University Hospital    True  \n",
       "2              Guangdong Provincial People's Hospital   False  \n",
       "3   The First Affiliated Hospital of College of Me...   False  \n",
       "4          Vanderbilt University/Ingram Cancer Center   False  \n",
       "5   Chao Family Comprehensive Cancer Center, Unive...    True  \n",
       "6              Stanford University School of Medicine    True  \n",
       "7   Rebecca and John Moores UCSD Cancer Center, Jo...   False  \n",
       "8                              Shanghai East Hospital   False  \n",
       "9   AOI Pharmaceuticals Investigative Site, AOI Ph...   False  \n",
       "10  Emory University / Winship Cancer Institute, U...   False  \n",
       "11                        Universitaetsklinikum Halle   False  \n",
       "12    University of Texas Southwestern Medical Center    True  \n",
       "13               Beijing Tsinghua Chang Gung Hospital    True  \n",
       "14  National Naval Medical Center, Warren Grant Ma...   False  \n",
       "15  Carsten T. Viehl, MD, Urban Laffer, MD, Markus...   False  \n",
       "16              St. Jude Children's Research Hospital    True  \n",
       "17          Emory University Winship Cancer Institute    True  \n",
       "18  Brigham and Women's Hospital, Dana Farber Canc...   False  \n",
       "19  Juntendo Urayasu Hospital, St. Marianna Univer...    True  \n",
       "20                  Sunnybrook Health Sciences Centre    True  \n",
       "21                                                NaN     NaN  \n",
       "22                    Princess Margaret Cancer Centre   False  \n",
       "23  Cancer Insititute and Hospital,Chinese Academy...   False  \n",
       "24  CCOP - Western Regional, Arizona, CCOP - Chris...   False  \n",
       "25                        M.D. Anderson Cancer Center    True  \n",
       "26  Emory University Winship Cancer Institute, The...    True  \n",
       "27  The 1st Affiliated Hospital of Henan Universit...   False  \n",
       "28                                  Dong-A University    True  \n",
       "29  The 307 Hospital of People's Liberation Army, ...   False  "
      ]
     },
     "execution_count": 17,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "from rapidfuzz import fuzz\n",
    "import re\n",
    "import pandas as pd\n",
    "\n",
    "# Cleaning function\n",
    "def clean_text(text):\n",
    "    if not isinstance(text, str):\n",
    "        return \"\"\n",
    "    text = text.lower()\n",
    "    text = re.sub(r'[^a-z0-9\\s]', '', text)  # remove punctuation\n",
    "    text = re.sub(r'\\s+', ' ', text).strip()  # normalize spaces\n",
    "    return text\n",
    "\n",
    "\n",
    "def fuzzy_match_and_replace(row, threshold=85):\n",
    "    org = row['organization_fullname']\n",
    "    loc = row['location_facility']\n",
    "    \n",
    "    if pd.isna(org) or pd.isna(loc):\n",
    "        return row  # skip if any is NaN\n",
    "\n",
    "    org_clean = clean_text(org)\n",
    "    loc_clean = clean_text(loc)\n",
    "    \n",
    "    score = fuzz.token_set_ratio(org_clean, loc_clean)\n",
    "    \n",
    "    if score >= threshold:\n",
    "        # Choose the longer original string (not cleaned)\n",
    "        unified_name = org if len(org) >= len(loc) else loc\n",
    "        row['organization_fullname'] = unified_name\n",
    "        row['location_facility'] = unified_name\n",
    "        row['is_same'] = True\n",
    "    else:\n",
    "        row['is_same'] = False\n",
    "\n",
    "    return row\n",
    "\n",
    "# Apply to the whole DataFrame\n",
    "df = df.apply(fuzzy_match_and_replace, axis=1)\n",
    "\n",
    "# View subset\n",
    "subset = df[['organization_fullname', 'location_facility', 'is_same']]\n",
    "subset.head(30)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "9f1d03fc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "is_same\n",
       "False    34724\n",
       "True     22691\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['is_same'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "0c18d87e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "collaborators                    37402\n",
       "keywords                         21799\n",
       "detailed_description             19102\n",
       "secondary_outcomes               10646\n",
       "overall_officials_affiliation    10398\n",
       "overall_officials_name           10274\n",
       "interventions_description         8983\n",
       "location_city                     3272\n",
       "location_state                    3272\n",
       "location_facility                 3272\n",
       "location_country                  3272\n",
       "is_same                           3272\n",
       "country                           3272\n",
       "primary_outcomes                  2693\n",
       "conditions                           1\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "interventions_name                   0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "organization_fullname                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "phase                                0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "31ebca20",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "overall_status\n",
       "COMPLETED                  22177\n",
       "TERMINATED                 18004\n",
       "RECRUITING                  7908\n",
       "UNKNOWN                     6200\n",
       "ACTIVE_NOT_RECRUITING       4306\n",
       "NOT_YET_RECRUITING          1998\n",
       "ENROLLING_BY_INVITATION       94\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 20,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['overall_status'].value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "7126ada5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'collaborators', 'completion_date', 'conditions',\n",
       "       'country', 'design_primary_purpose', 'detailed_description',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'is_same', 'keywords', 'last_update_post_date',\n",
       "       'lead_sponsor', 'location_city', 'location_country',\n",
       "       'location_facility', 'location_state', 'maximum_age', 'minimum_age',\n",
       "       'organization_fullname', 'overall_officials_affiliation',\n",
       "       'overall_officials_name', 'overall_status', 'oversight_has_dmc',\n",
       "       'phase', 'primary_completion_date', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'start_date', 'stdage',\n",
       "       'study_first_post_date', 'study_first_submit_date', 'study_type'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 21,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d5842b44",
   "metadata": {},
   "source": [
    "Checking what influence does collaborators have on completed/terminated"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "eae71127",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "When 'collaborators' is NULL:\n",
      "overall_status\n",
      "COMPLETED     12701\n",
      "TERMINATED    11752\n",
      "Name: count, dtype: int64\n",
      "Total: 24453\n",
      "\n",
      "When 'collaborators' is NOT NULL:\n",
      "overall_status\n",
      "COMPLETED     9476\n",
      "TERMINATED    6252\n",
      "Name: count, dtype: int64\n",
      "Total: 15728\n"
     ]
    }
   ],
   "source": [
    "# Case 1: collaborators is NULL and status is COMPLETED or TERMINATED\n",
    "null_mask = df['collaborators'].isnull()\n",
    "null_and_status = df[null_mask & df['overall_status'].isin(['COMPLETED', 'TERMINATED'])]\n",
    "print(\"When 'collaborators' is NULL:\")\n",
    "print(null_and_status['overall_status'].value_counts())\n",
    "print(f\"Total: {null_and_status.shape[0]}\\n\")\n",
    "\n",
    "# Case 2: collaborators is NOT NULL and status is COMPLETED or TERMINATED\n",
    "not_null_mask = df['collaborators'].notnull()\n",
    "not_null_and_status = df[not_null_mask & df['overall_status'].isin(['COMPLETED', 'TERMINATED'])]\n",
    "print(\"When 'collaborators' is NOT NULL:\")\n",
    "print(not_null_and_status['overall_status'].value_counts())\n",
    "print(f\"Total: {not_null_and_status.shape[0]}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "79e74313",
   "metadata": {},
   "source": [
    "The general data distribution shows no such trend as having an influence on the overall status as compeleted/terminated, so we can drop it"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "07441ab7",
   "metadata": {},
   "outputs": [],
   "source": [
    "df.drop('collaborators', axis=1, inplace=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "fa3b11a3",
   "metadata": {},
   "source": [
    "Checking for data types and their conversion (dates). Some fields have missing days, so I am manually setting day as 15\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "9dd4bf9d",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(60687, 35)"
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "ed026f27",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>conditions</th>\n",
       "      <th>country</th>\n",
       "      <th>design_primary_purpose</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>interventions_description</th>\n",
       "      <th>interventions_name</th>\n",
       "      <th>...</th>\n",
       "      <th>phase</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>primary_outcomes</th>\n",
       "      <th>secondary_outcomes</th>\n",
       "      <th>sex</th>\n",
       "      <th>start_date</th>\n",
       "      <th>stdage</th>\n",
       "      <th>study_first_post_date</th>\n",
       "      <th>study_first_submit_date</th>\n",
       "      <th>study_type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Nivolumab, also known as (Bristol Myers Squibb...</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Head and Neck Squamous Cell Carcinoma, Head an...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This research is being done to see if it is sa...</td>\n",
       "      <td>Inclusion:\\n\\nCohort 1: Subjects must have his...</td>\n",
       "      <td>26</td>\n",
       "      <td>One dose of Nivolumab 480mg given four weeks p...</td>\n",
       "      <td>Nivolumab 480mg and surgical resection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Safety as Measured by Number of Participants W...</td>\n",
       "      <td>Major Pathologic Response Rate; Progression Fr...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-03-18</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The aim of this explorative phase II clinical ...</td>\n",
       "      <td>2021-11-01</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an explorative phase 2 clinical trial ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must be ment...</td>\n",
       "      <td>10</td>\n",
       "      <td>Intratumoral application of an unattenuated in...</td>\n",
       "      <td>Influenza Vaccines</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-09-22</td>\n",
       "      <td>Safety - Adverse reactions are classified acco...</td>\n",
       "      <td>Efficacy - local immunological changes</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-10-19</td>\n",
       "      <td>2020-09-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>This study was a randomized, controlled, open-...</td>\n",
       "      <td>2027-06</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...</td>\n",
       "      <td>500</td>\n",
       "      <td>SHR-A2009 monotherapy ï¼SHR-A2009 will be admin...</td>\n",
       "      <td>SHR-A2009 monotherapy, platinum-based dual-age...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2026-12</td>\n",
       "      <td>Progression-free survival (PFS) assessed by BI...</td>\n",
       "      <td>overall survival (OS); Progression Free Surviv...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-11-04</td>\n",
       "      <td>2024-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>This is a randomised, double-blind, positive d...</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Diffuse Large B-Cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* 18-75 years old, male...</td>\n",
       "      <td>421</td>\n",
       "      <td>Injectionï¼100mg/10ml; Injectionï¼100mg/10ml</td>\n",
       "      <td>SIBP-02, Rituximab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Overall Response Rate (ORR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-04-24</td>\n",
       "      <td>2020-04-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>This phase II trial tests how well decitabine ...</td>\n",
       "      <td>2029-03</td>\n",
       "      <td>Recurrent Acute Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt;= 18 years at t...</td>\n",
       "      <td>51</td>\n",
       "      <td>Given by mouth; Given by mouth; Given by mouth...</td>\n",
       "      <td>Venetoclax, Decitabine, Cedazuridine, Bone Mar...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-03</td>\n",
       "      <td>Composite complete response (CR) rate (CR/comp...</td>\n",
       "      <td>Rate of partial response (PR) following treatm...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-04-05</td>\n",
       "      <td>2023-03-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>This is a phase 2 single-arm, open-label clini...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Gastric Adenocarcinoma, GastroEsophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment on study will be administered in 21 ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must have hi...</td>\n",
       "      <td>20</td>\n",
       "      <td>Given PO; Given IV</td>\n",
       "      <td>Cabozantinib, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-11-25</td>\n",
       "      <td>Percentage of Participants with Progression-fr...</td>\n",
       "      <td>Percentage of Grade 3-5 Adverse Events; Overal...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>2019-11-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>A phase I trial in patients with relapsed or r...</td>\n",
       "      <td>2009-07</td>\n",
       "      <td>Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n3.1.1 Age Patients must...</td>\n",
       "      <td>9</td>\n",
       "      <td>Dosage: 1.25mg/kg intravenous with dose escala...</td>\n",
       "      <td>MAb 216, Vincristine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2009-02</td>\n",
       "      <td>In this phase I study the endpoint is the dete...</td>\n",
       "      <td>A decrease in leukemic blasts. The study will ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-04-11</td>\n",
       "      <td>2006-04-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>RATIONALE: The timing of breast cancer surgery...</td>\n",
       "      <td>2004-10</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine if the timing of br...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>conventional surgery</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-01</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2000-04-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>To determine the safety, tolerability, and rec...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Advanced Tumor</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age: 18-75 years old...</td>\n",
       "      <td>40</td>\n",
       "      <td>In the phase, five dose groups were proposed.T...</td>\n",
       "      <td>QLF32004</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Dose-Limiting Toxicity (DLT); Maximum Tolerate...</td>\n",
       "      <td>Treatment-Emergent Adverse Event (TEAE); Maxim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-11-05</td>\n",
       "      <td>2021-10-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>2011-10</td>\n",
       "      <td>Colon Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. In the opinion of th...</td>\n",
       "      <td>381</td>\n",
       "      <td>Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...</td>\n",
       "      <td>Perifosine, Capecitabine, Perifosine Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2010-12</td>\n",
       "      <td>Effects of perifosine on time to progression</td>\n",
       "      <td>Toxicity; Comparison of time to progression to...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2005-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-14</td>\n",
       "      <td>2006-11-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>Acute Myeloid Leukemia, Chronic Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>Inclusion Criteria\\n\\n1. Patients 18 years or ...</td>\n",
       "      <td>49</td>\n",
       "      <td>PRI-724; PRI-724 in combination with dasatinib...</td>\n",
       "      <td>PRI-724, PRI-724, PRI-724</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>DLT (Dose Limiting Toxicity)</td>\n",
       "      <td>Preliminary Efficacy Endpoints</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-07</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2012-05-25</td>\n",
       "      <td>2012-05-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Longterm disease-free survival (DFS) of older ...</td>\n",
       "      <td>2017-09</td>\n",
       "      <td>AML</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Subjects must provid...</td>\n",
       "      <td>16</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tranylcypromine, Tretinoin</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-09</td>\n",
       "      <td>Analysis of the cumulative response rate (CR,C...</td>\n",
       "      <td>number of participants with adverse events as ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-10-10</td>\n",
       "      <td>2014-09-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>RATIONALE: Combinations of biological substanc...</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Leukemia, Myelodysplastic Syndromes, Blastic P...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the maximum tolerat...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...</td>\n",
       "      <td>11</td>\n",
       "      <td>Intravenously via a 3 cc plastic syringe as a ...</td>\n",
       "      <td>DT388IL3</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Overall Response Rate (CR+PR+SD): Percentage o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2013-05</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-09</td>\n",
       "      <td>2006-11-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>The purpose of this conversion therapy study i...</td>\n",
       "      <td>2024-04-30</td>\n",
       "      <td>NSCLC, Stage III</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>30</td>\n",
       "      <td>Tislelizumab: 200mg, IV, day 1 of each 21-day ...</td>\n",
       "      <td>Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-02-29</td>\n",
       "      <td>Resectability rate</td>\n",
       "      <td>Major pathological response rate (MPR); Pathol...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-03-12</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-11-10</td>\n",
       "      <td>2022-11-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>RATIONALE: MS-275 may stop the growth of cance...</td>\n",
       "      <td>2008-10</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the dose-limiting t...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>75</td>\n",
       "      <td>NaN</td>\n",
       "      <td>entinostat</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-04</td>\n",
       "      <td>Dose-limiting toxicities and maximum tolerated...</td>\n",
       "      <td>Acetylation of histones in peripheral blood; T...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2001-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2001-07-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>The study is a feasibility and validation stud...</td>\n",
       "      <td>2009-01</td>\n",
       "      <td>Colonic Neoplasms</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Colon cancer at any s...</td>\n",
       "      <td>192</td>\n",
       "      <td>After careful mobilization of the affected col...</td>\n",
       "      <td>Sentinel lymph node procedure, Bone marrow asp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2009-01</td>\n",
       "      <td>To assess the extent of upstaging due to the S...</td>\n",
       "      <td>To evaluate the accuracy of the SLN procedure ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2000-05</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2009-01-22</td>\n",
       "      <td>2009-01-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>This study is a phase I study designed to eval...</td>\n",
       "      <td>2031-01</td>\n",
       "      <td>Acute Lymphoblastic Leukemia, Recurrent Acute ...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment will include a single course of lymp...</td>\n",
       "      <td>Collection and Manufacturing Eligibility\\n\\nIn...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV; IV; IV; CAR T cell infusion will be given ...</td>\n",
       "      <td>Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2030-01</td>\n",
       "      <td>Recommended phase 2 dose (RP2D) of CD19-CD22-C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-05</td>\n",
       "      <td>CHILD, ADULT</td>\n",
       "      <td>2025-01-16</td>\n",
       "      <td>2025-01-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>This is an open-label (doctors and patients kn...</td>\n",
       "      <td>2015-11</td>\n",
       "      <td>Lymphoma, B-Cell, Follicular Lymphoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This study will assess whether adding bortezom...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tissue diagnosis of a...</td>\n",
       "      <td>37</td>\n",
       "      <td>Bortezomib 1.6 mg/mÂ² given on days 1 and 8; Ri...</td>\n",
       "      <td>Bortezomib, Rituximab, Doxorubicin, Cyclophosp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2015-11</td>\n",
       "      <td>Maximal Tolerated Doses of Bortezomib and Vinc...</td>\n",
       "      <td>An Estimate of the Overall Response Rate (ORR)...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2008-02</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2008-03-12</td>\n",
       "      <td>2008-02-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>This research is being done to compare rates o...</td>\n",
       "      <td>2028-06-01</td>\n",
       "      <td>Metastatic Breast Cancer, Chemotherapy-induced...</td>\n",
       "      <td>United States</td>\n",
       "      <td>SUPPORTIVE_CARE</td>\n",
       "      <td>This study is a prospective, controlled, pivot...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Men and women with a ...</td>\n",
       "      <td>120</td>\n",
       "      <td>Cap attached to coolant lines connected to a r...</td>\n",
       "      <td>Paxman Scalp Cooling System, Eribulin, Sacituz...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-06-01</td>\n",
       "      <td>Hair Loss Rate</td>\n",
       "      <td>Change in Patient Reported Quality of Life; Ch...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-10-07</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-03</td>\n",
       "      <td>2021-07-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>The purpose of this study is to assess the saf...</td>\n",
       "      <td>2024-10</td>\n",
       "      <td>Non-squamous Non-small-cell Lung Cancer, EGFR ...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Have a histologicall...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV infusion Q3W; Oral capsule once daily; IV i...</td>\n",
       "      <td>Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-31</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by B...</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by i...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-02-28</td>\n",
       "      <td>2022-02-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>This is a single-center, single-arm, open-labe...</td>\n",
       "      <td>2023-07-06</td>\n",
       "      <td>Neuroendocrine Tumors</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Adults (males or fema...</td>\n",
       "      <td>17</td>\n",
       "      <td>Avelumab will be administered intravenously as...</td>\n",
       "      <td>Avelumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-07-26</td>\n",
       "      <td>Overall response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-11-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-09-11</td>\n",
       "      <td>2017-08-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>The investigartors will conduct a randomized, ...</td>\n",
       "      <td>2032-02-01</td>\n",
       "      <td>Non-Muscle Invasive Bladder Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tumour recurrence aft...</td>\n",
       "      <td>272</td>\n",
       "      <td>Chemoablation</td>\n",
       "      <td>Mitomycin c</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2029-02-01</td>\n",
       "      <td>Two-year Recurrence Free Survival</td>\n",
       "      <td>Five-year RFS; Number of patients in need of a...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-24</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-01-17</td>\n",
       "      <td>2025-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>The purpose of this study is to see if using P...</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Pancreatic Ductal Carcinoma, Advanced Cancer, ...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PDO is a three-dimensional experimental model ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 years or over...</td>\n",
       "      <td>25</td>\n",
       "      <td>Cobimetinib is an antineoplastic agent and sel...</td>\n",
       "      <td>Cobimetinib, Ponatinib, Brigatinib, Colchicine...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Objective response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-02-06</td>\n",
       "      <td>2025-02-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>To evaluate the safety and effectiveness of au...</td>\n",
       "      <td>2019-11</td>\n",
       "      <td>Liver Cancer, Pancreatic Adenocarcinoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Able to read and und...</td>\n",
       "      <td>20</td>\n",
       "      <td>vaccination of autologous gp96 derived from tu...</td>\n",
       "      <td>autologous gp96 vaccination</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-11</td>\n",
       "      <td>blood count; blood count; blood count; blood c...</td>\n",
       "      <td>Disease-free survival; overall survive; change...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-05-07</td>\n",
       "      <td>2014-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>RATIONALE: Radiation therapy uses high-energy ...</td>\n",
       "      <td>?</td>\n",
       "      <td>Cervical Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the toxicity of rad...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically p...</td>\n",
       "      <td>40</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cisplatin, paclitaxel, brachytherapy, radiatio...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2007-01</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-11</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>1999-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>To learn if sacituzumab govitecan and pembroli...</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary Objective:\\n\\nâ¢ To determine the effic...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Female or male patie...</td>\n",
       "      <td>25</td>\n",
       "      <td>Given by IV (vein); Given by IV (vein)</td>\n",
       "      <td>Sacituzumab Govitecan, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Incidence of Adverse Events, Graded According ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-05-23</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-01-09</td>\n",
       "      <td>2022-12-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>The goal of this clinical research study is to...</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>Erlotinib hydrochloride is designed to block t...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female patie...</td>\n",
       "      <td>303</td>\n",
       "      <td>150 mg by mouth daily; Tablet by mouth daily</td>\n",
       "      <td>Erlotinib, Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer-free Survival in Participants Rece...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-11-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-22</td>\n",
       "      <td>2006-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>A Phase 1/2 Dose Escalation and Expansion Stud...</td>\n",
       "      <td>2025-04-30</td>\n",
       "      <td>ER+, HER2- Advanced Breast Cancer, Metastatic ...</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a phase â /â¡, open-label study of TFX06...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. voluntary participat...</td>\n",
       "      <td>74</td>\n",
       "      <td>TFX06 tablet taken orally</td>\n",
       "      <td>TFX06 tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Recommended phase 2 Dose (RP2D); Disease Contr...</td>\n",
       "      <td>Incidence of Treatment-Emergent Adverse Events...</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2023-04-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-07-03</td>\n",
       "      <td>2023-06-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Topical photodynamic therapy with methyl-amino...</td>\n",
       "      <td>2013-09</td>\n",
       "      <td>Nodular Basal Cell Carcinoma</td>\n",
       "      <td>Korea, Republic of</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Basal cell carcinoma (BCC) is the most common ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* patient's request for...</td>\n",
       "      <td>34</td>\n",
       "      <td>AFL was performed using a 2940-nm Er:YAG ablat...</td>\n",
       "      <td>Er:YAG AFL-PDT, MAL-PDT</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-02</td>\n",
       "      <td>Difference the efficacy between Er:YAG AFL-PDT...</td>\n",
       "      <td>Difference of the cosmetic outcomes between Er...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2011-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2013-12-23</td>\n",
       "      <td>2013-11-29</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>The purpose of this study is to evaluate the p...</td>\n",
       "      <td>2019-10-31</td>\n",
       "      <td>CD20 Positive B Cell NHL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a multi-center, randomized, double-bli...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Histological examinat...</td>\n",
       "      <td>60</td>\n",
       "      <td>Monoclonal antibodies, 100mg/10ml per injectio...</td>\n",
       "      <td>304 injection, rituximab injection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-30</td>\n",
       "      <td>AUC [0-t]; AUC [0-â]; Cmax</td>\n",
       "      <td>tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2018-12-18</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-06-10</td>\n",
       "      <td>2019-06-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>The purpose of the study is to address the fol...</td>\n",
       "      <td>2024-03</td>\n",
       "      <td>Triple Negative Breast Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed histo...</td>\n",
       "      <td>49</td>\n",
       "      <td>The PD-1 inhibitor Sintilimab 200mg for intrav...</td>\n",
       "      <td>Sintilimab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-12</td>\n",
       "      <td>Pathologic Complete Response (pCR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2021-03</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2021-03-22</td>\n",
       "      <td>2021-03-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Study of elotuzumab in combination with pomali...</td>\n",
       "      <td>2020-06-12</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>For more information regarding BMS clinical tr...</td>\n",
       "      <td>74</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Elotuzumab, Pomalidomide, Dexamethasone, Nivol...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-07-29</td>\n",
       "      <td>Progression Free Survival (PFS); Objective Res...</td>\n",
       "      <td>Objective Response Rate (ORR); Progression Fre...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-02-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-11-24</td>\n",
       "      <td>2015-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>RATIONALE: CT-322 may stop the growth of solid...</td>\n",
       "      <td>2009-02</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>DISEASE CHARACTERISTICS\\n\\n* Histologically pr...</td>\n",
       "      <td>40</td>\n",
       "      <td>IV solution, weekly or bi-weekly</td>\n",
       "      <td>CT-322</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-11</td>\n",
       "      <td>Safety and tolerability of CT-322</td>\n",
       "      <td>To evaluate the pharmacokinetics of CT-322 in ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-09-11</td>\n",
       "      <td>2006-09-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>This is a single-arm, single-center, open-labe...</td>\n",
       "      <td>2025-12-31</td>\n",
       "      <td>B-cell Acute Lymphoblastic Leukemia, B-ALL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Although the anti-CD19 CAR-T cell therapies ha...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female, aged...</td>\n",
       "      <td>30</td>\n",
       "      <td>UCAR-T Cellswill be administered by vein. The ...</td>\n",
       "      <td>UCAR-T Cells</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Dose-limiting toxicity (DLT); Incidence of Tre...</td>\n",
       "      <td>Persistence of CAR-T cells; Objective response...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-12-05</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-12-06</td>\n",
       "      <td>2022-11-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>The purpose of this study is to determine if t...</td>\n",
       "      <td>2024-08-07</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Croatia, Greece, United States, Argentina, Jap...</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>The study consists of 3 phases: Screening Phas...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Participant must have...</td>\n",
       "      <td>706</td>\n",
       "      <td>Participants will receive velcade 1.3 mg/m\\^2,...</td>\n",
       "      <td>Velcade, Melphalan, Prednisone, Daratumumab IV...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2017-11-21</td>\n",
       "      <td>Progression Free Survival (PFS)</td>\n",
       "      <td>Overall Response Rate (ORR); Percentage of Par...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-12-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-07-21</td>\n",
       "      <td>2014-07-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>This study is examining a chemotherapy regimen...</td>\n",
       "      <td>2022-02-11</td>\n",
       "      <td>Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age less than or equ...</td>\n",
       "      <td>20</td>\n",
       "      <td>Fludarabine: 30 mg/m2 daily for 5 days; Busulf...</td>\n",
       "      <td>Fludarabine, Busulfan, Rabbit ATG, Methotrexate</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-07</td>\n",
       "      <td>Number of patients who are surviving at 100-Da...</td>\n",
       "      <td>Time to marrow engraftment; Assessing all subj...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-09-06</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2016-09-28</td>\n",
       "      <td>2016-08-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>This is a single-center, single-arm, phase Ib/...</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>NMIBC</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age â¥18 years old, b...</td>\n",
       "      <td>58</td>\n",
       "      <td>SHR-1501, instillationï¼SHR-2005, instillation</td>\n",
       "      <td>SHR-1501+SHR-2005</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>Phase I : Incidence of dose limiting toxicitie...</td>\n",
       "      <td>Phase I : CR rate at 3 months; Phase II : Inci...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-09-19</td>\n",
       "      <td>2024-09-05</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>This is an open-label, multicenter, dose-escal...</td>\n",
       "      <td>2019-03</td>\n",
       "      <td>Acute Myeloid Leukemia, Acute Myelogenous Leuk...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n* Single agent (SA)...</td>\n",
       "      <td>94</td>\n",
       "      <td>FT-1101 will be supplied as 5 mg, 20 mg or 100...</td>\n",
       "      <td>FT-1101, Azacitidine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-03</td>\n",
       "      <td>Maximum Tolerated Dose (MTD); Dose Limiting To...</td>\n",
       "      <td>Area under the plasma concentration versus tim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-09-07</td>\n",
       "      <td>2015-09-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Dual center, single arm, two-stage, non-blinde...</td>\n",
       "      <td>2019-12-04</td>\n",
       "      <td>Glioblastoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* At least 18 years of ...</td>\n",
       "      <td>35</td>\n",
       "      <td>10mg/kg; 670mg/m2</td>\n",
       "      <td>Bevacizumab, TH-302</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-01-04</td>\n",
       "      <td>Number of Patients With Adverse Events</td>\n",
       "      <td>Progression Free Survival</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-05</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-01-19</td>\n",
       "      <td>2015-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy, such as...</td>\n",
       "      <td>2009-02-10</td>\n",
       "      <td>Head and Neck Cancer</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically o...</td>\n",
       "      <td>34</td>\n",
       "      <td>NaN</td>\n",
       "      <td>carboplatin, cisplatin, gemcitabine hydrochloride</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2008-09-29</td>\n",
       "      <td>Objective response measured by RECIST criteria...</td>\n",
       "      <td>Toxicity assessed by NCI CTC v2.0; Overall sur...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2003-10-27</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2004-03-09</td>\n",
       "      <td>2004-03-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>The purposes of this study are to determine th...</td>\n",
       "      <td>?</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Definition: The phase 2 study will provide imp...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Gemcitabine, Carboplatin, LY900003</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2002-06</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2002-08-06</td>\n",
       "      <td>2002-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>The main purpose of this Phase 1/2 study is to...</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>Small-cell Lung Cancer</td>\n",
       "      <td>Puerto Rico, United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n1. Patient is able ...</td>\n",
       "      <td>68</td>\n",
       "      <td>Administered IV; Administered IV</td>\n",
       "      <td>Pegzilarginase, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>1. Phase 1: Incidence of treatment-related adv...</td>\n",
       "      <td>Objective Response Rate; Clinical Benefit Rate...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-12-21</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-12-13</td>\n",
       "      <td>2017-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2013-09</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>HEALTH_SERVICES_RESEARCH</td>\n",
       "      <td>This study will test the separate and combined...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients aged 50-75 y...</td>\n",
       "      <td>569</td>\n",
       "      <td>Physicians at these clinics will participate i...</td>\n",
       "      <td>Physician Intervention, Physician and Patient ...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>2013-07</td>\n",
       "      <td>Colorectal Cancer (CRC) Screening Completion; ...</td>\n",
       "      <td>Provider Recommendation of CRC Screening</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-04</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-04-14</td>\n",
       "      <td>2010-04-12</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Maintenance durvalumab (MEDI4736) and olaparib...</td>\n",
       "      <td>2026-12</td>\n",
       "      <td>Small Cell Lung Carcinoma</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria Pre-Screening:\\n\\n* Newly d...</td>\n",
       "      <td>29</td>\n",
       "      <td>1500 mg i.v. Q4W; 300 mg BID orally</td>\n",
       "      <td>Durvalumab, Olaparib</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-09</td>\n",
       "      <td>Progression-free survival (PFS)</td>\n",
       "      <td>Incidence, severity and grading of adverse eve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-05-17</td>\n",
       "      <td>2024-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>There is no muture method to treat EGFR 20 ins...</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Lung cancer is one of the most common types of...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nParticipant must have h...</td>\n",
       "      <td>20</td>\n",
       "      <td>Osimertinib, 80mg, oral daily; bevacizumab (av...</td>\n",
       "      <td>Osimertinib Oral Tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-07-31</td>\n",
       "      <td>Progression free survival</td>\n",
       "      <td>Objective Response Rate (ORR); Overall Surviva...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-07-23</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>This is a randomized, open-label, phase 2 stud...</td>\n",
       "      <td>2027-02</td>\n",
       "      <td>Glioblastoma, IDH-wildtype</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a randomized, open-label phase 2 study...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>54</td>\n",
       "      <td>Ropidoxuridine is administered daily, 5 days a...</td>\n",
       "      <td>Ropidoxuridine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-08</td>\n",
       "      <td>Number of patients treated with oral ropidoxur...</td>\n",
       "      <td>Overall survival at 12 months; Radiographic Re...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-09-02</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-04-11</td>\n",
       "      <td>2024-03-24</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>From Protocol v3.0 dated 16Jun2022. This is an...</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Melanoma (Skin), Non-Small-Cell Lung Carcinoma</td>\n",
       "      <td>Spain, Belgium, United Kingdom</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Overall Study Design:\\n\\nâ¢ This is an open-lab...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nMain Inclusion Criteria...</td>\n",
       "      <td>34</td>\n",
       "      <td>Priming phase including 1 GAd-PEV administrati...</td>\n",
       "      <td>GAd-PEV, MVA-PEV</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Safety and tolerability: incidence of treatmen...</td>\n",
       "      <td>RP2D confirmation 2. Clinical efficacy:; Clini...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-06-11</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-04</td>\n",
       "      <td>2021-07-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>The proposed study will evaluate whether the c...</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Italy</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This phase III study represents a prospective ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt; 65 year old an...</td>\n",
       "      <td>511</td>\n",
       "      <td>Induction therapy:\\n\\n9 courses with weekly VE...</td>\n",
       "      <td>Bortezomib, Melphalan, Prednisone, Thalidomide...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2014-07</td>\n",
       "      <td>Determine whether the V-MPT combination improv...</td>\n",
       "      <td>Determine whether the VMPT combination improve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05</td>\n",
       "      <td>OLDER_ADULT</td>\n",
       "      <td>2010-02-05</td>\n",
       "      <td>2010-02-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>Extranodal NK/T-cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Previous study has confirmed the efficacy of a...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nHistopathology and immu...</td>\n",
       "      <td>20</td>\n",
       "      <td>200mg d1,ivdrip, repeated every 3 weeks; 10mg ...</td>\n",
       "      <td>Sintilimab, Decitabine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>complete response rate</td>\n",
       "      <td>overall response rate; 1-year progression free...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-04-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-02-21</td>\n",
       "      <td>2020-02-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>The purpose of this study is to evaluate the i...</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>Esophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed or re...</td>\n",
       "      <td>22</td>\n",
       "      <td>15 mCi 11C-choline will be administered intrav...</td>\n",
       "      <td>C11-Choline</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-08</td>\n",
       "      <td>To evaluate our ability to obtain reliable and...</td>\n",
       "      <td>Perform semi-quantitative analysis of tracer u...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-01-18</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>50 rows Ã 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        brief_summary completion_date  \\\n",
       "0   Nivolumab, also known as (Bristol Myers Squibb...      2023-10-17   \n",
       "1   The aim of this explorative phase II clinical ...      2021-11-01   \n",
       "2   This study was a randomized, controlled, open-...         2027-06   \n",
       "3   This is a randomised, double-blind, positive d...      2022-05-20   \n",
       "4   This phase II trial tests how well decitabine ...         2029-03   \n",
       "5   This is a phase 2 single-arm, open-label clini...      2024-12-30   \n",
       "6   A phase I trial in patients with relapsed or r...         2009-07   \n",
       "7   RATIONALE: The timing of breast cancer surgery...         2004-10   \n",
       "8   To determine the safety, tolerability, and rec...      2024-12-30   \n",
       "9   This is an exploratory phase 2, randomized pla...         2011-10   \n",
       "10  PRI-724 is a new investigational drug being st...      2016-12-30   \n",
       "11  Longterm disease-free survival (DFS) of older ...         2017-09   \n",
       "12  RATIONALE: Combinations of biological substanc...      2017-07-27   \n",
       "13  The purpose of this conversion therapy study i...      2024-04-30   \n",
       "14  RATIONALE: MS-275 may stop the growth of cance...         2008-10   \n",
       "15  The study is a feasibility and validation stud...         2009-01   \n",
       "16  This study is a phase I study designed to eval...         2031-01   \n",
       "17  This is an open-label (doctors and patients kn...         2015-11   \n",
       "18  This research is being done to compare rates o...      2028-06-01   \n",
       "19  The purpose of this study is to assess the saf...         2024-10   \n",
       "20  This is a single-center, single-arm, open-labe...      2023-07-06   \n",
       "21  The investigartors will conduct a randomized, ...      2032-02-01   \n",
       "22  The purpose of this study is to see if using P...      2028-02-17   \n",
       "23  To evaluate the safety and effectiveness of au...         2019-11   \n",
       "24  RATIONALE: Radiation therapy uses high-energy ...               ?   \n",
       "25  To learn if sacituzumab govitecan and pembroli...      2026-12-31   \n",
       "26  The goal of this clinical research study is to...      2018-06-04   \n",
       "27  A Phase 1/2 Dose Escalation and Expansion Stud...      2025-04-30   \n",
       "28  Topical photodynamic therapy with methyl-amino...         2013-09   \n",
       "29  The purpose of this study is to evaluate the p...      2019-10-31   \n",
       "30  The purpose of the study is to address the fol...         2024-03   \n",
       "31  Study of elotuzumab in combination with pomali...      2020-06-12   \n",
       "32  RATIONALE: CT-322 may stop the growth of solid...         2009-02   \n",
       "33  This is a single-arm, single-center, open-labe...      2025-12-31   \n",
       "34  The purpose of this study is to determine if t...      2024-08-07   \n",
       "35  This study is examining a chemotherapy regimen...      2022-02-11   \n",
       "36  This is a single-center, single-arm, phase Ib/...      2027-10-01   \n",
       "37  This is an open-label, multicenter, dose-escal...         2019-03   \n",
       "38  Dual center, single arm, two-stage, non-blinde...      2019-12-04   \n",
       "39  RATIONALE: Drugs used in chemotherapy, such as...      2009-02-10   \n",
       "40  The purposes of this study are to determine th...               ?   \n",
       "41  The main purpose of this Phase 1/2 study is to...      2021-01-01   \n",
       "42  The purpose of this study is to evaluate the e...         2013-09   \n",
       "43  Maintenance durvalumab (MEDI4736) and olaparib...         2026-12   \n",
       "44  There is no muture method to treat EGFR 20 ins...      2024-12-31   \n",
       "45  This is a randomized, open-label, phase 2 stud...         2027-02   \n",
       "46  From Protocol v3.0 dated 16Jun2022. This is an...      2024-10-31   \n",
       "47  The proposed study will evaluate whether the c...         2014-07   \n",
       "48  The purpose of this study is to evaluate the e...      2022-12-31   \n",
       "49  The purpose of this study is to evaluate the i...         2013-08   \n",
       "\n",
       "                                           conditions  \\\n",
       "0   Head and Neck Squamous Cell Carcinoma, Head an...   \n",
       "1                                   Colorectal Cancer   \n",
       "2                          Non-small Cell Lung Cancer   \n",
       "3                       Diffuse Large B-Cell Lymphoma   \n",
       "4                    Recurrent Acute Myeloid Leukemia   \n",
       "5     Gastric Adenocarcinoma, GastroEsophageal Cancer   \n",
       "6   Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...   \n",
       "7                                       Breast Cancer   \n",
       "8                                      Advanced Tumor   \n",
       "9                                        Colon Cancer   \n",
       "10   Acute Myeloid Leukemia, Chronic Myeloid Leukemia   \n",
       "11                                                AML   \n",
       "12  Leukemia, Myelodysplastic Syndromes, Blastic P...   \n",
       "13                                   NSCLC, Stage III   \n",
       "14                                             Cancer   \n",
       "15                                  Colonic Neoplasms   \n",
       "16  Acute Lymphoblastic Leukemia, Recurrent Acute ...   \n",
       "17              Lymphoma, B-Cell, Follicular Lymphoma   \n",
       "18  Metastatic Breast Cancer, Chemotherapy-induced...   \n",
       "19  Non-squamous Non-small-cell Lung Cancer, EGFR ...   \n",
       "20                              Neuroendocrine Tumors   \n",
       "21                 Non-Muscle Invasive Bladder Cancer   \n",
       "22  Pancreatic Ductal Carcinoma, Advanced Cancer, ...   \n",
       "23            Liver Cancer, Pancreatic Adenocarcinoma   \n",
       "24                                    Cervical Cancer   \n",
       "25                                      Breast Cancer   \n",
       "26                                        Oral Cancer   \n",
       "27  ER+, HER2- Advanced Breast Cancer, Metastatic ...   \n",
       "28                       Nodular Basal Cell Carcinoma   \n",
       "29                           CD20 Positive B Cell NHL   \n",
       "30                      Triple Negative Breast Cancer   \n",
       "31                                   Multiple Myeloma   \n",
       "32                                             Cancer   \n",
       "33         B-cell Acute Lymphoblastic Leukemia, B-ALL   \n",
       "34                                   Multiple Myeloma   \n",
       "35  Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...   \n",
       "36                                              NMIBC   \n",
       "37  Acute Myeloid Leukemia, Acute Myelogenous Leuk...   \n",
       "38                                       Glioblastoma   \n",
       "39                               Head and Neck Cancer   \n",
       "40  Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...   \n",
       "41                             Small-cell Lung Cancer   \n",
       "42                                  Colorectal Cancer   \n",
       "43                          Small Cell Lung Carcinoma   \n",
       "44                     Carcinoma, Non-Small-Cell Lung   \n",
       "45                         Glioblastoma, IDH-wildtype   \n",
       "46     Melanoma (Skin), Non-Small-Cell Lung Carcinoma   \n",
       "47                                   Multiple Myeloma   \n",
       "48                      Extranodal NK/T-cell Lymphoma   \n",
       "49                                  Esophageal Cancer   \n",
       "\n",
       "                                              country  \\\n",
       "0                                       United States   \n",
       "1                                             Denmark   \n",
       "2                                               China   \n",
       "3                                               China   \n",
       "4                                       United States   \n",
       "5                                       United States   \n",
       "6                                       United States   \n",
       "7                                       United States   \n",
       "8                                               China   \n",
       "9                                       United States   \n",
       "10                                      United States   \n",
       "11                                            Germany   \n",
       "12                                      United States   \n",
       "13                                              China   \n",
       "14                                      United States   \n",
       "15                                        Switzerland   \n",
       "16                                      United States   \n",
       "17                                      United States   \n",
       "18                                      United States   \n",
       "19                                              Japan   \n",
       "20                                             Canada   \n",
       "21                                                NaN   \n",
       "22                                             Canada   \n",
       "23                                              China   \n",
       "24                                      United States   \n",
       "25                                      United States   \n",
       "26                                      United States   \n",
       "27                                              China   \n",
       "28                                 Korea, Republic of   \n",
       "29                                              China   \n",
       "30                                              China   \n",
       "31                                      United States   \n",
       "32                                      United States   \n",
       "33                                              China   \n",
       "34  Croatia, Greece, United States, Argentina, Jap...   \n",
       "35                                      United States   \n",
       "36                                              China   \n",
       "37                                      United States   \n",
       "38                                      United States   \n",
       "39                                             Canada   \n",
       "40                                      United States   \n",
       "41                         Puerto Rico, United States   \n",
       "42                                      United States   \n",
       "43                                            Germany   \n",
       "44                                              China   \n",
       "45                                      United States   \n",
       "46                     Spain, Belgium, United Kingdom   \n",
       "47                                              Italy   \n",
       "48                                              China   \n",
       "49                                      United States   \n",
       "\n",
       "      design_primary_purpose  \\\n",
       "0                  TREATMENT   \n",
       "1                  TREATMENT   \n",
       "2                  TREATMENT   \n",
       "3                  TREATMENT   \n",
       "4                  TREATMENT   \n",
       "5                  TREATMENT   \n",
       "6                  TREATMENT   \n",
       "7                  TREATMENT   \n",
       "8                  TREATMENT   \n",
       "9                  TREATMENT   \n",
       "10                 TREATMENT   \n",
       "11                 TREATMENT   \n",
       "12                 TREATMENT   \n",
       "13                 TREATMENT   \n",
       "14                 TREATMENT   \n",
       "15                DIAGNOSTIC   \n",
       "16                 TREATMENT   \n",
       "17                 TREATMENT   \n",
       "18           SUPPORTIVE_CARE   \n",
       "19                 TREATMENT   \n",
       "20                 TREATMENT   \n",
       "21                 TREATMENT   \n",
       "22                 TREATMENT   \n",
       "23                 TREATMENT   \n",
       "24                 TREATMENT   \n",
       "25                 TREATMENT   \n",
       "26                PREVENTION   \n",
       "27                 TREATMENT   \n",
       "28                 TREATMENT   \n",
       "29                 TREATMENT   \n",
       "30                 TREATMENT   \n",
       "31                 TREATMENT   \n",
       "32                 TREATMENT   \n",
       "33                 TREATMENT   \n",
       "34                 TREATMENT   \n",
       "35                 TREATMENT   \n",
       "36                 TREATMENT   \n",
       "37                 TREATMENT   \n",
       "38                 TREATMENT   \n",
       "39                 TREATMENT   \n",
       "40                 TREATMENT   \n",
       "41                 TREATMENT   \n",
       "42  HEALTH_SERVICES_RESEARCH   \n",
       "43                 TREATMENT   \n",
       "44                 TREATMENT   \n",
       "45                 TREATMENT   \n",
       "46                 TREATMENT   \n",
       "47                 TREATMENT   \n",
       "48                 TREATMENT   \n",
       "49                DIAGNOSTIC   \n",
       "\n",
       "                                 detailed_description  \\\n",
       "0   This research is being done to see if it is sa...   \n",
       "1   This is an explorative phase 2 clinical trial ...   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4   PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...   \n",
       "5   Treatment on study will be administered in 21 ...   \n",
       "6                                                 NaN   \n",
       "7   OBJECTIVES:\\n\\n* Determine if the timing of br...   \n",
       "8                                                 NaN   \n",
       "9   This is an exploratory phase 2, randomized pla...   \n",
       "10  PRI-724 is a new investigational drug being st...   \n",
       "11                                                NaN   \n",
       "12  OBJECTIVES:\\n\\n* Determine the maximum tolerat...   \n",
       "13                                                NaN   \n",
       "14  OBJECTIVES:\\n\\n* Determine the dose-limiting t...   \n",
       "15                                                NaN   \n",
       "16  Treatment will include a single course of lymp...   \n",
       "17  This study will assess whether adding bortezom...   \n",
       "18  This study is a prospective, controlled, pivot...   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22  PDO is a three-dimensional experimental model ...   \n",
       "23                                                NaN   \n",
       "24  OBJECTIVES:\\n\\n* Determine the toxicity of rad...   \n",
       "25  Primary Objective:\\n\\nâ¢ To determine the effic...   \n",
       "26  Erlotinib hydrochloride is designed to block t...   \n",
       "27  This is a phase â /â¡, open-label study of TFX06...   \n",
       "28  Basal cell carcinoma (BCC) is the most common ...   \n",
       "29  This is a multi-center, randomized, double-bli...   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33  Although the anti-CD19 CAR-T cell therapies ha...   \n",
       "34  The study consists of 3 phases: Screening Phas...   \n",
       "35                                                NaN   \n",
       "36                                                NaN   \n",
       "37                                                NaN   \n",
       "38                                                NaN   \n",
       "39  OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...   \n",
       "40  Definition: The phase 2 study will provide imp...   \n",
       "41                                                NaN   \n",
       "42  This study will test the separate and combined...   \n",
       "43                                                NaN   \n",
       "44  Lung cancer is one of the most common types of...   \n",
       "45  This is a randomized, open-label phase 2 study...   \n",
       "46  Overall Study Design:\\n\\nâ¢ This is an open-lab...   \n",
       "47  This phase III study represents a prospective ...   \n",
       "48  Previous study has confirmed the efficacy of a...   \n",
       "49                                                NaN   \n",
       "\n",
       "                                 eligibility_criteria enrollment  \\\n",
       "0   Inclusion:\\n\\nCohort 1: Subjects must have his...         26   \n",
       "1   Inclusion Criteria:\\n\\n* Patients must be ment...         10   \n",
       "2   Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...        500   \n",
       "3   Inclusion Criteria:\\n\\n* 18-75 years old, male...        421   \n",
       "4   Inclusion Criteria:\\n\\n* Age \\>= 18 years at t...         51   \n",
       "5   Inclusion Criteria:\\n\\n* Patients must have hi...         20   \n",
       "6   Inclusion Criteria:\\n\\n3.1.1 Age Patients must...          9   \n",
       "7   DISEASE CHARACTERISTICS:\\n\\n* Histologically c...          ?   \n",
       "8   Inclusion Criteria:\\n\\n1. Age: 18-75 years old...         40   \n",
       "9   Inclusion Criteria:\\n\\n1. In the opinion of th...        381   \n",
       "10  Inclusion Criteria\\n\\n1. Patients 18 years or ...         49   \n",
       "11  Inclusion Criteria:\\n\\n1. Subjects must provid...         16   \n",
       "12  DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...         11   \n",
       "13  Inclusion Criteria:\\n\\n* Written informed cons...         30   \n",
       "14  DISEASE CHARACTERISTICS:\\n\\n* Histologically c...         75   \n",
       "15  Inclusion Criteria:\\n\\n* Colon cancer at any s...        192   \n",
       "16  Collection and Manufacturing Eligibility\\n\\nIn...         30   \n",
       "17  Inclusion Criteria:\\n\\n* Tissue diagnosis of a...         37   \n",
       "18  Inclusion Criteria:\\n\\n* Men and women with a ...        120   \n",
       "19  Inclusion Criteria:\\n\\n1. Have a histologicall...         30   \n",
       "20  Inclusion Criteria:\\n\\n* Adults (males or fema...         17   \n",
       "21  Inclusion Criteria:\\n\\n* Tumour recurrence aft...        272   \n",
       "22  Inclusion Criteria:\\n\\n1. Age 18 years or over...         25   \n",
       "23  Inclusion Criteria:\\n\\n1. Able to read and und...         20   \n",
       "24  DISEASE CHARACTERISTICS:\\n\\n* Histologically p...         40   \n",
       "25  Inclusion Criteria:\\n\\n1. Female or male patie...         25   \n",
       "26  Inclusion Criteria:\\n\\n1. Male or female patie...        303   \n",
       "27  Inclusion Criteria:\\n\\n1. voluntary participat...         74   \n",
       "28  Inclusion Criteria:\\n\\n* patient's request for...         34   \n",
       "29  Inclusion Criteria:\\n\\n* Histological examinat...         60   \n",
       "30  Inclusion Criteria:\\n\\n* Newly diagnosed histo...         49   \n",
       "31  For more information regarding BMS clinical tr...         74   \n",
       "32  DISEASE CHARACTERISTICS\\n\\n* Histologically pr...         40   \n",
       "33  Inclusion Criteria:\\n\\n1. Male or female, aged...         30   \n",
       "34  Inclusion Criteria:\\n\\n* Participant must have...        706   \n",
       "35  Inclusion Criteria:\\n\\n1. Age less than or equ...         20   \n",
       "36  Inclusion Criteria:\\n\\n1. Age â¥18 years old, b...         58   \n",
       "37  Key Inclusion Criteria:\\n\\n* Single agent (SA)...         94   \n",
       "38  Inclusion Criteria:\\n\\n* At least 18 years of ...         35   \n",
       "39  DISEASE CHARACTERISTICS:\\n\\n* Histologically o...         34   \n",
       "40  Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...          ?   \n",
       "41  Key Inclusion Criteria:\\n\\n1. Patient is able ...         68   \n",
       "42  Inclusion Criteria:\\n\\n* Patients aged 50-75 y...        569   \n",
       "43  Inclusion Criteria Pre-Screening:\\n\\n* Newly d...         29   \n",
       "44  Inclusion Criteria:\\n\\nParticipant must have h...         20   \n",
       "45  Inclusion Criteria:\\n\\n* Written informed cons...         54   \n",
       "46  Inclusion Criteria:\\n\\nMain Inclusion Criteria...         34   \n",
       "47  Inclusion Criteria:\\n\\n* Age \\> 65 year old an...        511   \n",
       "48  Inclusion Criteria:\\n\\nHistopathology and immu...         20   \n",
       "49  Inclusion Criteria:\\n\\n* Newly diagnosed or re...         22   \n",
       "\n",
       "                            interventions_description  \\\n",
       "0   One dose of Nivolumab 480mg given four weeks p...   \n",
       "1   Intratumoral application of an unattenuated in...   \n",
       "2   SHR-A2009 monotherapy ï¼SHR-A2009 will be admin...   \n",
       "3          Injectionï¼100mg/10ml; Injectionï¼100mg/10ml   \n",
       "4   Given by mouth; Given by mouth; Given by mouth...   \n",
       "5                                  Given PO; Given IV   \n",
       "6   Dosage: 1.25mg/kg intravenous with dose escala...   \n",
       "7                                                 NaN   \n",
       "8   In the phase, five dose groups were proposed.T...   \n",
       "9   Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...   \n",
       "10  PRI-724; PRI-724 in combination with dasatinib...   \n",
       "11                                                NaN   \n",
       "12  Intravenously via a 3 cc plastic syringe as a ...   \n",
       "13  Tislelizumab: 200mg, IV, day 1 of each 21-day ...   \n",
       "14                                                NaN   \n",
       "15  After careful mobilization of the affected col...   \n",
       "16  IV; IV; IV; CAR T cell infusion will be given ...   \n",
       "17  Bortezomib 1.6 mg/mÂ² given on days 1 and 8; Ri...   \n",
       "18  Cap attached to coolant lines connected to a r...   \n",
       "19  IV infusion Q3W; Oral capsule once daily; IV i...   \n",
       "20  Avelumab will be administered intravenously as...   \n",
       "21                                      Chemoablation   \n",
       "22  Cobimetinib is an antineoplastic agent and sel...   \n",
       "23  vaccination of autologous gp96 derived from tu...   \n",
       "24                                                NaN   \n",
       "25             Given by IV (vein); Given by IV (vein)   \n",
       "26       150 mg by mouth daily; Tablet by mouth daily   \n",
       "27                          TFX06 tablet taken orally   \n",
       "28  AFL was performed using a 2940-nm Er:YAG ablat...   \n",
       "29  Monoclonal antibodies, 100mg/10ml per injectio...   \n",
       "30  The PD-1 inhibitor Sintilimab 200mg for intrav...   \n",
       "31                                                NaN   \n",
       "32                   IV solution, weekly or bi-weekly   \n",
       "33  UCAR-T Cellswill be administered by vein. The ...   \n",
       "34  Participants will receive velcade 1.3 mg/m\\^2,...   \n",
       "35  Fludarabine: 30 mg/m2 daily for 5 days; Busulf...   \n",
       "36      SHR-1501, instillationï¼SHR-2005, instillation   \n",
       "37  FT-1101 will be supplied as 5 mg, 20 mg or 100...   \n",
       "38                                  10mg/kg; 670mg/m2   \n",
       "39                                                NaN   \n",
       "40                                                NaN   \n",
       "41                   Administered IV; Administered IV   \n",
       "42  Physicians at these clinics will participate i...   \n",
       "43                1500 mg i.v. Q4W; 300 mg BID orally   \n",
       "44  Osimertinib, 80mg, oral daily; bevacizumab (av...   \n",
       "45  Ropidoxuridine is administered daily, 5 days a...   \n",
       "46  Priming phase including 1 GAd-PEV administrati...   \n",
       "47  Induction therapy:\\n\\n9 courses with weekly VE...   \n",
       "48  200mg d1,ivdrip, repeated every 3 weeks; 10mg ...   \n",
       "49  15 mCi 11C-choline will be administered intrav...   \n",
       "\n",
       "                                   interventions_name  ...           phase  \\\n",
       "0              Nivolumab 480mg and surgical resection  ...          PHASE2   \n",
       "1                                  Influenza Vaccines  ...          PHASE2   \n",
       "2   SHR-A2009 monotherapy, platinum-based dual-age...  ...          PHASE3   \n",
       "3                                  SIBP-02, Rituximab  ...          PHASE3   \n",
       "4   Venetoclax, Decitabine, Cedazuridine, Bone Mar...  ...          PHASE2   \n",
       "5                         Cabozantinib, Pembrolizumab  ...          PHASE2   \n",
       "6                                MAb 216, Vincristine  ...          PHASE1   \n",
       "7                                conventional surgery  ...          PHASE3   \n",
       "8                                            QLF32004  ...          PHASE1   \n",
       "9        Perifosine, Capecitabine, Perifosine Placebo  ...          PHASE2   \n",
       "10                          PRI-724, PRI-724, PRI-724  ...  PHASE1, PHASE2   \n",
       "11                         Tranylcypromine, Tretinoin  ...  PHASE1, PHASE2   \n",
       "12                                           DT388IL3  ...  PHASE1, PHASE2   \n",
       "13  Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...  ...          PHASE2   \n",
       "14                                         entinostat  ...          PHASE1   \n",
       "15  Sentinel lymph node procedure, Bone marrow asp...  ...  PHASE1, PHASE2   \n",
       "16  Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...  ...          PHASE1   \n",
       "17  Bortezomib, Rituximab, Doxorubicin, Cyclophosp...  ...  PHASE1, PHASE2   \n",
       "18  Paxman Scalp Cooling System, Eribulin, Sacituz...  ...          PHASE2   \n",
       "19  Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...  ...          PHASE2   \n",
       "20                                           Avelumab  ...          PHASE2   \n",
       "21                                        Mitomycin c  ...          PHASE4   \n",
       "22  Cobimetinib, Ponatinib, Brigatinib, Colchicine...  ...          PHASE2   \n",
       "23                        autologous gp96 vaccination  ...  PHASE1, PHASE2   \n",
       "24  cisplatin, paclitaxel, brachytherapy, radiatio...  ...  PHASE1, PHASE2   \n",
       "25               Sacituzumab Govitecan, Pembrolizumab  ...          PHASE2   \n",
       "26                                 Erlotinib, Placebo  ...          PHASE3   \n",
       "27                                       TFX06 tablet  ...  PHASE1, PHASE2   \n",
       "28                            Er:YAG AFL-PDT, MAL-PDT  ...          PHASE1   \n",
       "29                 304 injection, rituximab injection  ...          PHASE1   \n",
       "30                                         Sintilimab  ...          PHASE2   \n",
       "31  Elotuzumab, Pomalidomide, Dexamethasone, Nivol...  ...          PHASE2   \n",
       "32                                             CT-322  ...          PHASE1   \n",
       "33                                       UCAR-T Cells  ...  PHASE1, PHASE2   \n",
       "34  Velcade, Melphalan, Prednisone, Daratumumab IV...  ...          PHASE3   \n",
       "35    Fludarabine, Busulfan, Rabbit ATG, Methotrexate  ...          PHASE1   \n",
       "36                                  SHR-1501+SHR-2005  ...  PHASE1, PHASE2   \n",
       "37                               FT-1101, Azacitidine  ...          PHASE1   \n",
       "38                                Bevacizumab, TH-302  ...          PHASE2   \n",
       "39  carboplatin, cisplatin, gemcitabine hydrochloride  ...          PHASE2   \n",
       "40                 Gemcitabine, Carboplatin, LY900003  ...          PHASE2   \n",
       "41                      Pegzilarginase, Pembrolizumab  ...  PHASE1, PHASE2   \n",
       "42  Physician Intervention, Physician and Patient ...  ...  PHASE2, PHASE3   \n",
       "43                               Durvalumab, Olaparib  ...          PHASE2   \n",
       "44                            Osimertinib Oral Tablet  ...          PHASE2   \n",
       "45                                     Ropidoxuridine  ...          PHASE2   \n",
       "46                                   GAd-PEV, MVA-PEV  ...          PHASE1   \n",
       "47  Bortezomib, Melphalan, Prednisone, Thalidomide...  ...          PHASE3   \n",
       "48                             Sintilimab, Decitabine  ...          PHASE2   \n",
       "49                                        C11-Choline  ...          PHASE1   \n",
       "\n",
       "   primary_completion_date                                   primary_outcomes  \\\n",
       "0               2023-10-17  Safety as Measured by Number of Participants W...   \n",
       "1               2021-09-22  Safety - Adverse reactions are classified acco...   \n",
       "2                  2026-12  Progression-free survival (PFS) assessed by BI...   \n",
       "3               2022-05-20                        Overall Response Rate (ORR)   \n",
       "4                  2028-03  Composite complete response (CR) rate (CR/comp...   \n",
       "5               2023-11-25  Percentage of Participants with Progression-fr...   \n",
       "6                  2009-02  In this phase I study the endpoint is the dete...   \n",
       "7                        ?                                                NaN   \n",
       "8               2024-12-30  Dose-Limiting Toxicity (DLT); Maximum Tolerate...   \n",
       "9                  2010-12       Effects of perifosine on time to progression   \n",
       "10              2016-12-30                       DLT (Dose Limiting Toxicity)   \n",
       "11                 2017-09  Analysis of the cumulative response rate (CR,C...   \n",
       "12              2017-07-27  Overall Response Rate (CR+PR+SD): Percentage o...   \n",
       "13              2024-02-29                                 Resectability rate   \n",
       "14                 2008-04  Dose-limiting toxicities and maximum tolerated...   \n",
       "15                 2009-01  To assess the extent of upstaging due to the S...   \n",
       "16                 2030-01  Recommended phase 2 dose (RP2D) of CD19-CD22-C...   \n",
       "17                 2015-11  Maximal Tolerated Doses of Bortezomib and Vinc...   \n",
       "18              2026-06-01                                     Hair Loss Rate   \n",
       "19              2023-10-31  Objective Response Rate (ORR) as Assessed by B...   \n",
       "20              2021-07-26                        Overall response rate (ORR)   \n",
       "21              2029-02-01                  Two-year Recurrence Free Survival   \n",
       "22              2028-02-17                      Objective response rate (ORR)   \n",
       "23                 2016-11  blood count; blood count; blood count; blood c...   \n",
       "24                 2007-01                                                NaN   \n",
       "25              2026-12-31  Incidence of Adverse Events, Graded According ...   \n",
       "26              2018-06-04  Oral Cancer-free Survival in Participants Rece...   \n",
       "27              2024-12-30  Recommended phase 2 Dose (RP2D); Disease Contr...   \n",
       "28                 2013-02  Difference the efficacy between Er:YAG AFL-PDT...   \n",
       "29              2019-06-30                         AUC [0-t]; AUC [0-â]; Cmax   \n",
       "30                 2023-12                 Pathologic Complete Response (pCR)   \n",
       "31              2019-07-29  Progression Free Survival (PFS); Objective Res...   \n",
       "32                 2008-11                  Safety and tolerability of CT-322   \n",
       "33              2024-12-31  Dose-limiting toxicity (DLT); Incidence of Tre...   \n",
       "34              2017-11-21                    Progression Free Survival (PFS)   \n",
       "35              2019-06-07  Number of patients who are surviving at 100-Da...   \n",
       "36              2027-10-01  Phase I : Incidence of dose limiting toxicitie...   \n",
       "37                 2019-03  Maximum Tolerated Dose (MTD); Dose Limiting To...   \n",
       "38              2019-01-04             Number of Patients With Adverse Events   \n",
       "39              2008-09-29  Objective response measured by RECIST criteria...   \n",
       "40                       ?                                                NaN   \n",
       "41              2021-01-01  1. Phase 1: Incidence of treatment-related adv...   \n",
       "42                 2013-07  Colorectal Cancer (CRC) Screening Completion; ...   \n",
       "43                 2026-09                    Progression-free survival (PFS)   \n",
       "44              2024-07-31                          Progression free survival   \n",
       "45                 2026-08  Number of patients treated with oral ropidoxur...   \n",
       "46              2024-10-31  Safety and tolerability: incidence of treatmen...   \n",
       "47                 2014-07  Determine whether the V-MPT combination improv...   \n",
       "48              2022-12-31                             complete response rate   \n",
       "49                 2013-08  To evaluate our ability to obtain reliable and...   \n",
       "\n",
       "                                   secondary_outcomes     sex  start_date  \\\n",
       "0   Major Pathologic Response Rate; Progression Fr...     ALL  2019-07-08   \n",
       "1              Efficacy - local immunological changes     ALL  2021-02-26   \n",
       "2   overall survival (OS); Progression Free Surviv...     ALL  2024-11-29   \n",
       "3                                                 NaN     ALL  2019-07-25   \n",
       "4   Rate of partial response (PR) following treatm...     ALL  2024-01-29   \n",
       "5   Percentage of Grade 3-5 Adverse Events; Overal...     ALL  2020-02-04   \n",
       "6   A decrease in leukemic blasts. The study will ...     ALL     2006-05   \n",
       "7                                                 NaN  FEMALE     1999-01   \n",
       "8   Treatment-Emergent Adverse Event (TEAE); Maxim...     ALL  2021-11-09   \n",
       "9   Toxicity; Comparison of time to progression to...     ALL     2005-08   \n",
       "10                     Preliminary Efficacy Endpoints     ALL     2012-07   \n",
       "11  number of participants with adverse events as ...     ALL     2014-09   \n",
       "12                                                NaN     ALL     2013-05   \n",
       "13  Major pathological response rate (MPR); Pathol...     ALL  2023-03-12   \n",
       "14  Acetylation of histones in peripheral blood; T...     ALL     2001-03   \n",
       "15  To evaluate the accuracy of the SLN procedure ...     ALL     2000-05   \n",
       "16                                                NaN     ALL     2025-05   \n",
       "17  An Estimate of the Overall Response Rate (ORR)...     ALL     2008-02   \n",
       "18  Change in Patient Reported Quality of Life; Ch...     ALL  2021-10-07   \n",
       "19  Objective Response Rate (ORR) as Assessed by i...     ALL  2022-07-01   \n",
       "20  Disease control rate (DCR); Duration of respon...     ALL  2017-11-15   \n",
       "21  Five-year RFS; Number of patients in need of a...     ALL  2025-02-24   \n",
       "22  Disease control rate (DCR); Duration of respon...     ALL  2025-02-17   \n",
       "23  Disease-free survival; overall survive; change...     ALL     2012-03   \n",
       "24                                                NaN  FEMALE     1999-11   \n",
       "25                                                NaN     ALL  2023-05-23   \n",
       "26                                                NaN     ALL  2006-11-03   \n",
       "27  Incidence of Treatment-Emergent Adverse Events...  FEMALE  2023-04-17   \n",
       "28  Difference of the cosmetic outcomes between Er...     ALL     2011-03   \n",
       "29      tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events     ALL  2018-12-18   \n",
       "30                                                NaN  FEMALE     2021-03   \n",
       "31  Objective Response Rate (ORR); Progression Fre...     ALL  2016-02-09   \n",
       "32  To evaluate the pharmacokinetics of CT-322 in ...     ALL     2006-08   \n",
       "33  Persistence of CAR-T cells; Objective response...     ALL  2022-12-05   \n",
       "34  Overall Response Rate (ORR); Percentage of Par...     ALL  2014-12-09   \n",
       "35  Time to marrow engraftment; Assessing all subj...     ALL  2016-09-06   \n",
       "36  Phase I : CR rate at 3 months; Phase II : Inci...     ALL  2024-10-01   \n",
       "37  Area under the plasma concentration versus tim...     ALL     2015-09   \n",
       "38                          Progression Free Survival     ALL     2015-05   \n",
       "39  Toxicity assessed by NCI CTC v2.0; Overall sur...     ALL  2003-10-27   \n",
       "40                                                NaN     ALL     2002-06   \n",
       "41  Objective Response Rate; Clinical Benefit Rate...     ALL  2017-12-21   \n",
       "42           Provider Recommendation of CRC Screening     ALL     2010-04   \n",
       "43  Incidence, severity and grading of adverse eve...     ALL  2024-10-09   \n",
       "44  Objective Response Rate (ORR); Overall Surviva...     ALL  2021-07-01   \n",
       "45  Overall survival at 12 months; Radiographic Re...     ALL  2024-09-02   \n",
       "46  RP2D confirmation 2. Clinical efficacy:; Clini...     ALL  2021-06-11   \n",
       "47  Determine whether the VMPT combination improve...     ALL     2006-05   \n",
       "48  overall response rate; 1-year progression free...     ALL  2020-04-01   \n",
       "49  Perform semi-quantitative analysis of tracer u...     ALL     2010-03   \n",
       "\n",
       "                       stdage study_first_post_date study_first_submit_date  \\\n",
       "0          ADULT, OLDER_ADULT            2019-03-18              2019-03-15   \n",
       "1          ADULT, OLDER_ADULT            2020-10-19              2020-09-07   \n",
       "2          ADULT, OLDER_ADULT            2024-11-04              2024-11-01   \n",
       "3          ADULT, OLDER_ADULT            2020-04-24              2020-04-22   \n",
       "4          ADULT, OLDER_ADULT            2023-04-05              2023-03-22   \n",
       "5          ADULT, OLDER_ADULT            2019-11-15              2019-11-13   \n",
       "6          ADULT, OLDER_ADULT            2006-04-11              2006-04-07   \n",
       "7   CHILD, ADULT, OLDER_ADULT            2003-01-27              2000-04-06   \n",
       "8          ADULT, OLDER_ADULT            2021-11-05              2021-10-22   \n",
       "9          ADULT, OLDER_ADULT            2006-11-14              2006-11-06   \n",
       "10         ADULT, OLDER_ADULT            2012-05-25              2012-05-16   \n",
       "11         ADULT, OLDER_ADULT            2014-10-10              2014-09-23   \n",
       "12         ADULT, OLDER_ADULT            2006-11-09              2006-11-08   \n",
       "13         ADULT, OLDER_ADULT            2022-11-10              2022-11-04   \n",
       "14         ADULT, OLDER_ADULT            2003-01-27              2001-07-11   \n",
       "15  CHILD, ADULT, OLDER_ADULT            2009-01-22              2009-01-13   \n",
       "16               CHILD, ADULT            2025-01-16              2025-01-10   \n",
       "17         ADULT, OLDER_ADULT            2008-03-12              2008-02-11   \n",
       "18         ADULT, OLDER_ADULT            2021-08-03              2021-07-20   \n",
       "19         ADULT, OLDER_ADULT            2022-02-28              2022-02-17   \n",
       "20         ADULT, OLDER_ADULT            2017-09-11              2017-08-23   \n",
       "21         ADULT, OLDER_ADULT            2025-01-17              2025-01-14   \n",
       "22         ADULT, OLDER_ADULT            2025-02-06              2025-02-03   \n",
       "23         ADULT, OLDER_ADULT            2014-05-07              2014-05-03   \n",
       "24         ADULT, OLDER_ADULT            2003-01-27              1999-11-01   \n",
       "25         ADULT, OLDER_ADULT            2023-01-09              2022-12-22   \n",
       "26         ADULT, OLDER_ADULT            2006-11-22              2006-11-20   \n",
       "27         ADULT, OLDER_ADULT            2023-07-03              2023-06-03   \n",
       "28         ADULT, OLDER_ADULT            2013-12-23              2013-11-29   \n",
       "29         ADULT, OLDER_ADULT            2019-06-10              2019-06-06   \n",
       "30                      ADULT            2021-03-22              2021-03-19   \n",
       "31         ADULT, OLDER_ADULT            2015-11-24              2015-11-20   \n",
       "32         ADULT, OLDER_ADULT            2006-09-11              2006-09-08   \n",
       "33  CHILD, ADULT, OLDER_ADULT            2022-12-06              2022-11-25   \n",
       "34         ADULT, OLDER_ADULT            2014-07-21              2014-07-18   \n",
       "35         ADULT, OLDER_ADULT            2016-09-28              2016-08-15   \n",
       "36         ADULT, OLDER_ADULT            2024-09-19              2024-09-05   \n",
       "37         ADULT, OLDER_ADULT            2015-09-07              2015-09-01   \n",
       "38         ADULT, OLDER_ADULT            2015-01-19              2015-01-14   \n",
       "39         ADULT, OLDER_ADULT            2004-03-09              2004-03-08   \n",
       "40         ADULT, OLDER_ADULT            2002-08-06              2002-08-02   \n",
       "41         ADULT, OLDER_ADULT            2017-12-13              2017-11-20   \n",
       "42         ADULT, OLDER_ADULT            2010-04-14              2010-04-12   \n",
       "43         ADULT, OLDER_ADULT            2024-05-17              2024-05-03   \n",
       "44         ADULT, OLDER_ADULT            2021-07-23              2021-07-16   \n",
       "45         ADULT, OLDER_ADULT            2024-04-11              2024-03-24   \n",
       "46         ADULT, OLDER_ADULT            2021-08-04              2021-07-15   \n",
       "47                OLDER_ADULT            2010-02-05              2010-02-04   \n",
       "48         ADULT, OLDER_ADULT            2020-02-21              2020-02-19   \n",
       "49         ADULT, OLDER_ADULT            2010-01-18              2010-01-15   \n",
       "\n",
       "        study_type  \n",
       "0   INTERVENTIONAL  \n",
       "1   INTERVENTIONAL  \n",
       "2   INTERVENTIONAL  \n",
       "3   INTERVENTIONAL  \n",
       "4   INTERVENTIONAL  \n",
       "5   INTERVENTIONAL  \n",
       "6   INTERVENTIONAL  \n",
       "7   INTERVENTIONAL  \n",
       "8   INTERVENTIONAL  \n",
       "9   INTERVENTIONAL  \n",
       "10  INTERVENTIONAL  \n",
       "11  INTERVENTIONAL  \n",
       "12  INTERVENTIONAL  \n",
       "13  INTERVENTIONAL  \n",
       "14  INTERVENTIONAL  \n",
       "15  INTERVENTIONAL  \n",
       "16  INTERVENTIONAL  \n",
       "17  INTERVENTIONAL  \n",
       "18  INTERVENTIONAL  \n",
       "19  INTERVENTIONAL  \n",
       "20  INTERVENTIONAL  \n",
       "21  INTERVENTIONAL  \n",
       "22  INTERVENTIONAL  \n",
       "23  INTERVENTIONAL  \n",
       "24  INTERVENTIONAL  \n",
       "25  INTERVENTIONAL  \n",
       "26  INTERVENTIONAL  \n",
       "27  INTERVENTIONAL  \n",
       "28  INTERVENTIONAL  \n",
       "29  INTERVENTIONAL  \n",
       "30  INTERVENTIONAL  \n",
       "31  INTERVENTIONAL  \n",
       "32  INTERVENTIONAL  \n",
       "33  INTERVENTIONAL  \n",
       "34  INTERVENTIONAL  \n",
       "35  INTERVENTIONAL  \n",
       "36  INTERVENTIONAL  \n",
       "37  INTERVENTIONAL  \n",
       "38  INTERVENTIONAL  \n",
       "39  INTERVENTIONAL  \n",
       "40  INTERVENTIONAL  \n",
       "41  INTERVENTIONAL  \n",
       "42  INTERVENTIONAL  \n",
       "43  INTERVENTIONAL  \n",
       "44  INTERVENTIONAL  \n",
       "45  INTERVENTIONAL  \n",
       "46  INTERVENTIONAL  \n",
       "47  INTERVENTIONAL  \n",
       "48  INTERVENTIONAL  \n",
       "49  INTERVENTIONAL  \n",
       "\n",
       "[50 rows x 35 columns]"
      ]
     },
     "execution_count": 25,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(50)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "id": "9388472b",
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "\n",
    "# Your date columns\n",
    "date_cols = [\n",
    "    'completion_date',\n",
    "    'last_update_post_date',\n",
    "    'primary_completion_date',\n",
    "    'start_date',\n",
    "    'study_first_post_date',\n",
    "    'study_first_submit_date'\n",
    "]\n",
    "\n",
    "# Function to insert day=15 if day is missing\n",
    "def fill_day_15(date_str):\n",
    "    if pd.isna(date_str):\n",
    "        return np.nan\n",
    "    date_str = str(date_str).strip()\n",
    "    \n",
    "    # Check if format is like \"Jan 2023\" or \"2023-01\"\n",
    "    if re.fullmatch(r'[A-Za-z]{3,9}\\s+\\d{4}', date_str):  # e.g., \"March 2021\"\n",
    "        return f'15 {date_str}'\n",
    "    elif re.fullmatch(r'\\d{4}-\\d{2}', date_str):  # e.g., \"2023-01\"\n",
    "        return f'{date_str}-15'\n",
    "    return date_str  # return unchanged if full date is already present\n",
    "\n",
    "# Apply transformation and convert to datetime\n",
    "for col in date_cols:\n",
    "    df[col] = df[col].apply(fill_day_15)  # Fill in day if needed\n",
    "    df[col] = pd.to_datetime(df[col], errors='coerce')  # Convert to datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "id": "2d671049",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>conditions</th>\n",
       "      <th>country</th>\n",
       "      <th>design_primary_purpose</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>interventions_description</th>\n",
       "      <th>interventions_name</th>\n",
       "      <th>...</th>\n",
       "      <th>phase</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>primary_outcomes</th>\n",
       "      <th>secondary_outcomes</th>\n",
       "      <th>sex</th>\n",
       "      <th>start_date</th>\n",
       "      <th>stdage</th>\n",
       "      <th>study_first_post_date</th>\n",
       "      <th>study_first_submit_date</th>\n",
       "      <th>study_type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Nivolumab, also known as (Bristol Myers Squibb...</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Head and Neck Squamous Cell Carcinoma, Head an...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This research is being done to see if it is sa...</td>\n",
       "      <td>Inclusion:\\n\\nCohort 1: Subjects must have his...</td>\n",
       "      <td>26</td>\n",
       "      <td>One dose of Nivolumab 480mg given four weeks p...</td>\n",
       "      <td>Nivolumab 480mg and surgical resection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-17</td>\n",
       "      <td>Safety as Measured by Number of Participants W...</td>\n",
       "      <td>Major Pathologic Response Rate; Progression Fr...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-08</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-03-18</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>The aim of this explorative phase II clinical ...</td>\n",
       "      <td>2021-11-01</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>Denmark</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an explorative phase 2 clinical trial ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must be ment...</td>\n",
       "      <td>10</td>\n",
       "      <td>Intratumoral application of an unattenuated in...</td>\n",
       "      <td>Influenza Vaccines</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-09-22</td>\n",
       "      <td>Safety - Adverse reactions are classified acco...</td>\n",
       "      <td>Efficacy - local immunological changes</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-02-26</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-10-19</td>\n",
       "      <td>2020-09-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>This study was a randomized, controlled, open-...</td>\n",
       "      <td>2027-06-15</td>\n",
       "      <td>Non-small Cell Lung Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...</td>\n",
       "      <td>500</td>\n",
       "      <td>SHR-A2009 monotherapy ï¼SHR-A2009 will be admin...</td>\n",
       "      <td>SHR-A2009 monotherapy, platinum-based dual-age...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>Progression-free survival (PFS) assessed by BI...</td>\n",
       "      <td>overall survival (OS); Progression Free Surviv...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-11-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-11-04</td>\n",
       "      <td>2024-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>This is a randomised, double-blind, positive d...</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Diffuse Large B-Cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* 18-75 years old, male...</td>\n",
       "      <td>421</td>\n",
       "      <td>Injectionï¼100mg/10ml; Injectionï¼100mg/10ml</td>\n",
       "      <td>SIBP-02, Rituximab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2022-05-20</td>\n",
       "      <td>Overall Response Rate (ORR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2019-07-25</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-04-24</td>\n",
       "      <td>2020-04-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>This phase II trial tests how well decitabine ...</td>\n",
       "      <td>2029-03-15</td>\n",
       "      <td>Recurrent Acute Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt;= 18 years at t...</td>\n",
       "      <td>51</td>\n",
       "      <td>Given by mouth; Given by mouth; Given by mouth...</td>\n",
       "      <td>Venetoclax, Decitabine, Cedazuridine, Bone Mar...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-03-15</td>\n",
       "      <td>Composite complete response (CR) rate (CR/comp...</td>\n",
       "      <td>Rate of partial response (PR) following treatm...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-01-29</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-04-05</td>\n",
       "      <td>2023-03-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>This is a phase 2 single-arm, open-label clini...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Gastric Adenocarcinoma, GastroEsophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment on study will be administered in 21 ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients must have hi...</td>\n",
       "      <td>20</td>\n",
       "      <td>Given PO; Given IV</td>\n",
       "      <td>Cabozantinib, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-11-25</td>\n",
       "      <td>Percentage of Participants with Progression-fr...</td>\n",
       "      <td>Percentage of Grade 3-5 Adverse Events; Overal...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-02-04</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>2019-11-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>A phase I trial in patients with relapsed or r...</td>\n",
       "      <td>2009-07-15</td>\n",
       "      <td>Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n3.1.1 Age Patients must...</td>\n",
       "      <td>9</td>\n",
       "      <td>Dosage: 1.25mg/kg intravenous with dose escala...</td>\n",
       "      <td>MAb 216, Vincristine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2009-02-15</td>\n",
       "      <td>In this phase I study the endpoint is the dete...</td>\n",
       "      <td>A decrease in leukemic blasts. The study will ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-04-11</td>\n",
       "      <td>2006-04-07</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>RATIONALE: The timing of breast cancer surgery...</td>\n",
       "      <td>2004-10-15</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine if the timing of br...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>conventional surgery</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-01-15</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2000-04-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>To determine the safety, tolerability, and rec...</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Advanced Tumor</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age: 18-75 years old...</td>\n",
       "      <td>40</td>\n",
       "      <td>In the phase, five dose groups were proposed.T...</td>\n",
       "      <td>QLF32004</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Dose-Limiting Toxicity (DLT); Maximum Tolerate...</td>\n",
       "      <td>Treatment-Emergent Adverse Event (TEAE); Maxim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-11-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-11-05</td>\n",
       "      <td>2021-10-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>2011-10-15</td>\n",
       "      <td>Colon Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is an exploratory phase 2, randomized pla...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. In the opinion of th...</td>\n",
       "      <td>381</td>\n",
       "      <td>Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...</td>\n",
       "      <td>Perifosine, Capecitabine, Perifosine Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2010-12-15</td>\n",
       "      <td>Effects of perifosine on time to progression</td>\n",
       "      <td>Toxicity; Comparison of time to progression to...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2005-08-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-14</td>\n",
       "      <td>2006-11-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>Acute Myeloid Leukemia, Chronic Myeloid Leukemia</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PRI-724 is a new investigational drug being st...</td>\n",
       "      <td>Inclusion Criteria\\n\\n1. Patients 18 years or ...</td>\n",
       "      <td>49</td>\n",
       "      <td>PRI-724; PRI-724 in combination with dasatinib...</td>\n",
       "      <td>PRI-724, PRI-724, PRI-724</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-12-30</td>\n",
       "      <td>DLT (Dose Limiting Toxicity)</td>\n",
       "      <td>Preliminary Efficacy Endpoints</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-07-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2012-05-25</td>\n",
       "      <td>2012-05-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Longterm disease-free survival (DFS) of older ...</td>\n",
       "      <td>2017-09-15</td>\n",
       "      <td>AML</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Subjects must provid...</td>\n",
       "      <td>16</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Tranylcypromine, Tretinoin</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-09-15</td>\n",
       "      <td>Analysis of the cumulative response rate (CR,C...</td>\n",
       "      <td>number of participants with adverse events as ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-09-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-10-10</td>\n",
       "      <td>2014-09-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>RATIONALE: Combinations of biological substanc...</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Leukemia, Myelodysplastic Syndromes, Blastic P...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the maximum tolerat...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...</td>\n",
       "      <td>11</td>\n",
       "      <td>Intravenously via a 3 cc plastic syringe as a ...</td>\n",
       "      <td>DT388IL3</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2017-07-27</td>\n",
       "      <td>Overall Response Rate (CR+PR+SD): Percentage o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2013-05-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-09</td>\n",
       "      <td>2006-11-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>The purpose of this conversion therapy study i...</td>\n",
       "      <td>2024-04-30</td>\n",
       "      <td>NSCLC, Stage III</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>30</td>\n",
       "      <td>Tislelizumab: 200mg, IV, day 1 of each 21-day ...</td>\n",
       "      <td>Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-02-29</td>\n",
       "      <td>Resectability rate</td>\n",
       "      <td>Major pathological response rate (MPR); Pathol...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-03-12</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-11-10</td>\n",
       "      <td>2022-11-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>RATIONALE: MS-275 may stop the growth of cance...</td>\n",
       "      <td>2008-10-15</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the dose-limiting t...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically c...</td>\n",
       "      <td>75</td>\n",
       "      <td>NaN</td>\n",
       "      <td>entinostat</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-04-15</td>\n",
       "      <td>Dose-limiting toxicities and maximum tolerated...</td>\n",
       "      <td>Acetylation of histones in peripheral blood; T...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2001-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>2001-07-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>The study is a feasibility and validation stud...</td>\n",
       "      <td>2009-01-15</td>\n",
       "      <td>Colonic Neoplasms</td>\n",
       "      <td>Switzerland</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Colon cancer at any s...</td>\n",
       "      <td>192</td>\n",
       "      <td>After careful mobilization of the affected col...</td>\n",
       "      <td>Sentinel lymph node procedure, Bone marrow asp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2009-01-15</td>\n",
       "      <td>To assess the extent of upstaging due to the S...</td>\n",
       "      <td>To evaluate the accuracy of the SLN procedure ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2000-05-15</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2009-01-22</td>\n",
       "      <td>2009-01-13</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>This study is a phase I study designed to eval...</td>\n",
       "      <td>2031-01-15</td>\n",
       "      <td>Acute Lymphoblastic Leukemia, Recurrent Acute ...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Treatment will include a single course of lymp...</td>\n",
       "      <td>Collection and Manufacturing Eligibility\\n\\nIn...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV; IV; IV; CAR T cell infusion will be given ...</td>\n",
       "      <td>Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2030-01-15</td>\n",
       "      <td>Recommended phase 2 dose (RP2D) of CD19-CD22-C...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-05-15</td>\n",
       "      <td>CHILD, ADULT</td>\n",
       "      <td>2025-01-16</td>\n",
       "      <td>2025-01-10</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>This is an open-label (doctors and patients kn...</td>\n",
       "      <td>2015-11-15</td>\n",
       "      <td>Lymphoma, B-Cell, Follicular Lymphoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This study will assess whether adding bortezom...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tissue diagnosis of a...</td>\n",
       "      <td>37</td>\n",
       "      <td>Bortezomib 1.6 mg/mÂ² given on days 1 and 8; Ri...</td>\n",
       "      <td>Bortezomib, Rituximab, Doxorubicin, Cyclophosp...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2015-11-15</td>\n",
       "      <td>Maximal Tolerated Doses of Bortezomib and Vinc...</td>\n",
       "      <td>An Estimate of the Overall Response Rate (ORR)...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2008-02-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2008-03-12</td>\n",
       "      <td>2008-02-11</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>18</th>\n",
       "      <td>This research is being done to compare rates o...</td>\n",
       "      <td>2028-06-01</td>\n",
       "      <td>Metastatic Breast Cancer, Chemotherapy-induced...</td>\n",
       "      <td>United States</td>\n",
       "      <td>SUPPORTIVE_CARE</td>\n",
       "      <td>This study is a prospective, controlled, pivot...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Men and women with a ...</td>\n",
       "      <td>120</td>\n",
       "      <td>Cap attached to coolant lines connected to a r...</td>\n",
       "      <td>Paxman Scalp Cooling System, Eribulin, Sacituz...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-06-01</td>\n",
       "      <td>Hair Loss Rate</td>\n",
       "      <td>Change in Patient Reported Quality of Life; Ch...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-10-07</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-03</td>\n",
       "      <td>2021-07-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>19</th>\n",
       "      <td>The purpose of this study is to assess the saf...</td>\n",
       "      <td>2024-10-15</td>\n",
       "      <td>Non-squamous Non-small-cell Lung Cancer, EGFR ...</td>\n",
       "      <td>Japan</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Have a histologicall...</td>\n",
       "      <td>30</td>\n",
       "      <td>IV infusion Q3W; Oral capsule once daily; IV i...</td>\n",
       "      <td>Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-10-31</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by B...</td>\n",
       "      <td>Objective Response Rate (ORR) as Assessed by i...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-02-28</td>\n",
       "      <td>2022-02-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>This is a single-center, single-arm, open-labe...</td>\n",
       "      <td>2023-07-06</td>\n",
       "      <td>Neuroendocrine Tumors</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Adults (males or fema...</td>\n",
       "      <td>17</td>\n",
       "      <td>Avelumab will be administered intravenously as...</td>\n",
       "      <td>Avelumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2021-07-26</td>\n",
       "      <td>Overall response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-11-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-09-11</td>\n",
       "      <td>2017-08-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>21</th>\n",
       "      <td>The investigartors will conduct a randomized, ...</td>\n",
       "      <td>2032-02-01</td>\n",
       "      <td>Non-Muscle Invasive Bladder Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tumour recurrence aft...</td>\n",
       "      <td>272</td>\n",
       "      <td>Chemoablation</td>\n",
       "      <td>Mitomycin c</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2029-02-01</td>\n",
       "      <td>Two-year Recurrence Free Survival</td>\n",
       "      <td>Five-year RFS; Number of patients in need of a...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-24</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-01-17</td>\n",
       "      <td>2025-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>22</th>\n",
       "      <td>The purpose of this study is to see if using P...</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Pancreatic Ductal Carcinoma, Advanced Cancer, ...</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>PDO is a three-dimensional experimental model ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age 18 years or over...</td>\n",
       "      <td>25</td>\n",
       "      <td>Cobimetinib is an antineoplastic agent and sel...</td>\n",
       "      <td>Cobimetinib, Ponatinib, Brigatinib, Colchicine...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2028-02-17</td>\n",
       "      <td>Objective response rate (ORR)</td>\n",
       "      <td>Disease control rate (DCR); Duration of respon...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-02-06</td>\n",
       "      <td>2025-02-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>23</th>\n",
       "      <td>To evaluate the safety and effectiveness of au...</td>\n",
       "      <td>2019-11-15</td>\n",
       "      <td>Liver Cancer, Pancreatic Adenocarcinoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Able to read and und...</td>\n",
       "      <td>20</td>\n",
       "      <td>vaccination of autologous gp96 derived from tu...</td>\n",
       "      <td>autologous gp96 vaccination</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2016-11-15</td>\n",
       "      <td>blood count; blood count; blood count; blood c...</td>\n",
       "      <td>Disease-free survival; overall survive; change...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-05-07</td>\n",
       "      <td>2014-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>24</th>\n",
       "      <td>RATIONALE: Radiation therapy uses high-energy ...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Cervical Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\n* Determine the toxicity of rad...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically p...</td>\n",
       "      <td>40</td>\n",
       "      <td>NaN</td>\n",
       "      <td>cisplatin, paclitaxel, brachytherapy, radiatio...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2007-01-15</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>1999-11-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2003-01-27</td>\n",
       "      <td>1999-11-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>25</th>\n",
       "      <td>To learn if sacituzumab govitecan and pembroli...</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Breast Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Primary Objective:\\n\\nâ¢ To determine the effic...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Female or male patie...</td>\n",
       "      <td>25</td>\n",
       "      <td>Given by IV (vein); Given by IV (vein)</td>\n",
       "      <td>Sacituzumab Govitecan, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-12-31</td>\n",
       "      <td>Incidence of Adverse Events, Graded According ...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2023-05-23</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-01-09</td>\n",
       "      <td>2022-12-22</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>26</th>\n",
       "      <td>The goal of this clinical research study is to...</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>Erlotinib hydrochloride is designed to block t...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female patie...</td>\n",
       "      <td>303</td>\n",
       "      <td>150 mg by mouth daily; Tablet by mouth daily</td>\n",
       "      <td>Erlotinib, Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2018-06-04</td>\n",
       "      <td>Oral Cancer-free Survival in Participants Rece...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-11-03</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-11-22</td>\n",
       "      <td>2006-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27</th>\n",
       "      <td>A Phase 1/2 Dose Escalation and Expansion Stud...</td>\n",
       "      <td>2025-04-30</td>\n",
       "      <td>ER+, HER2- Advanced Breast Cancer, Metastatic ...</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a phase â /â¡, open-label study of TFX06...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. voluntary participat...</td>\n",
       "      <td>74</td>\n",
       "      <td>TFX06 tablet taken orally</td>\n",
       "      <td>TFX06 tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-30</td>\n",
       "      <td>Recommended phase 2 Dose (RP2D); Disease Contr...</td>\n",
       "      <td>Incidence of Treatment-Emergent Adverse Events...</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2023-04-17</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2023-07-03</td>\n",
       "      <td>2023-06-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>28</th>\n",
       "      <td>Topical photodynamic therapy with methyl-amino...</td>\n",
       "      <td>2013-09-15</td>\n",
       "      <td>Nodular Basal Cell Carcinoma</td>\n",
       "      <td>Korea, Republic of</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Basal cell carcinoma (BCC) is the most common ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* patient's request for...</td>\n",
       "      <td>34</td>\n",
       "      <td>AFL was performed using a 2940-nm Er:YAG ablat...</td>\n",
       "      <td>Er:YAG AFL-PDT, MAL-PDT</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-02-15</td>\n",
       "      <td>Difference the efficacy between Er:YAG AFL-PDT...</td>\n",
       "      <td>Difference of the cosmetic outcomes between Er...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2011-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2013-12-23</td>\n",
       "      <td>2013-11-29</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>29</th>\n",
       "      <td>The purpose of this study is to evaluate the p...</td>\n",
       "      <td>2019-10-31</td>\n",
       "      <td>CD20 Positive B Cell NHL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a multi-center, randomized, double-bli...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Histological examinat...</td>\n",
       "      <td>60</td>\n",
       "      <td>Monoclonal antibodies, 100mg/10ml per injectio...</td>\n",
       "      <td>304 injection, rituximab injection</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-30</td>\n",
       "      <td>AUC [0-t]; AUC [0-â]; Cmax</td>\n",
       "      <td>tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2018-12-18</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2019-06-10</td>\n",
       "      <td>2019-06-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30</th>\n",
       "      <td>The purpose of the study is to address the fol...</td>\n",
       "      <td>2024-03-15</td>\n",
       "      <td>Triple Negative Breast Cancer</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed histo...</td>\n",
       "      <td>49</td>\n",
       "      <td>The PD-1 inhibitor Sintilimab 200mg for intrav...</td>\n",
       "      <td>Sintilimab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2023-12-15</td>\n",
       "      <td>Pathologic Complete Response (pCR)</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2021-03-15</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2021-03-22</td>\n",
       "      <td>2021-03-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>31</th>\n",
       "      <td>Study of elotuzumab in combination with pomali...</td>\n",
       "      <td>2020-06-12</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>For more information regarding BMS clinical tr...</td>\n",
       "      <td>74</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Elotuzumab, Pomalidomide, Dexamethasone, Nivol...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-07-29</td>\n",
       "      <td>Progression Free Survival (PFS); Objective Res...</td>\n",
       "      <td>Objective Response Rate (ORR); Progression Fre...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-02-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-11-24</td>\n",
       "      <td>2015-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>32</th>\n",
       "      <td>RATIONALE: CT-322 may stop the growth of solid...</td>\n",
       "      <td>2009-02-15</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>DISEASE CHARACTERISTICS\\n\\n* Histologically pr...</td>\n",
       "      <td>40</td>\n",
       "      <td>IV solution, weekly or bi-weekly</td>\n",
       "      <td>CT-322</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2008-11-15</td>\n",
       "      <td>Safety and tolerability of CT-322</td>\n",
       "      <td>To evaluate the pharmacokinetics of CT-322 in ...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-08-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2006-09-11</td>\n",
       "      <td>2006-09-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>33</th>\n",
       "      <td>This is a single-arm, single-center, open-labe...</td>\n",
       "      <td>2025-12-31</td>\n",
       "      <td>B-cell Acute Lymphoblastic Leukemia, B-ALL</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Although the anti-CD19 CAR-T cell therapies ha...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Male or female, aged...</td>\n",
       "      <td>30</td>\n",
       "      <td>UCAR-T Cellswill be administered by vein. The ...</td>\n",
       "      <td>UCAR-T Cells</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Dose-limiting toxicity (DLT); Incidence of Tre...</td>\n",
       "      <td>Persistence of CAR-T cells; Objective response...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2022-12-05</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2022-12-06</td>\n",
       "      <td>2022-11-25</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34</th>\n",
       "      <td>The purpose of this study is to determine if t...</td>\n",
       "      <td>2024-08-07</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Croatia, Greece, United States, Argentina, Jap...</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>The study consists of 3 phases: Screening Phas...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Participant must have...</td>\n",
       "      <td>706</td>\n",
       "      <td>Participants will receive velcade 1.3 mg/m\\^2,...</td>\n",
       "      <td>Velcade, Melphalan, Prednisone, Daratumumab IV...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2017-11-21</td>\n",
       "      <td>Progression Free Survival (PFS)</td>\n",
       "      <td>Overall Response Rate (ORR); Percentage of Par...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-12-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2014-07-21</td>\n",
       "      <td>2014-07-18</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>35</th>\n",
       "      <td>This study is examining a chemotherapy regimen...</td>\n",
       "      <td>2022-02-11</td>\n",
       "      <td>Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age less than or equ...</td>\n",
       "      <td>20</td>\n",
       "      <td>Fludarabine: 30 mg/m2 daily for 5 days; Busulf...</td>\n",
       "      <td>Fludarabine, Busulfan, Rabbit ATG, Methotrexate</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-06-07</td>\n",
       "      <td>Number of patients who are surviving at 100-Da...</td>\n",
       "      <td>Time to marrow engraftment; Assessing all subj...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2016-09-06</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2016-09-28</td>\n",
       "      <td>2016-08-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>36</th>\n",
       "      <td>This is a single-center, single-arm, phase Ib/...</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>NMIBC</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Age â¥18 years old, b...</td>\n",
       "      <td>58</td>\n",
       "      <td>SHR-1501, instillationï¼SHR-2005, instillation</td>\n",
       "      <td>SHR-1501+SHR-2005</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2027-10-01</td>\n",
       "      <td>Phase I : Incidence of dose limiting toxicitie...</td>\n",
       "      <td>Phase I : CR rate at 3 months; Phase II : Inci...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-09-19</td>\n",
       "      <td>2024-09-05</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>37</th>\n",
       "      <td>This is an open-label, multicenter, dose-escal...</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>Acute Myeloid Leukemia, Acute Myelogenous Leuk...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n* Single agent (SA)...</td>\n",
       "      <td>94</td>\n",
       "      <td>FT-1101 will be supplied as 5 mg, 20 mg or 100...</td>\n",
       "      <td>FT-1101, Azacitidine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2019-03-15</td>\n",
       "      <td>Maximum Tolerated Dose (MTD); Dose Limiting To...</td>\n",
       "      <td>Area under the plasma concentration versus tim...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-09-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-09-07</td>\n",
       "      <td>2015-09-01</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38</th>\n",
       "      <td>Dual center, single arm, two-stage, non-blinde...</td>\n",
       "      <td>2019-12-04</td>\n",
       "      <td>Glioblastoma</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* At least 18 years of ...</td>\n",
       "      <td>35</td>\n",
       "      <td>10mg/kg; 670mg/m2</td>\n",
       "      <td>Bevacizumab, TH-302</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2019-01-04</td>\n",
       "      <td>Number of Patients With Adverse Events</td>\n",
       "      <td>Progression Free Survival</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2015-05-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2015-01-19</td>\n",
       "      <td>2015-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>39</th>\n",
       "      <td>RATIONALE: Drugs used in chemotherapy, such as...</td>\n",
       "      <td>2009-02-10</td>\n",
       "      <td>Head and Neck Cancer</td>\n",
       "      <td>Canada</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...</td>\n",
       "      <td>DISEASE CHARACTERISTICS:\\n\\n* Histologically o...</td>\n",
       "      <td>34</td>\n",
       "      <td>NaN</td>\n",
       "      <td>carboplatin, cisplatin, gemcitabine hydrochloride</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2008-09-29</td>\n",
       "      <td>Objective response measured by RECIST criteria...</td>\n",
       "      <td>Toxicity assessed by NCI CTC v2.0; Overall sur...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2003-10-27</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2004-03-09</td>\n",
       "      <td>2004-03-08</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>40</th>\n",
       "      <td>The purposes of this study are to determine th...</td>\n",
       "      <td>NaT</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Definition: The phase 2 study will provide imp...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...</td>\n",
       "      <td>?</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Gemcitabine, Carboplatin, LY900003</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>NaT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2002-06-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2002-08-06</td>\n",
       "      <td>2002-08-02</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>41</th>\n",
       "      <td>The main purpose of this Phase 1/2 study is to...</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>Small-cell Lung Cancer</td>\n",
       "      <td>Puerto Rico, United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Key Inclusion Criteria:\\n\\n1. Patient is able ...</td>\n",
       "      <td>68</td>\n",
       "      <td>Administered IV; Administered IV</td>\n",
       "      <td>Pegzilarginase, Pembrolizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1, PHASE2</td>\n",
       "      <td>2021-01-01</td>\n",
       "      <td>1. Phase 1: Incidence of treatment-related adv...</td>\n",
       "      <td>Objective Response Rate; Clinical Benefit Rate...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2017-12-21</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2017-12-13</td>\n",
       "      <td>2017-11-20</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>42</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2013-09-15</td>\n",
       "      <td>Colorectal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>HEALTH_SERVICES_RESEARCH</td>\n",
       "      <td>This study will test the separate and combined...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Patients aged 50-75 y...</td>\n",
       "      <td>569</td>\n",
       "      <td>Physicians at these clinics will participate i...</td>\n",
       "      <td>Physician Intervention, Physician and Patient ...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>2013-07-15</td>\n",
       "      <td>Colorectal Cancer (CRC) Screening Completion; ...</td>\n",
       "      <td>Provider Recommendation of CRC Screening</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-04-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-04-14</td>\n",
       "      <td>2010-04-12</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>43</th>\n",
       "      <td>Maintenance durvalumab (MEDI4736) and olaparib...</td>\n",
       "      <td>2026-12-15</td>\n",
       "      <td>Small Cell Lung Carcinoma</td>\n",
       "      <td>Germany</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria Pre-Screening:\\n\\n* Newly d...</td>\n",
       "      <td>29</td>\n",
       "      <td>1500 mg i.v. Q4W; 300 mg BID orally</td>\n",
       "      <td>Durvalumab, Olaparib</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-09-15</td>\n",
       "      <td>Progression-free survival (PFS)</td>\n",
       "      <td>Incidence, severity and grading of adverse eve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-10-09</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-05-17</td>\n",
       "      <td>2024-05-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>44</th>\n",
       "      <td>There is no muture method to treat EGFR 20 ins...</td>\n",
       "      <td>2024-12-31</td>\n",
       "      <td>Carcinoma, Non-Small-Cell Lung</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Lung cancer is one of the most common types of...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nParticipant must have h...</td>\n",
       "      <td>20</td>\n",
       "      <td>Osimertinib, 80mg, oral daily; bevacizumab (av...</td>\n",
       "      <td>Osimertinib Oral Tablet</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2024-07-31</td>\n",
       "      <td>Progression free survival</td>\n",
       "      <td>Objective Response Rate (ORR); Overall Surviva...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-07-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-07-23</td>\n",
       "      <td>2021-07-16</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45</th>\n",
       "      <td>This is a randomized, open-label, phase 2 stud...</td>\n",
       "      <td>2027-02-15</td>\n",
       "      <td>Glioblastoma, IDH-wildtype</td>\n",
       "      <td>United States</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This is a randomized, open-label phase 2 study...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Written informed cons...</td>\n",
       "      <td>54</td>\n",
       "      <td>Ropidoxuridine is administered daily, 5 days a...</td>\n",
       "      <td>Ropidoxuridine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2026-08-15</td>\n",
       "      <td>Number of patients treated with oral ropidoxur...</td>\n",
       "      <td>Overall survival at 12 months; Radiographic Re...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2024-09-02</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2024-04-11</td>\n",
       "      <td>2024-03-24</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>46</th>\n",
       "      <td>From Protocol v3.0 dated 16Jun2022. This is an...</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Melanoma (Skin), Non-Small-Cell Lung Carcinoma</td>\n",
       "      <td>Spain, Belgium, United Kingdom</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Overall Study Design:\\n\\nâ¢ This is an open-lab...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nMain Inclusion Criteria...</td>\n",
       "      <td>34</td>\n",
       "      <td>Priming phase including 1 GAd-PEV administrati...</td>\n",
       "      <td>GAd-PEV, MVA-PEV</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2024-10-31</td>\n",
       "      <td>Safety and tolerability: incidence of treatmen...</td>\n",
       "      <td>RP2D confirmation 2. Clinical efficacy:; Clini...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2021-06-11</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2021-08-04</td>\n",
       "      <td>2021-07-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>47</th>\n",
       "      <td>The proposed study will evaluate whether the c...</td>\n",
       "      <td>2014-07-15</td>\n",
       "      <td>Multiple Myeloma</td>\n",
       "      <td>Italy</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>This phase III study represents a prospective ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age \\&gt; 65 year old an...</td>\n",
       "      <td>511</td>\n",
       "      <td>Induction therapy:\\n\\n9 courses with weekly VE...</td>\n",
       "      <td>Bortezomib, Melphalan, Prednisone, Thalidomide...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2014-07-15</td>\n",
       "      <td>Determine whether the V-MPT combination improv...</td>\n",
       "      <td>Determine whether the VMPT combination improve...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2006-05-15</td>\n",
       "      <td>OLDER_ADULT</td>\n",
       "      <td>2010-02-05</td>\n",
       "      <td>2010-02-04</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>48</th>\n",
       "      <td>The purpose of this study is to evaluate the e...</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>Extranodal NK/T-cell Lymphoma</td>\n",
       "      <td>China</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Previous study has confirmed the efficacy of a...</td>\n",
       "      <td>Inclusion Criteria:\\n\\nHistopathology and immu...</td>\n",
       "      <td>20</td>\n",
       "      <td>200mg d1,ivdrip, repeated every 3 weeks; 10mg ...</td>\n",
       "      <td>Sintilimab, Decitabine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>complete response rate</td>\n",
       "      <td>overall response rate; 1-year progression free...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-04-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-02-21</td>\n",
       "      <td>2020-02-19</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>49</th>\n",
       "      <td>The purpose of this study is to evaluate the i...</td>\n",
       "      <td>2013-08-15</td>\n",
       "      <td>Esophageal Cancer</td>\n",
       "      <td>United States</td>\n",
       "      <td>DIAGNOSTIC</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Newly diagnosed or re...</td>\n",
       "      <td>22</td>\n",
       "      <td>15 mCi 11C-choline will be administered intrav...</td>\n",
       "      <td>C11-Choline</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-08-15</td>\n",
       "      <td>To evaluate our ability to obtain reliable and...</td>\n",
       "      <td>Perform semi-quantitative analysis of tracer u...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2010-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2010-01-18</td>\n",
       "      <td>2010-01-15</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>50 rows Ã 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                        brief_summary completion_date  \\\n",
       "0   Nivolumab, also known as (Bristol Myers Squibb...      2023-10-17   \n",
       "1   The aim of this explorative phase II clinical ...      2021-11-01   \n",
       "2   This study was a randomized, controlled, open-...      2027-06-15   \n",
       "3   This is a randomised, double-blind, positive d...      2022-05-20   \n",
       "4   This phase II trial tests how well decitabine ...      2029-03-15   \n",
       "5   This is a phase 2 single-arm, open-label clini...      2024-12-30   \n",
       "6   A phase I trial in patients with relapsed or r...      2009-07-15   \n",
       "7   RATIONALE: The timing of breast cancer surgery...      2004-10-15   \n",
       "8   To determine the safety, tolerability, and rec...      2024-12-30   \n",
       "9   This is an exploratory phase 2, randomized pla...      2011-10-15   \n",
       "10  PRI-724 is a new investigational drug being st...      2016-12-30   \n",
       "11  Longterm disease-free survival (DFS) of older ...      2017-09-15   \n",
       "12  RATIONALE: Combinations of biological substanc...      2017-07-27   \n",
       "13  The purpose of this conversion therapy study i...      2024-04-30   \n",
       "14  RATIONALE: MS-275 may stop the growth of cance...      2008-10-15   \n",
       "15  The study is a feasibility and validation stud...      2009-01-15   \n",
       "16  This study is a phase I study designed to eval...      2031-01-15   \n",
       "17  This is an open-label (doctors and patients kn...      2015-11-15   \n",
       "18  This research is being done to compare rates o...      2028-06-01   \n",
       "19  The purpose of this study is to assess the saf...      2024-10-15   \n",
       "20  This is a single-center, single-arm, open-labe...      2023-07-06   \n",
       "21  The investigartors will conduct a randomized, ...      2032-02-01   \n",
       "22  The purpose of this study is to see if using P...      2028-02-17   \n",
       "23  To evaluate the safety and effectiveness of au...      2019-11-15   \n",
       "24  RATIONALE: Radiation therapy uses high-energy ...             NaT   \n",
       "25  To learn if sacituzumab govitecan and pembroli...      2026-12-31   \n",
       "26  The goal of this clinical research study is to...      2018-06-04   \n",
       "27  A Phase 1/2 Dose Escalation and Expansion Stud...      2025-04-30   \n",
       "28  Topical photodynamic therapy with methyl-amino...      2013-09-15   \n",
       "29  The purpose of this study is to evaluate the p...      2019-10-31   \n",
       "30  The purpose of the study is to address the fol...      2024-03-15   \n",
       "31  Study of elotuzumab in combination with pomali...      2020-06-12   \n",
       "32  RATIONALE: CT-322 may stop the growth of solid...      2009-02-15   \n",
       "33  This is a single-arm, single-center, open-labe...      2025-12-31   \n",
       "34  The purpose of this study is to determine if t...      2024-08-07   \n",
       "35  This study is examining a chemotherapy regimen...      2022-02-11   \n",
       "36  This is a single-center, single-arm, phase Ib/...      2027-10-01   \n",
       "37  This is an open-label, multicenter, dose-escal...      2019-03-15   \n",
       "38  Dual center, single arm, two-stage, non-blinde...      2019-12-04   \n",
       "39  RATIONALE: Drugs used in chemotherapy, such as...      2009-02-10   \n",
       "40  The purposes of this study are to determine th...             NaT   \n",
       "41  The main purpose of this Phase 1/2 study is to...      2021-01-01   \n",
       "42  The purpose of this study is to evaluate the e...      2013-09-15   \n",
       "43  Maintenance durvalumab (MEDI4736) and olaparib...      2026-12-15   \n",
       "44  There is no muture method to treat EGFR 20 ins...      2024-12-31   \n",
       "45  This is a randomized, open-label, phase 2 stud...      2027-02-15   \n",
       "46  From Protocol v3.0 dated 16Jun2022. This is an...      2024-10-31   \n",
       "47  The proposed study will evaluate whether the c...      2014-07-15   \n",
       "48  The purpose of this study is to evaluate the e...      2022-12-31   \n",
       "49  The purpose of this study is to evaluate the i...      2013-08-15   \n",
       "\n",
       "                                           conditions  \\\n",
       "0   Head and Neck Squamous Cell Carcinoma, Head an...   \n",
       "1                                   Colorectal Cancer   \n",
       "2                          Non-small Cell Lung Cancer   \n",
       "3                       Diffuse Large B-Cell Lymphoma   \n",
       "4                    Recurrent Acute Myeloid Leukemia   \n",
       "5     Gastric Adenocarcinoma, GastroEsophageal Cancer   \n",
       "6   Leukemia, Lymphocytic, Leukemia, Acute Lymphoc...   \n",
       "7                                       Breast Cancer   \n",
       "8                                      Advanced Tumor   \n",
       "9                                        Colon Cancer   \n",
       "10   Acute Myeloid Leukemia, Chronic Myeloid Leukemia   \n",
       "11                                                AML   \n",
       "12  Leukemia, Myelodysplastic Syndromes, Blastic P...   \n",
       "13                                   NSCLC, Stage III   \n",
       "14                                             Cancer   \n",
       "15                                  Colonic Neoplasms   \n",
       "16  Acute Lymphoblastic Leukemia, Recurrent Acute ...   \n",
       "17              Lymphoma, B-Cell, Follicular Lymphoma   \n",
       "18  Metastatic Breast Cancer, Chemotherapy-induced...   \n",
       "19  Non-squamous Non-small-cell Lung Cancer, EGFR ...   \n",
       "20                              Neuroendocrine Tumors   \n",
       "21                 Non-Muscle Invasive Bladder Cancer   \n",
       "22  Pancreatic Ductal Carcinoma, Advanced Cancer, ...   \n",
       "23            Liver Cancer, Pancreatic Adenocarcinoma   \n",
       "24                                    Cervical Cancer   \n",
       "25                                      Breast Cancer   \n",
       "26                                        Oral Cancer   \n",
       "27  ER+, HER2- Advanced Breast Cancer, Metastatic ...   \n",
       "28                       Nodular Basal Cell Carcinoma   \n",
       "29                           CD20 Positive B Cell NHL   \n",
       "30                      Triple Negative Breast Cancer   \n",
       "31                                   Multiple Myeloma   \n",
       "32                                             Cancer   \n",
       "33         B-cell Acute Lymphoblastic Leukemia, B-ALL   \n",
       "34                                   Multiple Myeloma   \n",
       "35  Leukemia, Lymphoid, Leukemia, Myeloid, Myelody...   \n",
       "36                                              NMIBC   \n",
       "37  Acute Myeloid Leukemia, Acute Myelogenous Leuk...   \n",
       "38                                       Glioblastoma   \n",
       "39                               Head and Neck Cancer   \n",
       "40  Carcinoma, Non-Small-Cell Lung, Pulmonary Neop...   \n",
       "41                             Small-cell Lung Cancer   \n",
       "42                                  Colorectal Cancer   \n",
       "43                          Small Cell Lung Carcinoma   \n",
       "44                     Carcinoma, Non-Small-Cell Lung   \n",
       "45                         Glioblastoma, IDH-wildtype   \n",
       "46     Melanoma (Skin), Non-Small-Cell Lung Carcinoma   \n",
       "47                                   Multiple Myeloma   \n",
       "48                      Extranodal NK/T-cell Lymphoma   \n",
       "49                                  Esophageal Cancer   \n",
       "\n",
       "                                              country  \\\n",
       "0                                       United States   \n",
       "1                                             Denmark   \n",
       "2                                               China   \n",
       "3                                               China   \n",
       "4                                       United States   \n",
       "5                                       United States   \n",
       "6                                       United States   \n",
       "7                                       United States   \n",
       "8                                               China   \n",
       "9                                       United States   \n",
       "10                                      United States   \n",
       "11                                            Germany   \n",
       "12                                      United States   \n",
       "13                                              China   \n",
       "14                                      United States   \n",
       "15                                        Switzerland   \n",
       "16                                      United States   \n",
       "17                                      United States   \n",
       "18                                      United States   \n",
       "19                                              Japan   \n",
       "20                                             Canada   \n",
       "21                                                NaN   \n",
       "22                                             Canada   \n",
       "23                                              China   \n",
       "24                                      United States   \n",
       "25                                      United States   \n",
       "26                                      United States   \n",
       "27                                              China   \n",
       "28                                 Korea, Republic of   \n",
       "29                                              China   \n",
       "30                                              China   \n",
       "31                                      United States   \n",
       "32                                      United States   \n",
       "33                                              China   \n",
       "34  Croatia, Greece, United States, Argentina, Jap...   \n",
       "35                                      United States   \n",
       "36                                              China   \n",
       "37                                      United States   \n",
       "38                                      United States   \n",
       "39                                             Canada   \n",
       "40                                      United States   \n",
       "41                         Puerto Rico, United States   \n",
       "42                                      United States   \n",
       "43                                            Germany   \n",
       "44                                              China   \n",
       "45                                      United States   \n",
       "46                     Spain, Belgium, United Kingdom   \n",
       "47                                              Italy   \n",
       "48                                              China   \n",
       "49                                      United States   \n",
       "\n",
       "      design_primary_purpose  \\\n",
       "0                  TREATMENT   \n",
       "1                  TREATMENT   \n",
       "2                  TREATMENT   \n",
       "3                  TREATMENT   \n",
       "4                  TREATMENT   \n",
       "5                  TREATMENT   \n",
       "6                  TREATMENT   \n",
       "7                  TREATMENT   \n",
       "8                  TREATMENT   \n",
       "9                  TREATMENT   \n",
       "10                 TREATMENT   \n",
       "11                 TREATMENT   \n",
       "12                 TREATMENT   \n",
       "13                 TREATMENT   \n",
       "14                 TREATMENT   \n",
       "15                DIAGNOSTIC   \n",
       "16                 TREATMENT   \n",
       "17                 TREATMENT   \n",
       "18           SUPPORTIVE_CARE   \n",
       "19                 TREATMENT   \n",
       "20                 TREATMENT   \n",
       "21                 TREATMENT   \n",
       "22                 TREATMENT   \n",
       "23                 TREATMENT   \n",
       "24                 TREATMENT   \n",
       "25                 TREATMENT   \n",
       "26                PREVENTION   \n",
       "27                 TREATMENT   \n",
       "28                 TREATMENT   \n",
       "29                 TREATMENT   \n",
       "30                 TREATMENT   \n",
       "31                 TREATMENT   \n",
       "32                 TREATMENT   \n",
       "33                 TREATMENT   \n",
       "34                 TREATMENT   \n",
       "35                 TREATMENT   \n",
       "36                 TREATMENT   \n",
       "37                 TREATMENT   \n",
       "38                 TREATMENT   \n",
       "39                 TREATMENT   \n",
       "40                 TREATMENT   \n",
       "41                 TREATMENT   \n",
       "42  HEALTH_SERVICES_RESEARCH   \n",
       "43                 TREATMENT   \n",
       "44                 TREATMENT   \n",
       "45                 TREATMENT   \n",
       "46                 TREATMENT   \n",
       "47                 TREATMENT   \n",
       "48                 TREATMENT   \n",
       "49                DIAGNOSTIC   \n",
       "\n",
       "                                 detailed_description  \\\n",
       "0   This research is being done to see if it is sa...   \n",
       "1   This is an explorative phase 2 clinical trial ...   \n",
       "2                                                 NaN   \n",
       "3                                                 NaN   \n",
       "4   PRIMARY OBJECTIVE:\\n\\nI. To assess the effect ...   \n",
       "5   Treatment on study will be administered in 21 ...   \n",
       "6                                                 NaN   \n",
       "7   OBJECTIVES:\\n\\n* Determine if the timing of br...   \n",
       "8                                                 NaN   \n",
       "9   This is an exploratory phase 2, randomized pla...   \n",
       "10  PRI-724 is a new investigational drug being st...   \n",
       "11                                                NaN   \n",
       "12  OBJECTIVES:\\n\\n* Determine the maximum tolerat...   \n",
       "13                                                NaN   \n",
       "14  OBJECTIVES:\\n\\n* Determine the dose-limiting t...   \n",
       "15                                                NaN   \n",
       "16  Treatment will include a single course of lymp...   \n",
       "17  This study will assess whether adding bortezom...   \n",
       "18  This study is a prospective, controlled, pivot...   \n",
       "19                                                NaN   \n",
       "20                                                NaN   \n",
       "21                                                NaN   \n",
       "22  PDO is a three-dimensional experimental model ...   \n",
       "23                                                NaN   \n",
       "24  OBJECTIVES:\\n\\n* Determine the toxicity of rad...   \n",
       "25  Primary Objective:\\n\\nâ¢ To determine the effic...   \n",
       "26  Erlotinib hydrochloride is designed to block t...   \n",
       "27  This is a phase â /â¡, open-label study of TFX06...   \n",
       "28  Basal cell carcinoma (BCC) is the most common ...   \n",
       "29  This is a multi-center, randomized, double-bli...   \n",
       "30                                                NaN   \n",
       "31                                                NaN   \n",
       "32                                                NaN   \n",
       "33  Although the anti-CD19 CAR-T cell therapies ha...   \n",
       "34  The study consists of 3 phases: Screening Phas...   \n",
       "35                                                NaN   \n",
       "36                                                NaN   \n",
       "37                                                NaN   \n",
       "38                                                NaN   \n",
       "39  OBJECTIVES:\\n\\nPrimary\\n\\n* Determine the acti...   \n",
       "40  Definition: The phase 2 study will provide imp...   \n",
       "41                                                NaN   \n",
       "42  This study will test the separate and combined...   \n",
       "43                                                NaN   \n",
       "44  Lung cancer is one of the most common types of...   \n",
       "45  This is a randomized, open-label phase 2 study...   \n",
       "46  Overall Study Design:\\n\\nâ¢ This is an open-lab...   \n",
       "47  This phase III study represents a prospective ...   \n",
       "48  Previous study has confirmed the efficacy of a...   \n",
       "49                                                NaN   \n",
       "\n",
       "                                 eligibility_criteria enrollment  \\\n",
       "0   Inclusion:\\n\\nCohort 1: Subjects must have his...         26   \n",
       "1   Inclusion Criteria:\\n\\n* Patients must be ment...         10   \n",
       "2   Inclusion Criteria:\\n\\n1. Age 18 to 75 years o...        500   \n",
       "3   Inclusion Criteria:\\n\\n* 18-75 years old, male...        421   \n",
       "4   Inclusion Criteria:\\n\\n* Age \\>= 18 years at t...         51   \n",
       "5   Inclusion Criteria:\\n\\n* Patients must have hi...         20   \n",
       "6   Inclusion Criteria:\\n\\n3.1.1 Age Patients must...          9   \n",
       "7   DISEASE CHARACTERISTICS:\\n\\n* Histologically c...          ?   \n",
       "8   Inclusion Criteria:\\n\\n1. Age: 18-75 years old...         40   \n",
       "9   Inclusion Criteria:\\n\\n1. In the opinion of th...        381   \n",
       "10  Inclusion Criteria\\n\\n1. Patients 18 years or ...         49   \n",
       "11  Inclusion Criteria:\\n\\n1. Subjects must provid...         16   \n",
       "12  DISEASE CHARACTERISTICS:\\n\\n* Diagnosis of 1 o...         11   \n",
       "13  Inclusion Criteria:\\n\\n* Written informed cons...         30   \n",
       "14  DISEASE CHARACTERISTICS:\\n\\n* Histologically c...         75   \n",
       "15  Inclusion Criteria:\\n\\n* Colon cancer at any s...        192   \n",
       "16  Collection and Manufacturing Eligibility\\n\\nIn...         30   \n",
       "17  Inclusion Criteria:\\n\\n* Tissue diagnosis of a...         37   \n",
       "18  Inclusion Criteria:\\n\\n* Men and women with a ...        120   \n",
       "19  Inclusion Criteria:\\n\\n1. Have a histologicall...         30   \n",
       "20  Inclusion Criteria:\\n\\n* Adults (males or fema...         17   \n",
       "21  Inclusion Criteria:\\n\\n* Tumour recurrence aft...        272   \n",
       "22  Inclusion Criteria:\\n\\n1. Age 18 years or over...         25   \n",
       "23  Inclusion Criteria:\\n\\n1. Able to read and und...         20   \n",
       "24  DISEASE CHARACTERISTICS:\\n\\n* Histologically p...         40   \n",
       "25  Inclusion Criteria:\\n\\n1. Female or male patie...         25   \n",
       "26  Inclusion Criteria:\\n\\n1. Male or female patie...        303   \n",
       "27  Inclusion Criteria:\\n\\n1. voluntary participat...         74   \n",
       "28  Inclusion Criteria:\\n\\n* patient's request for...         34   \n",
       "29  Inclusion Criteria:\\n\\n* Histological examinat...         60   \n",
       "30  Inclusion Criteria:\\n\\n* Newly diagnosed histo...         49   \n",
       "31  For more information regarding BMS clinical tr...         74   \n",
       "32  DISEASE CHARACTERISTICS\\n\\n* Histologically pr...         40   \n",
       "33  Inclusion Criteria:\\n\\n1. Male or female, aged...         30   \n",
       "34  Inclusion Criteria:\\n\\n* Participant must have...        706   \n",
       "35  Inclusion Criteria:\\n\\n1. Age less than or equ...         20   \n",
       "36  Inclusion Criteria:\\n\\n1. Age â¥18 years old, b...         58   \n",
       "37  Key Inclusion Criteria:\\n\\n* Single agent (SA)...         94   \n",
       "38  Inclusion Criteria:\\n\\n* At least 18 years of ...         35   \n",
       "39  DISEASE CHARACTERISTICS:\\n\\n* Histologically o...         34   \n",
       "40  Inclusion Criteria:\\n\\n* Diagnosis of Non-Smal...          ?   \n",
       "41  Key Inclusion Criteria:\\n\\n1. Patient is able ...         68   \n",
       "42  Inclusion Criteria:\\n\\n* Patients aged 50-75 y...        569   \n",
       "43  Inclusion Criteria Pre-Screening:\\n\\n* Newly d...         29   \n",
       "44  Inclusion Criteria:\\n\\nParticipant must have h...         20   \n",
       "45  Inclusion Criteria:\\n\\n* Written informed cons...         54   \n",
       "46  Inclusion Criteria:\\n\\nMain Inclusion Criteria...         34   \n",
       "47  Inclusion Criteria:\\n\\n* Age \\> 65 year old an...        511   \n",
       "48  Inclusion Criteria:\\n\\nHistopathology and immu...         20   \n",
       "49  Inclusion Criteria:\\n\\n* Newly diagnosed or re...         22   \n",
       "\n",
       "                            interventions_description  \\\n",
       "0   One dose of Nivolumab 480mg given four weeks p...   \n",
       "1   Intratumoral application of an unattenuated in...   \n",
       "2   SHR-A2009 monotherapy ï¼SHR-A2009 will be admin...   \n",
       "3          Injectionï¼100mg/10ml; Injectionï¼100mg/10ml   \n",
       "4   Given by mouth; Given by mouth; Given by mouth...   \n",
       "5                                  Given PO; Given IV   \n",
       "6   Dosage: 1.25mg/kg intravenous with dose escala...   \n",
       "7                                                 NaN   \n",
       "8   In the phase, five dose groups were proposed.T...   \n",
       "9   Perifosine 50 mg/d qd; Capecitabine 825 mg/m\\^...   \n",
       "10  PRI-724; PRI-724 in combination with dasatinib...   \n",
       "11                                                NaN   \n",
       "12  Intravenously via a 3 cc plastic syringe as a ...   \n",
       "13  Tislelizumab: 200mg, IV, day 1 of each 21-day ...   \n",
       "14                                                NaN   \n",
       "15  After careful mobilization of the affected col...   \n",
       "16  IV; IV; IV; CAR T cell infusion will be given ...   \n",
       "17  Bortezomib 1.6 mg/mÂ² given on days 1 and 8; Ri...   \n",
       "18  Cap attached to coolant lines connected to a r...   \n",
       "19  IV infusion Q3W; Oral capsule once daily; IV i...   \n",
       "20  Avelumab will be administered intravenously as...   \n",
       "21                                      Chemoablation   \n",
       "22  Cobimetinib is an antineoplastic agent and sel...   \n",
       "23  vaccination of autologous gp96 derived from tu...   \n",
       "24                                                NaN   \n",
       "25             Given by IV (vein); Given by IV (vein)   \n",
       "26       150 mg by mouth daily; Tablet by mouth daily   \n",
       "27                          TFX06 tablet taken orally   \n",
       "28  AFL was performed using a 2940-nm Er:YAG ablat...   \n",
       "29  Monoclonal antibodies, 100mg/10ml per injectio...   \n",
       "30  The PD-1 inhibitor Sintilimab 200mg for intrav...   \n",
       "31                                                NaN   \n",
       "32                   IV solution, weekly or bi-weekly   \n",
       "33  UCAR-T Cellswill be administered by vein. The ...   \n",
       "34  Participants will receive velcade 1.3 mg/m\\^2,...   \n",
       "35  Fludarabine: 30 mg/m2 daily for 5 days; Busulf...   \n",
       "36      SHR-1501, instillationï¼SHR-2005, instillation   \n",
       "37  FT-1101 will be supplied as 5 mg, 20 mg or 100...   \n",
       "38                                  10mg/kg; 670mg/m2   \n",
       "39                                                NaN   \n",
       "40                                                NaN   \n",
       "41                   Administered IV; Administered IV   \n",
       "42  Physicians at these clinics will participate i...   \n",
       "43                1500 mg i.v. Q4W; 300 mg BID orally   \n",
       "44  Osimertinib, 80mg, oral daily; bevacizumab (av...   \n",
       "45  Ropidoxuridine is administered daily, 5 days a...   \n",
       "46  Priming phase including 1 GAd-PEV administrati...   \n",
       "47  Induction therapy:\\n\\n9 courses with weekly VE...   \n",
       "48  200mg d1,ivdrip, repeated every 3 weeks; 10mg ...   \n",
       "49  15 mCi 11C-choline will be administered intrav...   \n",
       "\n",
       "                                   interventions_name  ...           phase  \\\n",
       "0              Nivolumab 480mg and surgical resection  ...          PHASE2   \n",
       "1                                  Influenza Vaccines  ...          PHASE2   \n",
       "2   SHR-A2009 monotherapy, platinum-based dual-age...  ...          PHASE3   \n",
       "3                                  SIBP-02, Rituximab  ...          PHASE3   \n",
       "4   Venetoclax, Decitabine, Cedazuridine, Bone Mar...  ...          PHASE2   \n",
       "5                         Cabozantinib, Pembrolizumab  ...          PHASE2   \n",
       "6                                MAb 216, Vincristine  ...          PHASE1   \n",
       "7                                conventional surgery  ...          PHASE3   \n",
       "8                                            QLF32004  ...          PHASE1   \n",
       "9        Perifosine, Capecitabine, Perifosine Placebo  ...          PHASE2   \n",
       "10                          PRI-724, PRI-724, PRI-724  ...  PHASE1, PHASE2   \n",
       "11                         Tranylcypromine, Tretinoin  ...  PHASE1, PHASE2   \n",
       "12                                           DT388IL3  ...  PHASE1, PHASE2   \n",
       "13  Tislelizumab, Pemetrexed (Nonsquamous NSCLC) o...  ...          PHASE2   \n",
       "14                                         entinostat  ...          PHASE1   \n",
       "15  Sentinel lymph node procedure, Bone marrow asp...  ...  PHASE1, PHASE2   \n",
       "16  Fludarabine, Cyclophosphamide, Mesna, CD19-CD2...  ...          PHASE1   \n",
       "17  Bortezomib, Rituximab, Doxorubicin, Cyclophosp...  ...  PHASE1, PHASE2   \n",
       "18  Paxman Scalp Cooling System, Eribulin, Sacituz...  ...          PHASE2   \n",
       "19  Pembrolizumab, Lenvatinib, Carboplatin, Pemetr...  ...          PHASE2   \n",
       "20                                           Avelumab  ...          PHASE2   \n",
       "21                                        Mitomycin c  ...          PHASE4   \n",
       "22  Cobimetinib, Ponatinib, Brigatinib, Colchicine...  ...          PHASE2   \n",
       "23                        autologous gp96 vaccination  ...  PHASE1, PHASE2   \n",
       "24  cisplatin, paclitaxel, brachytherapy, radiatio...  ...  PHASE1, PHASE2   \n",
       "25               Sacituzumab Govitecan, Pembrolizumab  ...          PHASE2   \n",
       "26                                 Erlotinib, Placebo  ...          PHASE3   \n",
       "27                                       TFX06 tablet  ...  PHASE1, PHASE2   \n",
       "28                            Er:YAG AFL-PDT, MAL-PDT  ...          PHASE1   \n",
       "29                 304 injection, rituximab injection  ...          PHASE1   \n",
       "30                                         Sintilimab  ...          PHASE2   \n",
       "31  Elotuzumab, Pomalidomide, Dexamethasone, Nivol...  ...          PHASE2   \n",
       "32                                             CT-322  ...          PHASE1   \n",
       "33                                       UCAR-T Cells  ...  PHASE1, PHASE2   \n",
       "34  Velcade, Melphalan, Prednisone, Daratumumab IV...  ...          PHASE3   \n",
       "35    Fludarabine, Busulfan, Rabbit ATG, Methotrexate  ...          PHASE1   \n",
       "36                                  SHR-1501+SHR-2005  ...  PHASE1, PHASE2   \n",
       "37                               FT-1101, Azacitidine  ...          PHASE1   \n",
       "38                                Bevacizumab, TH-302  ...          PHASE2   \n",
       "39  carboplatin, cisplatin, gemcitabine hydrochloride  ...          PHASE2   \n",
       "40                 Gemcitabine, Carboplatin, LY900003  ...          PHASE2   \n",
       "41                      Pegzilarginase, Pembrolizumab  ...  PHASE1, PHASE2   \n",
       "42  Physician Intervention, Physician and Patient ...  ...  PHASE2, PHASE3   \n",
       "43                               Durvalumab, Olaparib  ...          PHASE2   \n",
       "44                            Osimertinib Oral Tablet  ...          PHASE2   \n",
       "45                                     Ropidoxuridine  ...          PHASE2   \n",
       "46                                   GAd-PEV, MVA-PEV  ...          PHASE1   \n",
       "47  Bortezomib, Melphalan, Prednisone, Thalidomide...  ...          PHASE3   \n",
       "48                             Sintilimab, Decitabine  ...          PHASE2   \n",
       "49                                        C11-Choline  ...          PHASE1   \n",
       "\n",
       "   primary_completion_date                                   primary_outcomes  \\\n",
       "0               2023-10-17  Safety as Measured by Number of Participants W...   \n",
       "1               2021-09-22  Safety - Adverse reactions are classified acco...   \n",
       "2               2026-12-15  Progression-free survival (PFS) assessed by BI...   \n",
       "3               2022-05-20                        Overall Response Rate (ORR)   \n",
       "4               2028-03-15  Composite complete response (CR) rate (CR/comp...   \n",
       "5               2023-11-25  Percentage of Participants with Progression-fr...   \n",
       "6               2009-02-15  In this phase I study the endpoint is the dete...   \n",
       "7                      NaT                                                NaN   \n",
       "8               2024-12-30  Dose-Limiting Toxicity (DLT); Maximum Tolerate...   \n",
       "9               2010-12-15       Effects of perifosine on time to progression   \n",
       "10              2016-12-30                       DLT (Dose Limiting Toxicity)   \n",
       "11              2017-09-15  Analysis of the cumulative response rate (CR,C...   \n",
       "12              2017-07-27  Overall Response Rate (CR+PR+SD): Percentage o...   \n",
       "13              2024-02-29                                 Resectability rate   \n",
       "14              2008-04-15  Dose-limiting toxicities and maximum tolerated...   \n",
       "15              2009-01-15  To assess the extent of upstaging due to the S...   \n",
       "16              2030-01-15  Recommended phase 2 dose (RP2D) of CD19-CD22-C...   \n",
       "17              2015-11-15  Maximal Tolerated Doses of Bortezomib and Vinc...   \n",
       "18              2026-06-01                                     Hair Loss Rate   \n",
       "19              2023-10-31  Objective Response Rate (ORR) as Assessed by B...   \n",
       "20              2021-07-26                        Overall response rate (ORR)   \n",
       "21              2029-02-01                  Two-year Recurrence Free Survival   \n",
       "22              2028-02-17                      Objective response rate (ORR)   \n",
       "23              2016-11-15  blood count; blood count; blood count; blood c...   \n",
       "24              2007-01-15                                                NaN   \n",
       "25              2026-12-31  Incidence of Adverse Events, Graded According ...   \n",
       "26              2018-06-04  Oral Cancer-free Survival in Participants Rece...   \n",
       "27              2024-12-30  Recommended phase 2 Dose (RP2D); Disease Contr...   \n",
       "28              2013-02-15  Difference the efficacy between Er:YAG AFL-PDT...   \n",
       "29              2019-06-30                         AUC [0-t]; AUC [0-â]; Cmax   \n",
       "30              2023-12-15                 Pathologic Complete Response (pCR)   \n",
       "31              2019-07-29  Progression Free Survival (PFS); Objective Res...   \n",
       "32              2008-11-15                  Safety and tolerability of CT-322   \n",
       "33              2024-12-31  Dose-limiting toxicity (DLT); Incidence of Tre...   \n",
       "34              2017-11-21                    Progression Free Survival (PFS)   \n",
       "35              2019-06-07  Number of patients who are surviving at 100-Da...   \n",
       "36              2027-10-01  Phase I : Incidence of dose limiting toxicitie...   \n",
       "37              2019-03-15  Maximum Tolerated Dose (MTD); Dose Limiting To...   \n",
       "38              2019-01-04             Number of Patients With Adverse Events   \n",
       "39              2008-09-29  Objective response measured by RECIST criteria...   \n",
       "40                     NaT                                                NaN   \n",
       "41              2021-01-01  1. Phase 1: Incidence of treatment-related adv...   \n",
       "42              2013-07-15  Colorectal Cancer (CRC) Screening Completion; ...   \n",
       "43              2026-09-15                    Progression-free survival (PFS)   \n",
       "44              2024-07-31                          Progression free survival   \n",
       "45              2026-08-15  Number of patients treated with oral ropidoxur...   \n",
       "46              2024-10-31  Safety and tolerability: incidence of treatmen...   \n",
       "47              2014-07-15  Determine whether the V-MPT combination improv...   \n",
       "48              2022-12-31                             complete response rate   \n",
       "49              2013-08-15  To evaluate our ability to obtain reliable and...   \n",
       "\n",
       "                                   secondary_outcomes     sex start_date  \\\n",
       "0   Major Pathologic Response Rate; Progression Fr...     ALL 2019-07-08   \n",
       "1              Efficacy - local immunological changes     ALL 2021-02-26   \n",
       "2   overall survival (OS); Progression Free Surviv...     ALL 2024-11-29   \n",
       "3                                                 NaN     ALL 2019-07-25   \n",
       "4   Rate of partial response (PR) following treatm...     ALL 2024-01-29   \n",
       "5   Percentage of Grade 3-5 Adverse Events; Overal...     ALL 2020-02-04   \n",
       "6   A decrease in leukemic blasts. The study will ...     ALL 2006-05-15   \n",
       "7                                                 NaN  FEMALE 1999-01-15   \n",
       "8   Treatment-Emergent Adverse Event (TEAE); Maxim...     ALL 2021-11-09   \n",
       "9   Toxicity; Comparison of time to progression to...     ALL 2005-08-15   \n",
       "10                     Preliminary Efficacy Endpoints     ALL 2012-07-15   \n",
       "11  number of participants with adverse events as ...     ALL 2014-09-15   \n",
       "12                                                NaN     ALL 2013-05-15   \n",
       "13  Major pathological response rate (MPR); Pathol...     ALL 2023-03-12   \n",
       "14  Acetylation of histones in peripheral blood; T...     ALL 2001-03-15   \n",
       "15  To evaluate the accuracy of the SLN procedure ...     ALL 2000-05-15   \n",
       "16                                                NaN     ALL 2025-05-15   \n",
       "17  An Estimate of the Overall Response Rate (ORR)...     ALL 2008-02-15   \n",
       "18  Change in Patient Reported Quality of Life; Ch...     ALL 2021-10-07   \n",
       "19  Objective Response Rate (ORR) as Assessed by i...     ALL 2022-07-01   \n",
       "20  Disease control rate (DCR); Duration of respon...     ALL 2017-11-15   \n",
       "21  Five-year RFS; Number of patients in need of a...     ALL 2025-02-24   \n",
       "22  Disease control rate (DCR); Duration of respon...     ALL 2025-02-17   \n",
       "23  Disease-free survival; overall survive; change...     ALL 2012-03-15   \n",
       "24                                                NaN  FEMALE 1999-11-15   \n",
       "25                                                NaN     ALL 2023-05-23   \n",
       "26                                                NaN     ALL 2006-11-03   \n",
       "27  Incidence of Treatment-Emergent Adverse Events...  FEMALE 2023-04-17   \n",
       "28  Difference of the cosmetic outcomes between Er...     ALL 2011-03-15   \n",
       "29      tmax; t1/2; MRT; Vz; CLz; ADA; Adverse events     ALL 2018-12-18   \n",
       "30                                                NaN  FEMALE 2021-03-15   \n",
       "31  Objective Response Rate (ORR); Progression Fre...     ALL 2016-02-09   \n",
       "32  To evaluate the pharmacokinetics of CT-322 in ...     ALL 2006-08-15   \n",
       "33  Persistence of CAR-T cells; Objective response...     ALL 2022-12-05   \n",
       "34  Overall Response Rate (ORR); Percentage of Par...     ALL 2014-12-09   \n",
       "35  Time to marrow engraftment; Assessing all subj...     ALL 2016-09-06   \n",
       "36  Phase I : CR rate at 3 months; Phase II : Inci...     ALL 2024-10-01   \n",
       "37  Area under the plasma concentration versus tim...     ALL 2015-09-15   \n",
       "38                          Progression Free Survival     ALL 2015-05-15   \n",
       "39  Toxicity assessed by NCI CTC v2.0; Overall sur...     ALL 2003-10-27   \n",
       "40                                                NaN     ALL 2002-06-15   \n",
       "41  Objective Response Rate; Clinical Benefit Rate...     ALL 2017-12-21   \n",
       "42           Provider Recommendation of CRC Screening     ALL 2010-04-15   \n",
       "43  Incidence, severity and grading of adverse eve...     ALL 2024-10-09   \n",
       "44  Objective Response Rate (ORR); Overall Surviva...     ALL 2021-07-01   \n",
       "45  Overall survival at 12 months; Radiographic Re...     ALL 2024-09-02   \n",
       "46  RP2D confirmation 2. Clinical efficacy:; Clini...     ALL 2021-06-11   \n",
       "47  Determine whether the VMPT combination improve...     ALL 2006-05-15   \n",
       "48  overall response rate; 1-year progression free...     ALL 2020-04-01   \n",
       "49  Perform semi-quantitative analysis of tracer u...     ALL 2010-03-15   \n",
       "\n",
       "                       stdage study_first_post_date study_first_submit_date  \\\n",
       "0          ADULT, OLDER_ADULT            2019-03-18              2019-03-15   \n",
       "1          ADULT, OLDER_ADULT            2020-10-19              2020-09-07   \n",
       "2          ADULT, OLDER_ADULT            2024-11-04              2024-11-01   \n",
       "3          ADULT, OLDER_ADULT            2020-04-24              2020-04-22   \n",
       "4          ADULT, OLDER_ADULT            2023-04-05              2023-03-22   \n",
       "5          ADULT, OLDER_ADULT            2019-11-15              2019-11-13   \n",
       "6          ADULT, OLDER_ADULT            2006-04-11              2006-04-07   \n",
       "7   CHILD, ADULT, OLDER_ADULT            2003-01-27              2000-04-06   \n",
       "8          ADULT, OLDER_ADULT            2021-11-05              2021-10-22   \n",
       "9          ADULT, OLDER_ADULT            2006-11-14              2006-11-06   \n",
       "10         ADULT, OLDER_ADULT            2012-05-25              2012-05-16   \n",
       "11         ADULT, OLDER_ADULT            2014-10-10              2014-09-23   \n",
       "12         ADULT, OLDER_ADULT            2006-11-09              2006-11-08   \n",
       "13         ADULT, OLDER_ADULT            2022-11-10              2022-11-04   \n",
       "14         ADULT, OLDER_ADULT            2003-01-27              2001-07-11   \n",
       "15  CHILD, ADULT, OLDER_ADULT            2009-01-22              2009-01-13   \n",
       "16               CHILD, ADULT            2025-01-16              2025-01-10   \n",
       "17         ADULT, OLDER_ADULT            2008-03-12              2008-02-11   \n",
       "18         ADULT, OLDER_ADULT            2021-08-03              2021-07-20   \n",
       "19         ADULT, OLDER_ADULT            2022-02-28              2022-02-17   \n",
       "20         ADULT, OLDER_ADULT            2017-09-11              2017-08-23   \n",
       "21         ADULT, OLDER_ADULT            2025-01-17              2025-01-14   \n",
       "22         ADULT, OLDER_ADULT            2025-02-06              2025-02-03   \n",
       "23         ADULT, OLDER_ADULT            2014-05-07              2014-05-03   \n",
       "24         ADULT, OLDER_ADULT            2003-01-27              1999-11-01   \n",
       "25         ADULT, OLDER_ADULT            2023-01-09              2022-12-22   \n",
       "26         ADULT, OLDER_ADULT            2006-11-22              2006-11-20   \n",
       "27         ADULT, OLDER_ADULT            2023-07-03              2023-06-03   \n",
       "28         ADULT, OLDER_ADULT            2013-12-23              2013-11-29   \n",
       "29         ADULT, OLDER_ADULT            2019-06-10              2019-06-06   \n",
       "30                      ADULT            2021-03-22              2021-03-19   \n",
       "31         ADULT, OLDER_ADULT            2015-11-24              2015-11-20   \n",
       "32         ADULT, OLDER_ADULT            2006-09-11              2006-09-08   \n",
       "33  CHILD, ADULT, OLDER_ADULT            2022-12-06              2022-11-25   \n",
       "34         ADULT, OLDER_ADULT            2014-07-21              2014-07-18   \n",
       "35         ADULT, OLDER_ADULT            2016-09-28              2016-08-15   \n",
       "36         ADULT, OLDER_ADULT            2024-09-19              2024-09-05   \n",
       "37         ADULT, OLDER_ADULT            2015-09-07              2015-09-01   \n",
       "38         ADULT, OLDER_ADULT            2015-01-19              2015-01-14   \n",
       "39         ADULT, OLDER_ADULT            2004-03-09              2004-03-08   \n",
       "40         ADULT, OLDER_ADULT            2002-08-06              2002-08-02   \n",
       "41         ADULT, OLDER_ADULT            2017-12-13              2017-11-20   \n",
       "42         ADULT, OLDER_ADULT            2010-04-14              2010-04-12   \n",
       "43         ADULT, OLDER_ADULT            2024-05-17              2024-05-03   \n",
       "44         ADULT, OLDER_ADULT            2021-07-23              2021-07-16   \n",
       "45         ADULT, OLDER_ADULT            2024-04-11              2024-03-24   \n",
       "46         ADULT, OLDER_ADULT            2021-08-04              2021-07-15   \n",
       "47                OLDER_ADULT            2010-02-05              2010-02-04   \n",
       "48         ADULT, OLDER_ADULT            2020-02-21              2020-02-19   \n",
       "49         ADULT, OLDER_ADULT            2010-01-18              2010-01-15   \n",
       "\n",
       "        study_type  \n",
       "0   INTERVENTIONAL  \n",
       "1   INTERVENTIONAL  \n",
       "2   INTERVENTIONAL  \n",
       "3   INTERVENTIONAL  \n",
       "4   INTERVENTIONAL  \n",
       "5   INTERVENTIONAL  \n",
       "6   INTERVENTIONAL  \n",
       "7   INTERVENTIONAL  \n",
       "8   INTERVENTIONAL  \n",
       "9   INTERVENTIONAL  \n",
       "10  INTERVENTIONAL  \n",
       "11  INTERVENTIONAL  \n",
       "12  INTERVENTIONAL  \n",
       "13  INTERVENTIONAL  \n",
       "14  INTERVENTIONAL  \n",
       "15  INTERVENTIONAL  \n",
       "16  INTERVENTIONAL  \n",
       "17  INTERVENTIONAL  \n",
       "18  INTERVENTIONAL  \n",
       "19  INTERVENTIONAL  \n",
       "20  INTERVENTIONAL  \n",
       "21  INTERVENTIONAL  \n",
       "22  INTERVENTIONAL  \n",
       "23  INTERVENTIONAL  \n",
       "24  INTERVENTIONAL  \n",
       "25  INTERVENTIONAL  \n",
       "26  INTERVENTIONAL  \n",
       "27  INTERVENTIONAL  \n",
       "28  INTERVENTIONAL  \n",
       "29  INTERVENTIONAL  \n",
       "30  INTERVENTIONAL  \n",
       "31  INTERVENTIONAL  \n",
       "32  INTERVENTIONAL  \n",
       "33  INTERVENTIONAL  \n",
       "34  INTERVENTIONAL  \n",
       "35  INTERVENTIONAL  \n",
       "36  INTERVENTIONAL  \n",
       "37  INTERVENTIONAL  \n",
       "38  INTERVENTIONAL  \n",
       "39  INTERVENTIONAL  \n",
       "40  INTERVENTIONAL  \n",
       "41  INTERVENTIONAL  \n",
       "42  INTERVENTIONAL  \n",
       "43  INTERVENTIONAL  \n",
       "44  INTERVENTIONAL  \n",
       "45  INTERVENTIONAL  \n",
       "46  INTERVENTIONAL  \n",
       "47  INTERVENTIONAL  \n",
       "48  INTERVENTIONAL  \n",
       "49  INTERVENTIONAL  \n",
       "\n",
       "[50 rows x 35 columns]"
      ]
     },
     "execution_count": 28,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head(50)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1016c95e",
   "metadata": {},
   "source": [
    "Remove all the rows that have Nan values in their date columns "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "7f976375",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(55759, 35)"
      ]
     },
     "execution_count": 29,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "# Replace '?' with NaN in a temporary view of the date columns\n",
    "df_temp = df[date_cols].replace('?', pd.NA)\n",
    "\n",
    "# Identify rows that have NaN or '?'\n",
    "rows_with_nan_or_question = df_temp.isna().any(axis=1)\n",
    "\n",
    "# Remove those rows from the original dataframe\n",
    "df = df[~rows_with_nan_or_question].reset_index(drop=True)\n",
    "df.shape\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "id": "19aee9b2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Index(['brief_summary', 'completion_date', 'conditions', 'country',\n",
       "       'design_primary_purpose', 'detailed_description',\n",
       "       'eligibility_criteria', 'enrollment', 'interventions_description',\n",
       "       'interventions_name', 'is_same', 'keywords', 'last_update_post_date',\n",
       "       'lead_sponsor', 'location_city', 'location_country',\n",
       "       'location_facility', 'location_state', 'maximum_age', 'minimum_age',\n",
       "       'organization_fullname', 'overall_officials_affiliation',\n",
       "       'overall_officials_name', 'overall_status', 'oversight_has_dmc',\n",
       "       'phase', 'primary_completion_date', 'primary_outcomes',\n",
       "       'secondary_outcomes', 'sex', 'start_date', 'stdage',\n",
       "       'study_first_post_date', 'study_first_submit_date', 'study_type'],\n",
       "      dtype='object')"
      ]
     },
     "execution_count": 30,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.columns"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "615da2d3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "keywords                         20526\n",
       "detailed_description             17746\n",
       "overall_officials_affiliation     9682\n",
       "overall_officials_name            9612\n",
       "secondary_outcomes                8345\n",
       "interventions_description         5343\n",
       "location_city                     2848\n",
       "location_state                    2848\n",
       "location_facility                 2848\n",
       "location_country                  2848\n",
       "is_same                           2848\n",
       "country                           2848\n",
       "primary_outcomes                  1000\n",
       "conditions                           1\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "interventions_name                   0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "organization_fullname                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "phase                                0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 31,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "9435ec7a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>brief_summary</th>\n",
       "      <th>completion_date</th>\n",
       "      <th>conditions</th>\n",
       "      <th>country</th>\n",
       "      <th>design_primary_purpose</th>\n",
       "      <th>detailed_description</th>\n",
       "      <th>eligibility_criteria</th>\n",
       "      <th>enrollment</th>\n",
       "      <th>interventions_description</th>\n",
       "      <th>interventions_name</th>\n",
       "      <th>...</th>\n",
       "      <th>phase</th>\n",
       "      <th>primary_completion_date</th>\n",
       "      <th>primary_outcomes</th>\n",
       "      <th>secondary_outcomes</th>\n",
       "      <th>sex</th>\n",
       "      <th>start_date</th>\n",
       "      <th>stdage</th>\n",
       "      <th>study_first_post_date</th>\n",
       "      <th>study_first_submit_date</th>\n",
       "      <th>study_type</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>20</th>\n",
       "      <td>The investigartors will conduct a randomized, ...</td>\n",
       "      <td>2032-02-01</td>\n",
       "      <td>Non-Muscle Invasive Bladder Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Tumour recurrence aft...</td>\n",
       "      <td>272</td>\n",
       "      <td>Chemoablation</td>\n",
       "      <td>Mitomycin c</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2029-02-01</td>\n",
       "      <td>Two-year Recurrence Free Survival</td>\n",
       "      <td>Five-year RFS; Number of patients in need of a...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2025-02-24</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2025-01-17</td>\n",
       "      <td>2025-01-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>86</th>\n",
       "      <td>This is an open-label, single arm, phase 2 stu...</td>\n",
       "      <td>2022-12-31</td>\n",
       "      <td>Acute Myeloid Leukemia</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>In this single-center, open-label, nonrandomiz...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Age: 60-75\\n* Relapse...</td>\n",
       "      <td>29</td>\n",
       "      <td>A humanized monoclonal immunoglobulin; A DNA m...</td>\n",
       "      <td>Camrelizumab(SHR-1210), Decitabine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2020-12-31</td>\n",
       "      <td>Overall response rate; Complete remission (CR)...</td>\n",
       "      <td>Progress-free survival (PFS); Overall survival...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2020-04-25</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2020-04-20</td>\n",
       "      <td>2020-04-14</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>120</th>\n",
       "      <td>Time to progression (physical examination and ...</td>\n",
       "      <td>2008-06-15</td>\n",
       "      <td>Ovarian Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* patients with primary...</td>\n",
       "      <td>105</td>\n",
       "      <td>4 cycles of Carboplatin AUC 5 every 3 weeks. 1...</td>\n",
       "      <td>Paclitaxel</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2008-04-15</td>\n",
       "      <td>Progression-free Survival. Progression is Defi...</td>\n",
       "      <td>Toxicity</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2003-07-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2005-09-12</td>\n",
       "      <td>2005-09-09</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>148</th>\n",
       "      <td>Our study aims at assessment of response, surv...</td>\n",
       "      <td>2022-09-01</td>\n",
       "      <td>Advanced Ovarian Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Ovarian cancer is the most lethal gynecologic ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Female patients diagn...</td>\n",
       "      <td>40</td>\n",
       "      <td>The chemotherapy regimen will be Paclitaxel (1...</td>\n",
       "      <td>Bevacizumab</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2</td>\n",
       "      <td>2022-08-31</td>\n",
       "      <td>progression free survival</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2018-09-01</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2018-08-02</td>\n",
       "      <td>2018-07-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>163</th>\n",
       "      <td>Endometrial cancer (EC) is the 8th most common...</td>\n",
       "      <td>2014-04-15</td>\n",
       "      <td>Recurrent Endometrial Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Patients receive weekly Ixabepilone 32 mg/m2 (...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n1. Histologically confi...</td>\n",
       "      <td>24</td>\n",
       "      <td>Ixabepilone 40 mg/m2 Lapatinib 250 mg</td>\n",
       "      <td>Lapatinib and ixempra</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2013-04-15</td>\n",
       "      <td>Determine the Maximum Tolerated Dosage (MTD) o...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>FEMALE</td>\n",
       "      <td>2011-03-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2011-10-19</td>\n",
       "      <td>2011-09-28</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55603</th>\n",
       "      <td>The investigators plan to to study an extended...</td>\n",
       "      <td>2013-01-15</td>\n",
       "      <td>Bipolar Disorder, Mania</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>Clonidine has been reported to be effective in...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* meet SCID criteria fo...</td>\n",
       "      <td>5</td>\n",
       "      <td>Subjects will received 0.2 mg extended-release...</td>\n",
       "      <td>extended-release clonidine</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE4</td>\n",
       "      <td>2013-01-15</td>\n",
       "      <td>Score on a Mania Rating Scale</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2012-01-15</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2017-02-28</td>\n",
       "      <td>2012-11-06</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55625</th>\n",
       "      <td>The purpose of this study is to assess the eff...</td>\n",
       "      <td>2011-09-15</td>\n",
       "      <td>Allergic Rhinitis Due to Dust Mite</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>After the screening period, the patients will ...</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Male or female outpat...</td>\n",
       "      <td>471</td>\n",
       "      <td>300 IR, once a day, for one year.; once a day,...</td>\n",
       "      <td>Dpte and Dfar Allergen Extracts, placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2011-01-15</td>\n",
       "      <td>Efficacy Assessment</td>\n",
       "      <td>Efficacy Assessment at the end of the treatmen...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2009-10-15</td>\n",
       "      <td>CHILD</td>\n",
       "      <td>2010-09-10</td>\n",
       "      <td>2010-09-09</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55647</th>\n",
       "      <td>The purpose of this study is to provide an inv...</td>\n",
       "      <td>2005-05-15</td>\n",
       "      <td>Hypercholesterolemia, Familial, Lipid Metaboli...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Homozygous familial h...</td>\n",
       "      <td>49</td>\n",
       "      <td>Ezetimibe (MK0653) 10 mg once daily for 3 years.</td>\n",
       "      <td>Comparator: ezetimibe</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE3</td>\n",
       "      <td>2005-05-15</td>\n",
       "      <td>Incidence of clinical and laboratory adverse e...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2002-07-15</td>\n",
       "      <td>CHILD, ADULT, OLDER_ADULT</td>\n",
       "      <td>2004-09-28</td>\n",
       "      <td>2004-09-23</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55719</th>\n",
       "      <td>This study will assess the efficacy of a singl...</td>\n",
       "      <td>2011-08-15</td>\n",
       "      <td>Staphylococcus Aureus, Bacteremia, Mediastinitis</td>\n",
       "      <td>NaN</td>\n",
       "      <td>PREVENTION</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Participant is schedu...</td>\n",
       "      <td>8031</td>\n",
       "      <td>0.5-mL single injection of V710 (60 Âµg); 0.5-m...</td>\n",
       "      <td>V710, Placebo</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE2, PHASE3</td>\n",
       "      <td>2011-08-15</td>\n",
       "      <td>Number of Participants With Staphylococcus Aur...</td>\n",
       "      <td>Number of Participants With Invasive Staphyloc...</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2007-12-15</td>\n",
       "      <td>ADULT, OLDER_ADULT</td>\n",
       "      <td>2007-08-21</td>\n",
       "      <td>2007-08-17</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>55739</th>\n",
       "      <td>In this study, we propose to employ a randomiz...</td>\n",
       "      <td>2016-09-11</td>\n",
       "      <td>Post-traumatic Stress Disorder</td>\n",
       "      <td>NaN</td>\n",
       "      <td>TREATMENT</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Inclusion Criteria:\\n\\n* Men and women between...</td>\n",
       "      <td>10</td>\n",
       "      <td>Pomaglumetad Methionil 160mg, one dose, one ti...</td>\n",
       "      <td>Pomaglumetad Methionil 160mg, Pomaglumetad Met...</td>\n",
       "      <td>...</td>\n",
       "      <td>PHASE1</td>\n",
       "      <td>2016-02-11</td>\n",
       "      <td>To Evaluate the Effect of 160mg and 40mg of Po...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>ALL</td>\n",
       "      <td>2014-09-15</td>\n",
       "      <td>ADULT</td>\n",
       "      <td>2014-09-09</td>\n",
       "      <td>2014-09-03</td>\n",
       "      <td>INTERVENTIONAL</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>2848 rows Ã 35 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "                                           brief_summary completion_date  \\\n",
       "20     The investigartors will conduct a randomized, ...      2032-02-01   \n",
       "86     This is an open-label, single arm, phase 2 stu...      2022-12-31   \n",
       "120    Time to progression (physical examination and ...      2008-06-15   \n",
       "148    Our study aims at assessment of response, surv...      2022-09-01   \n",
       "163    Endometrial cancer (EC) is the 8th most common...      2014-04-15   \n",
       "...                                                  ...             ...   \n",
       "55603  The investigators plan to to study an extended...      2013-01-15   \n",
       "55625  The purpose of this study is to assess the eff...      2011-09-15   \n",
       "55647  The purpose of this study is to provide an inv...      2005-05-15   \n",
       "55719  This study will assess the efficacy of a singl...      2011-08-15   \n",
       "55739  In this study, we propose to employ a randomiz...      2016-09-11   \n",
       "\n",
       "                                              conditions country  \\\n",
       "20                    Non-Muscle Invasive Bladder Cancer     NaN   \n",
       "86                                Acute Myeloid Leukemia     NaN   \n",
       "120                                       Ovarian Cancer     NaN   \n",
       "148                              Advanced Ovarian Cancer     NaN   \n",
       "163                         Recurrent Endometrial Cancer     NaN   \n",
       "...                                                  ...     ...   \n",
       "55603                            Bipolar Disorder, Mania     NaN   \n",
       "55625                 Allergic Rhinitis Due to Dust Mite     NaN   \n",
       "55647  Hypercholesterolemia, Familial, Lipid Metaboli...     NaN   \n",
       "55719   Staphylococcus Aureus, Bacteremia, Mediastinitis     NaN   \n",
       "55739                     Post-traumatic Stress Disorder     NaN   \n",
       "\n",
       "      design_primary_purpose  \\\n",
       "20                 TREATMENT   \n",
       "86                 TREATMENT   \n",
       "120                TREATMENT   \n",
       "148                TREATMENT   \n",
       "163                TREATMENT   \n",
       "...                      ...   \n",
       "55603              TREATMENT   \n",
       "55625              TREATMENT   \n",
       "55647              TREATMENT   \n",
       "55719             PREVENTION   \n",
       "55739              TREATMENT   \n",
       "\n",
       "                                    detailed_description  \\\n",
       "20                                                   NaN   \n",
       "86     In this single-center, open-label, nonrandomiz...   \n",
       "120                                                  NaN   \n",
       "148    Ovarian cancer is the most lethal gynecologic ...   \n",
       "163    Patients receive weekly Ixabepilone 32 mg/m2 (...   \n",
       "...                                                  ...   \n",
       "55603  Clonidine has been reported to be effective in...   \n",
       "55625  After the screening period, the patients will ...   \n",
       "55647                                                NaN   \n",
       "55719                                                NaN   \n",
       "55739                                                NaN   \n",
       "\n",
       "                                    eligibility_criteria enrollment  \\\n",
       "20     Inclusion Criteria:\\n\\n* Tumour recurrence aft...        272   \n",
       "86     Inclusion Criteria:\\n\\n* Age: 60-75\\n* Relapse...         29   \n",
       "120    Inclusion Criteria:\\n\\n* patients with primary...        105   \n",
       "148    Inclusion Criteria:\\n\\n* Female patients diagn...         40   \n",
       "163    Inclusion Criteria:\\n\\n1. Histologically confi...         24   \n",
       "...                                                  ...        ...   \n",
       "55603  Inclusion Criteria:\\n\\n* meet SCID criteria fo...          5   \n",
       "55625  Inclusion Criteria:\\n\\n* Male or female outpat...        471   \n",
       "55647  Inclusion Criteria:\\n\\n* Homozygous familial h...         49   \n",
       "55719  Inclusion Criteria:\\n\\n* Participant is schedu...       8031   \n",
       "55739  Inclusion Criteria:\\n\\n* Men and women between...         10   \n",
       "\n",
       "                               interventions_description  \\\n",
       "20                                         Chemoablation   \n",
       "86     A humanized monoclonal immunoglobulin; A DNA m...   \n",
       "120    4 cycles of Carboplatin AUC 5 every 3 weeks. 1...   \n",
       "148    The chemotherapy regimen will be Paclitaxel (1...   \n",
       "163                Ixabepilone 40 mg/m2 Lapatinib 250 mg   \n",
       "...                                                  ...   \n",
       "55603  Subjects will received 0.2 mg extended-release...   \n",
       "55625  300 IR, once a day, for one year.; once a day,...   \n",
       "55647   Ezetimibe (MK0653) 10 mg once daily for 3 years.   \n",
       "55719  0.5-mL single injection of V710 (60 Âµg); 0.5-m...   \n",
       "55739  Pomaglumetad Methionil 160mg, one dose, one ti...   \n",
       "\n",
       "                                      interventions_name  ...           phase  \\\n",
       "20                                           Mitomycin c  ...          PHASE4   \n",
       "86                    Camrelizumab(SHR-1210), Decitabine  ...          PHASE2   \n",
       "120                                           Paclitaxel  ...          PHASE2   \n",
       "148                                          Bevacizumab  ...          PHASE2   \n",
       "163                                Lapatinib and ixempra  ...          PHASE1   \n",
       "...                                                  ...  ...             ...   \n",
       "55603                         extended-release clonidine  ...          PHASE4   \n",
       "55625           Dpte and Dfar Allergen Extracts, placebo  ...          PHASE3   \n",
       "55647                              Comparator: ezetimibe  ...          PHASE3   \n",
       "55719                                      V710, Placebo  ...  PHASE2, PHASE3   \n",
       "55739  Pomaglumetad Methionil 160mg, Pomaglumetad Met...  ...          PHASE1   \n",
       "\n",
       "      primary_completion_date  \\\n",
       "20                 2029-02-01   \n",
       "86                 2020-12-31   \n",
       "120                2008-04-15   \n",
       "148                2022-08-31   \n",
       "163                2013-04-15   \n",
       "...                       ...   \n",
       "55603              2013-01-15   \n",
       "55625              2011-01-15   \n",
       "55647              2005-05-15   \n",
       "55719              2011-08-15   \n",
       "55739              2016-02-11   \n",
       "\n",
       "                                        primary_outcomes  \\\n",
       "20                     Two-year Recurrence Free Survival   \n",
       "86     Overall response rate; Complete remission (CR)...   \n",
       "120    Progression-free Survival. Progression is Defi...   \n",
       "148                            progression free survival   \n",
       "163    Determine the Maximum Tolerated Dosage (MTD) o...   \n",
       "...                                                  ...   \n",
       "55603                      Score on a Mania Rating Scale   \n",
       "55625                                Efficacy Assessment   \n",
       "55647  Incidence of clinical and laboratory adverse e...   \n",
       "55719  Number of Participants With Staphylococcus Aur...   \n",
       "55739  To Evaluate the Effect of 160mg and 40mg of Po...   \n",
       "\n",
       "                                      secondary_outcomes     sex start_date  \\\n",
       "20     Five-year RFS; Number of patients in need of a...     ALL 2025-02-24   \n",
       "86     Progress-free survival (PFS); Overall survival...     ALL 2020-04-25   \n",
       "120                                             Toxicity  FEMALE 2003-07-15   \n",
       "148                                                  NaN  FEMALE 2018-09-01   \n",
       "163                                                  NaN  FEMALE 2011-03-15   \n",
       "...                                                  ...     ...        ...   \n",
       "55603                                                NaN     ALL 2012-01-15   \n",
       "55625  Efficacy Assessment at the end of the treatmen...     ALL 2009-10-15   \n",
       "55647                                                NaN     ALL 2002-07-15   \n",
       "55719  Number of Participants With Invasive Staphyloc...     ALL 2007-12-15   \n",
       "55739                                                NaN     ALL 2014-09-15   \n",
       "\n",
       "                          stdage study_first_post_date  \\\n",
       "20            ADULT, OLDER_ADULT            2025-01-17   \n",
       "86            ADULT, OLDER_ADULT            2020-04-20   \n",
       "120           ADULT, OLDER_ADULT            2005-09-12   \n",
       "148           ADULT, OLDER_ADULT            2018-08-02   \n",
       "163           ADULT, OLDER_ADULT            2011-10-19   \n",
       "...                          ...                   ...   \n",
       "55603                      ADULT            2017-02-28   \n",
       "55625                      CHILD            2010-09-10   \n",
       "55647  CHILD, ADULT, OLDER_ADULT            2004-09-28   \n",
       "55719         ADULT, OLDER_ADULT            2007-08-21   \n",
       "55739                      ADULT            2014-09-09   \n",
       "\n",
       "      study_first_submit_date      study_type  \n",
       "20                 2025-01-14  INTERVENTIONAL  \n",
       "86                 2020-04-14  INTERVENTIONAL  \n",
       "120                2005-09-09  INTERVENTIONAL  \n",
       "148                2018-07-17  INTERVENTIONAL  \n",
       "163                2011-09-28  INTERVENTIONAL  \n",
       "...                       ...             ...  \n",
       "55603              2012-11-06  INTERVENTIONAL  \n",
       "55625              2010-09-09  INTERVENTIONAL  \n",
       "55647              2004-09-23  INTERVENTIONAL  \n",
       "55719              2007-08-17  INTERVENTIONAL  \n",
       "55739              2014-09-03  INTERVENTIONAL  \n",
       "\n",
       "[2848 rows x 35 columns]"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df['is_same'].isna()]"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6858cda0",
   "metadata": {},
   "source": [
    "Dropping data for which primary outcomes are null"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "b99bb206",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0        Safety as Measured by Number of Participants W...\n",
       "1        Safety - Adverse reactions are classified acco...\n",
       "2        Progression-free survival (PFS) assessed by BI...\n",
       "3                              Overall Response Rate (ORR)\n",
       "4        Composite complete response (CR) rate (CR/comp...\n",
       "                               ...                        \n",
       "55754    Number of Participants With Treatment Emergent...\n",
       "55755    Best Objective Response Rate (ORR) Within 6 Mo...\n",
       "55756    Frequency of dose-limiting toxicities (DLT's) ...\n",
       "55757    Remission of the metabolic syndrome following ...\n",
       "55758    Percentage of Participants Who Achieved Comple...\n",
       "Name: primary_outcomes, Length: 55759, dtype: object"
      ]
     },
     "execution_count": 33,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['primary_outcomes']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "id": "8d818180",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df[~(df['primary_outcomes'].isna() | (df['primary_outcomes'].str.strip() == ''))]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "id": "cf8d7403",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = df[~(df['conditions'].isna())]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "1b8a09d2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "keywords                         20453\n",
       "detailed_description             17630\n",
       "overall_officials_affiliation     9587\n",
       "overall_officials_name            9518\n",
       "secondary_outcomes                7347\n",
       "interventions_description         4425\n",
       "location_city                     2790\n",
       "location_state                    2790\n",
       "location_facility                 2790\n",
       "location_country                  2790\n",
       "is_same                           2790\n",
       "country                           2790\n",
       "conditions                           0\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "interventions_name                   0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "organization_fullname                0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "phase                                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "primary_outcomes                     0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "id": "ec08e85a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(54758, 35)"
      ]
     },
     "execution_count": 37,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "05481d11",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "0                                 Johns Hopkins University\n",
       "1                              Zealand University Hospital\n",
       "2                                                      NaN\n",
       "3                           SINOPHARM, Zhejiang University\n",
       "4               Vanderbilt University/Ingram Cancer Center\n",
       "                               ...                        \n",
       "55754                                               AbbVie\n",
       "55755                          M.D. Anderson Cancer Center\n",
       "55756    Emory University Hospital/Winship Cancer Insti...\n",
       "55757    Hospital Universitari San Joan de Reus (Tarrag...\n",
       "55758                                                  NaN\n",
       "Name: overall_officials_affiliation, Length: 54758, dtype: object"
      ]
     },
     "execution_count": 38,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['overall_officials_affiliation']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "0354b4d2",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "keywords                         20453\n",
       "detailed_description             17630\n",
       "overall_officials_affiliation     9587\n",
       "overall_officials_name            9518\n",
       "secondary_outcomes                7347\n",
       "interventions_description         4425\n",
       "location_city                     2790\n",
       "location_state                    2790\n",
       "location_facility                 2790\n",
       "location_country                  2790\n",
       "is_same                           2790\n",
       "country                           2790\n",
       "conditions                           0\n",
       "brief_summary                        0\n",
       "completion_date                      0\n",
       "interventions_name                   0\n",
       "enrollment                           0\n",
       "design_primary_purpose               0\n",
       "eligibility_criteria                 0\n",
       "maximum_age                          0\n",
       "lead_sponsor                         0\n",
       "last_update_post_date                0\n",
       "organization_fullname                0\n",
       "overall_status                       0\n",
       "oversight_has_dmc                    0\n",
       "phase                                0\n",
       "minimum_age                          0\n",
       "primary_completion_date              0\n",
       "primary_outcomes                     0\n",
       "sex                                  0\n",
       "start_date                           0\n",
       "stdage                               0\n",
       "study_first_post_date                0\n",
       "study_first_submit_date              0\n",
       "study_type                           0\n",
       "dtype: int64"
      ]
     },
     "execution_count": 39,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.isnull().sum().sort_values(ascending=False)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
